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ABSTRACT 
Natural products are an important source for drug discovery. At present there is a 
resurgent interest in phannacognosy as a platform for new combinations of active 
principles to provide highly potent and low-cost medications to treat a growing 
population with an increasing longevity. This project studied phytochemical 
interactions in Artemisia annua plant extracts using anti-plasmodium and anti-
proliferation assays to identify interactions with potent~al therapeutic implications. 
To enable the study a rapid tandem quadrupole mass spectrometry (TQD) method was 
developed for metabolites in the plant and the validation indices showed the method 
to be robust, quick, sensitive and adequate for a range of applications. 
The plasmodium assay tests showed mild-to-strong antagonistic interactions between 
artemisinin, the main anti-malaria agent in the plant, and some related metabolites. 
Caffeoylquinic acids, artemisinic acid and arteannuin B showed additive interactions 
while rosmarinic acid showed synergistic interaction with artemisinin in the 
chloroquine-sensitive plasmodium strain (CQS). Arteannuin B potentiated the activity 
of artemisinin in resistant strain only. In the cytotoxic assay, an aqueous Artemisia 
annua extract showed inconsistent activity. 3-Caffeoylquinic acid (3CA) in 
combination with artemisinin resulted in total loss of cytotoxicity, while combination 
of 3CA with cisplatin, another anti-cancer drug, showed a 13% improvement in 
activity. A mechanistic explanation was suggested for these observations. 
Metabolite interaction was also employed to solve the artemisinin purification 
problem. The interactions of methoxylated flavonoids, especially casticin, artemetin 
and retusin, with artemisinin were identified as putative causative factors for low 
crystallisation yields from extracts. An elevated level of artemetin was found in the 
East African biomass, which also demonstrated poor crystallisation yields, whilst 
doping experiments confirmed the negative impact of these flavonoids on 
crystallisation of artemisinin. 
Consequently, the study showed that phytochemical interactions could be exploited 
and applied with benefits in phannaceutical and chemical purification processes. 
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CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW 
1.1 Natural products as sources of drug candidates 
Natural products are an important source for drug discovery (Newman and Cragg, 
2007). The Ayurvedic, Chinese and other traditional medicine systems based on 
millennia of experience in natural remedies provides a -rich source of folk knowledge 
which can be exploited for discovering novel compounds of medicinal value 
(Verpoorte et ai., 2009). 
Bioactive phytochemicals are a large variety of chemical compounds which are 
mainly secondary metabolites (Hattenschwiler and Vitousek, 2000, Ebada et ai., 
2008). In plants, these compounds are often involved in protection against biotic and 
abiotic stresses and are not essential for cell maintenance or structure. Some 
secondary metabolites, like flavonoids and carotenoids playa major role in plant 
reproduction through their involvement in pigmentation of flower and seed cells 
(Watson et ai., 2001). 
The chemical and pharmacological properties of some secondary metabolites are of 
importance to human and animal health (Raskin et al., 2002, Reddy et al., 2003 ). 
About 50 % of prescribed and over the counter (OTC) medications are derived 
directly or indirectly from plants (Newman et al., 2000). Metabolites groups such as 
alkaloids, terpenoids and flavonoids are used as drugs or as dietary supplements in the 
treatment and prevention of various diseases (Raskin et al., 2002). 
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The search for new active principles for the treatment of major diseases such as 
malaria, AIDS, cancers and associated multi-drug resistant challenges and the need 
for more effective and low cost medications resulting from increasing global life 
expectancy are driving the resurgent interest in pharmacognosy (Karou et aI., 2007). 
This is also in part due to the failure of the combinatorial synthetic approaches to 
deliver new bio-actives. 
The advantage of natural product-based therapies is evident for example in oncology, 
where some synthetic cancer drugs cause non-specific killing of cells while natural 
products provide therapeutic and protective actions to all cells and are beneficial in 
producing nutrient replacements to people with compromised health (Reddy et al., 
2003 ). Moreover, the biological activities of plant extracts are often the results of the 
additive or synergistic effects of its constituents, which enhance their use in multi-
component or combination therapies where resistance to single ingredient drug is 
anticipated (Ebel and Cosio, 1994 ). 
Pharmacognosy has had several major successes. The isolation of pac1itaxel or taxol 
from the bark of yew tree is an example. Paclitaxel exerts its anti-cancer effect by 
inhibiting mitosis and is now a drug approved by the Food and Drug Administration 
(FDA) for ovarian and breast cancers (Nobili et al., 2009). Another pharmacognosy 
success is the anti-malaria compound artemisinin a sesquiterpene lactone derived 
from Artemisia annua L used in World Health Organization (WHO) backed 
Artemisinin Combination Therapy (ACT) for the treatment of uncomplicated 
Plasmodiumfalciparum malaria infection (Stringham et al., 2011, WHO, 2006). 
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1.2 Artemisia annua - botany and metabolic profile 
Artemisia annua known as sweet wormwood, sweet Annie and Qinghao (Chinese), is 
an annual herb native to Asia. The generic name Artemisia came from the Greek 
goddess Artemis (Diana) of maternity as a result of the earlier use of the plant in 
controlling menstrual pain and disorders (Riddle and Estes, 1992). Ancient Chinese 
pharamacopia mentioned the use of the plant (flower and leaves) for treatment of 
fevers and heats (Hsu, 2006a). 
1.2.1 Botany 
The plant is an aromatic annual and a vigorous weedy herb that is single stemmed and 
grows up to two meters (Figure 1.1). It grows in temperate conditions and high 
altitude in tropical areas. The seeds are very small and are sown to seedling stage 
before transplanting. Artemisinin, the anti-malaria agent is synthesized and stored in 
the glandular trichomes (GST). These are specialised cells that protrude from the 
epidermis of leaves, flowers and stems of the plant (Dalrymple, 2006). 
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Figure 1-1 Artemisia annua fresh and dried leaves (Chevallier, 1996). 
1.2.2 Metabolic profile 
Several authors (Bhakuni et al., 2002, Bhakuni et aI., 2001, Chen et aI., 2008, Brown, 
2010) have reviewed the phyto-chemistry of A. annua and described about six 
hundred metabolites in the plant. Different criteria have been used to broadly 
categorize this vast array of plant secondary metabolites. Some more common ones 
are based on the recurring structural features in the compounds, increasing oxidative 
states of their molecule or similarity in their biosynthetic routes (biogenetic 
classification). In the latter, secondary metabolites are grouped starting from simple 
molecules - such as derivatives of aliphatic and aromatic hydrocarbons to complex 
steroid molecules. This classification is used in the succeeding sections as adopted in 
the Dictionary of Natural Products (Bruckingham, 2000, Brown, 2010). 
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1.2.2.1 Aliphatic and aromatic hydrocarbons, alcohols aldehydes, ketones and acids 
All of the un-branched hydrocarbon from CI6 to CI8 and the saturated fatty acids 
from C 12 (dodecanoic acid) to C20 (eicosanoic acid) have been reported in A. annua. 
Several unsaturated fatty acids have also been identified in the plant with oleic acid 
being the most abundant of the un-saturated acids (Brown, 2010). 
OH 
oleic acid benzoic acid (R=C02H) 
anisole (R= OM e) 
CO~ 
&~ 
salicylic acid 
Scheme 1.1 Aliphatic and aromatic acids and ketone in A. annua. 
Example of aromatic ketones and acids in Artemisia plant are anisole, benzoic acid 
and its derivatives like salicylic acid (Scheme 1.1) (Brown, 2010). Oleic acid has 
reported antimicrobial and anti-cancer activities (Dilika et al., 2000, Mizushina et aI., 
2012). Salicylic acid and some compounds in this group (like ethylene) are known 
plant hormones (Cseke et al., 2010). Salicylic acid is used in anti-aging treatments 
and is an important metabolite of the anti-inflammatory agent acetyl-salicylic acid 
(Yang et al., 2004). 
1.2.2.2 Phenylpropanoids 
This group of metabolites is based on a 3-carbon substituent fused to an aromatic 
phenyl group. An important subgroup is hydroxycinnamic esters formed by various 
combinations of ferulic and cinnamic acids with the 4-hydroxyl group of quinic acid 
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to give compounds like chlorogenic acids (Brown, 2010). The bioactivity of 
chlorogenic acids is reviewed in detail in Section 1.7.2. 
A number of coumarins including those shown in Scheme 1.2 have been identified in 
A. annua. Coumarins (benzopyrones) and their derivatives have a range of activities 
including anti-proliferative, anti-viral, anti-coagulant, anti-inflammatory, anti-
microbial and anti-oxidant properties (Riveiro et al., 2010). 
R, 
o 
Compound Rl R2 R3 R4 
Coumarin H H H H 
Scopoletin H OMe OH H 
Scoparone H OMe OMe H 
Scopolin H OMe OGlc H 
Isofraxidin H OMe OH OMe 
Tomentin OH OMe OMe H 
Scheme 1.2 Coumarins in Artemisia plants. 
1. 2. 2. 3 Flavonoids 
Flavonoids are polyphenolic compounds based on a IS-carbon skeleton arranged in 
three rings (C6-C3-C6). Of the over 4,500 flavonoids found in plants, about 40 have 
been identified in A. annua (Ferreira et al., 2010, Lai et al., 2007). Lai et al. showed 
the main flavonoids in the plant to be rhamnetin, chrysosplenol D, quercetin 
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glucoside, flaviolin and pillion (Lai et al., 2007). Highly significant quantities of 
polymethoxylated flavonoids and several long chained 5-alkyl resorcinols have also 
been reported (Brown, 1992). Methoxylated· flavonoids have been linked to the 
activation in vitro of artemisinin (Bilia et al., 2002) and they have also been shown to 
synergistically potentiate the anti-plasmodial activity of artemisinin but not 
chloroquine (Elford et al., 1987). 
ORo 
HO 
R 
OH s· l' 
Apigenin 
Rl R2 R3 R4 
Quercetin H H H H 
Quercetin 3-methyl ether Me H H H 
Isoquercitrin Olc H H H 
Quercetrin 3-rutinoside Sugar H H H 
Isorhamnetin 3-glucoside Olc H Me H 
Rhamnetin H Me H H 
Quercimeritin H Olc H H 
Isorhamnetin H H Me H 
Quercetrin 3' -glucoside H H Olc H 
Tamarixetin H H H Me 
Scheme 1.3. Pentahydroxy -flavonols in A. annua. 
Apigenin, quercetin, rhamnetin and other flavonoid shown in Scheme 1.3 have all 
demonstrated some level of anti-proliferative activities alone and as chemosensitisers 
to anti-cancer drugs (Ferreira et aI., 2010, Limtrakul et al., 2005). The reported anti-
inflammatory activities of these flavonoids would suggest their possible application in 
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treating pathological disturbances such as obesity, arteriosclerosis, diabetes and 
neurodegenerative illnesses (Garcia-Lafuente et al., 2009). 
1.2.2.4 Monoterpenoids 
Monoterpenoids are generally ten-carbon molecules a.I!d principal components of A. 
annua essential oils. They are believed to be localized in the trichomes (Brown, 2010) 
and can be extracted by steam. The oil yield in A. annua could be between 0.3% and 
4.0% (dry weight) depending on the part and chemotype of the plant (Woerdenbag et 
al., 1993a, Bhakuni et al., 2001). The main constituents of the essential oils in A. 
annua are varied and may include artemisia ketone, artemisia alcohols, cineole, 
myrcene (Scheme 1.4) and camphor. 
myrcene artemisia ketone 
artemisia alcohol 1-4 cineole 1-8 cineole 
Scheme 1.4. Cyclic and acyclic monoterpenoids. 
The observed differences in the bioactivity of these essential oils reflects the wide 
variation in their constitution (Woerdenbag et al., 1993a). Several authors have 
reported both anti-bacterial and anti-fungi activities of A. annua essential oils (Juteau 
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et ai., 2002, Cavar et ai., 2012, Lopes-Lutz et al., 2008). A mild antioxidant activity 
has also been reported. 
1.2.2.5 Sesquiterpenoids 
Sesquiterpenoids (CIS) constitutes the most abundant and most diverse group of 
metabolites in A. annua. Structurally they range from simple acylic to tricyclic 
conformation (Brown, 2010). Germacrene D (Scheme I.S), a monocyc1ic 
sesquiterepene may constitute up to 20% of the essential oils of A. annua (Goel et al., 
2008). 
Scheme 1.5. Structure of germacrene D 
The bicyclic amorphane (cardinane) are the largest group of sesquiterpenoids found in 
the plant. Artemisinin, dihydroartemisinin, artemisinic acid and arteannuin B (Figure 
1.2) are the most abundant of this group (You-you et al., 1982, Brown, 2010, Suberu 
et al., 2013a). A series of arteannuins (A to 0 with the exception of D and G) and 
other artemisinin-related metabolites have been identified in the plant (Brown, 20 I 0). 
Apart from the anti-malaria activities associated with some of these compounds 
(Ryden and Kayser, 2007), their antiviral (Efferth et aI., 2008) and anti-cancer (Zhu et 
al., 2013) activities have also been reported. 
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1.2.2.6 Other terpenoids and steroids 
A. annua also contains diterpenoids like abscisic acids (ABA) and phytol, 
triterpenoids like a and p-amyrins, oleanolic acids and sterols like beta-sistosterol 
(Scheme 1.6). Alpha and p-amyrin have known anxiolytic (anti-anxiety) and 
antidepressant effects (Aragao et ai., 2006). 
RO 
p-sitosterol (R=H) 
Compound 
p-Amyrin 
p-Amyrin 3-acetate 
Oleanolic acid 
24 23 
HO 
stigmasterol 
30 29 
R1 
H 
(C=O)CH3 
H 
R2 
Scheme 1.6. Some higher terpenoids and steroids in A. annua. 
Sistostero1 and stigmasterol (Scheme 1.6) are the most common of phytosterols in 
Chinese traditional medicine with known bioactivities to include, 
hypercholesterolemic (cholesterol reducing) (Chandler et ai., 1979), anti-
inflammatory (Gabay et aI., 20lO) and anti-proliferative (Ghosh et ai., 2011). 
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1.3 Artemisinin - biosynthesis and chemistry 
1.3.1 Biosynthesis 
The biosynthesis of artemisinin has been reviewed by several authors (Brown, 2010, 
Ryden and Kayser, 2007, Akhila et al., 1987) and evidence supports that it is 
localized in the granular secreting trichomes (GST) (Covello et al., 2007) . 
. 
Artemisinin, like other terpenoids, share a common biosynthetic precursor -
isopentenyl diphosphate (IPP) and its isomer - dimethylallyl diphosphate (DMAPP). 
These two 5-carbon compounds have independent pathways to femesyl 
pyrophosphate (FPP, also known as femesyl diphosphate, FDP) and originate from 
the cytosol and plastid respectively, see Figure 1.2 (Weathers et ai., 2006, Weathers et 
al., 2011). These two upstream branches of terpenoid biosynthesis are regulated by 1-
deoxyxylulose 5-phosphate synthase (DXS) and I-deoxyxylulose 5-phosphate 
reductoisomerase (DXR) or 3-hdroxy-3-methylglutaryl-CoA reductase (HMGR) 
respectively. One DMAPP and two IPP molecules are joined in a "head to tail" 
condensation by the enzyme femesyl diphosphate synthase (FPS) to give a 15-carbon 
intermediate, femesyl diphosphate (FDP). 
Next, the FPP is cyclized to armorpha-4, 11-diene by amorpha-diene synthase (ADS) 
(Weathers et ai., 2006). Some authors have reported without clarity that 
dihydroartemisinic acid and/or artemisinic acid are intermediates in the conversion of 
amorpha-4, 11-diene to artemisinin (Wallaart et ai., 1999, Abdin et ai., 2003, Bertea 
et ai., 2005). However preponderant evidence seem to support the role of 
dihydroartemisinic acid (DHAA) as a late intermediate (Weathers et ai., 2011, Bertea 
et al., 2005). 
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Figure 1-2 Proposed pathways by Weathers et al. for the biosynthesis of artemisinin 
with structures for artemisinic acid, dihydroartemisinic acid and arteannuin B 
(Weathers et aL, 2006). HMGR = 3-hydroxy-3-methylglutaryl-CoA reductase, DXS = 1-
deoxyxylulose 5-phosphate synthase, DXR I-deoxyxylulose 5-phosphate 
reductoisomerase, ADS = amorphadiene synthase, ALDHI = aldehyde dehydrogenase 1, 
CYP71A VI = cytochrome P450 enzyme, DBR2 = double bond reductase 2, IPP = 
isopentenyl diphosphate, DMAPP = dimethylallyl diphosphate, MEP = methyl erythritol 
phosphate, MV A = mevalonic acid. 
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Amorpha-4, ll-diene is oxidized to DHAA via artemisinic aldehyde by the actions of 
a cytochrome P450 enzyme, CYP71AVl (Ro et al., 2006a), double bond reductase 2, 
DBR2 (Olofsson et al., 2011) and most likely an aldehyde dehydrogenase 1 enzyme, 
ALDHl (Teoh et al., 2009 ) (Figure 1.2). The fma1 step, which is the conversion of 
dihydroartemisinic acid to artemisinin is suggested to be non-enzymatic (Brown, 
2010). The production of artemisinic acid is via a branch in the pathway at artemisinic 
aldehyde catalyzed by the action of CY7l AVl and/or ALDH1. It is also suggested 
that arteannuin B is produced by a non-enzymatic conversion of artemisinic acid. The 
semi-synthetic route for artemisinin production has been developed and the main 
method involves the conversion of artemisinic acid in the biomass to artemisinin 
(Levesque and Seeberger, 2012). 
1.3.2 Chemistry 
Artemisinin is a sesquiterpene lactone incorporating an endoperoxide bridge in its 
molecule. The artemisinin-related anti-malarial derivatives are composed of a 1,2,4-
trioxane ring, which is central to the molecule's bioactivity. The compound is stable 
at temperatures below 100°C (WHO, 2011). The aqueous solubility of artemisinin is 
poor but it is very soluble in some non-polar solvents (Ryden and Kayser, 2007). 
Modification of the lactone group in artemisinin has resulted in derivatives with better 
solubility and improved potency. The majority of these derivatives are currently used 
in anti-malarial therapies (Scheme 1.7). 
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Compound 
Dihydroartemisinin 
Artemether 
Arteether 
Artelinate 
Artesunate 
OR 
R 
. 
H (a +~) 
CH3 (~) 
CH2CH3 (~) 
CH2C6~COONa (~) 
COCH2CH2COONa (a) 
Scheme 1.7. Pharmaceutical derivatives of artemisinin (Ryden and Kayser, 2007). 
1.4 Anti-plasmodial activity and mechanism of artemisinins 
1.4.1 Anti-plasmodial activity 
In early clinical studies, artemisinin showed fast action, low toxicity and good 
efficacy against both the chloroquine-resistant and sensitive strains. The drawback 
however was its sparing solubility in both water and oils. To combat these limitations, 
programs to develop more soluble and effective analogues of artemisinin were 
initiated, leading to the development of APIs such as the oil soluble artemether and 
water-soluble sodium artesunate (Scheme 1.7) (Li et ai., 2000). Due to the short half-
life of both the parent and the derivative compounds, treatment with this class of anti-
malarials is performed over 5 -7 days when used alone. A high rate of recrudescence 
(or re-infection) among patients administered with artemisinin based drugs has been 
reported (Ittarat et ai., 2003). World Health Organization (WHO) have therefore 
recommended the use of these agents in combination with longer half-life drugs to 
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improve efficacy and reduce the possibility of the emergence of drug resistance 
(Ridley, 2002). 
1.4.2 Mechanism of anti-plasmodial action 
The effectiveness of artemisinin compared to earlier anti-malarials is structurally due 
to the trioxane pharmacophore (O'Neill et al., 2010a). Critical to artemisinin anti-
plasmodium activity is the cleavage of the endoperoxide bridge. The mechanism of 
the interaction between the activated moiety and the parasite is not well understood. 
Four different but not mutually exclusive mechanistic models have been proposed 
with evidence for and against each model (Figure 1.3) (Ding et aI., 2011). The heme 
pathway model suggests that the erythrocytic Plasmodia in its digestive vacuole 
breaks down the host's haemoglobin as a source of amino acids releasing heme in the 
process (Ying-Zi et al., 1994, O'Neill et al., 20 lOa). The free heme is detoxified by 
crystallisation to haemozoin. However, in the presence of artemisinin iron from free 
heme catalyses cleavage of the endoperoxide bridge into free radicals, which alkylates 
heme and disrupts their detoxification. The build up of toxicity eventually leads to the 
death of the parasite. 
Another model hypothesised that non-heme iron might cause the cleavage of 
artemisinin into reactive species, which causes the alkylation of other parasites 
proteins including Plasmodium falciparum translationally controlled tumour protein 
(PITCTP) also leading to the death of the parasite (Meshnick, 2002, Asawamahasakda 
et al., 1994). 
Recently, work with mice and yeast models have lead to the postulation that the 
parasite mitochondrial electron transport chain (ETC) directly activates artemisinin, 
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resulting in a build up of reactive oxygen species (ROS) and (or) carbon centred 
radicals which inhibits the electron donor (NADH) dehydrogenase and in tum leads to 
the depolarisation of the mitochondrial membrane and apoptosis (Wang et ai., 2010a, 
Li et ai., 2005, Ding et al., 2011). 
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Figure 1-3 Erytrocytic life cycle of P.falciparum witb enlargement oftbe tropbozite stage sbowing possible mecbanistic models for artemisinin 
activity and parasite resistance. Art = artemisnin. ER = endoplasmic reticulum. Hb = bemoglobin. PfCRT = Plasmodiumfalciparum cbloroquine 
resistant transporter. PfMDRl = Plasmodiumfalciparum multi-drug resistant 1 transporter. PffCTP = Plasmodiumfalciparum translationally 
controlled tumour protein. ETC = electron transport cbain. PfATPase6 = Ca2+ transporter pump. UBP-l = putative de-ubiquitinating enzyme. ROS 
= reactive oxygen species. PfMDR6 = Plasmodiumfalciparum multi-drug resistant 6 transporter (Cui et al, 2012). 
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A fourth model postulates that artemisinin targets the Ca2+ transporter pump 
(PfA TPase6) of the parasite's endoplasmic reticulum (ER) by inhibiting the activity of 
PfA TPase6 eventually leading to death (Eckstein-Ludwig et aI., 2003). A single 
residue modulating PfA TPase6 activity has been identified and mutation in this residue 
affects sensitivity to artemisinin suggesting a potential resistance mechanism 
(Uhlemann et ai., 2005). 
The emergence of artemisinin resistant P. faiciparum has been reported (Phyo et ai., 
2012). The parasite's resistance mechanism is still unclear. Current understanding is 
that some genes are associated with drug sensitivity. Two of these genes products 
found in the membrane of the digestive vacuole of the parasite are P. faiciparum 
multi drug resistance 1 transporter (pfmdr 1) and P. falciparum chloroquine resistance 
transporter (pfcrt). These efflux channels transport anti-malarial drugs and other 
solutes into the food vacuole (Sanchez et aI., 2010). Pfatpase6 gene in the endoplasmic 
reticulum and pfmdr6 (G7) in the apicoplast have been linked with sensitivity and so is 
the putative de-ubiquitinating enzyme UBP-1, Figure 1.3 (Cui et aI., 2012, Dahlstrom 
et ai., 2009, Ding et ai., 2011, Dondorp et ai., 2009, Dondorp et aI., 2010, Eastman and 
Fidock, 2009, O'Brien et aI., 2011, Parija and Praharaj, 2011, Sidhu et aI., 2006, 
Uhlemann et al., 2005). Point mutation and variation in copy number of pfmdr1 have 
been shown to alter the sensitivity to artemisinin and other anti-malarial compounds 
(Golenser et aI., 2006). A quiescence or dormancy mechanism has been postulated to 
explain the observation that ring stage parasite is able to tolerate high concentration of 
artemisinin (Witkowski et al., 2010). This corroborates data from the field where 
delayed parasite clearance has been observed (Phyo et ai., 2012). 
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Several in vitro studies (Tucker et al., 2012, Cui et al., 2012, Beez et al., 2011, 
Witkowski et al., 2010) of the phenotypic and genetic mutation in resistant parasites 
selected by exposure to elevated drug level have shown through their varied outcomes, 
that plasmodium resistance is a multi-factorial trait. In one of these studies, CuI et al. 
using dihydroartemisinin showed that sensitivity was associated with increased pfmr 1 
copy number and elevated anti-oxidant activity (Cui et al., 2012). 
1.5 Extraction and purification of artemisinin and co-metabolites 
Plants are a complex matrix of metabolites. These metabolites have distinct 
physiochemical characteristics (e.g. solubility), which make some method of extraction 
for a type of compound more suited or efficient than the alternatives. The plant 
material is generally dried and in some cases pulverized before extraction. Below are 
some methods employed in the extraction and purification of artemisinin and co-
metabolites in A. annua. 
1.5.1 Traditional solvent extraction method 
This method is widely used in industrial scale purification of artemisinin and co-
metabolites. The traditional method of solvent extraction is characterized by the use of 
a large volume of petrochemical solvents and is labor and time intensive because of the 
longer extraction time and the multiple steps involved in obtaining a product of 
reasonable purity (Christen and Veuthey, 2001, Lapkin et al., 2006). There is however 
a growing shift to more greener, faster and efficient methods with lower cost and 
environmental impact (Lapkin et al., 2010). A variation of conventional extraction 
methods like maceration, Soxhlet, percolation and sonication are used in these systems. 
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Maceration involves leaving the pulverized biomass to soak in the extraction solvent in 
a closed container and may involve mechanical stirring or shaking to ensure 
homogeneous mixing (Sarker et al., 2005). An example is the method by Elsholy et al. 
for the isolation of artemisinin, artemisinic acid and arteannuin B from A. annua using 
n-hexane as extraction solvent. Extracts were further purified by partitioning in 20% 
aqueous acetonitrile with hexane (1:3) and then on silica gel (ElSohly et al., 1990). 
In conventional Soxhlet extraction system the plant material is placed in a cellulose 
thimble in an extraction chamber. Below the extraction chamber is the distillation 
flask filled with the extraction solvent and on top is the reflux condenser (Figure 1.4). 
Extraction chamber 
Thimble 
Siphon arm 
Extraction solvent 
Boiling flask 
Figure 1-4. A scheme of an experimental Soxhlet extractor apparatus. 
Hexane is the solvent of choice in Soxhlet extraction but there is an increasing use of 
alternative solvents like iso-propanol and even water due to safety and environmental 
concerns. The use of alternative solvents however often result in a lower recovery due 
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to the comparatively lower molecular affinity between solvent and solutes (Wang and 
Weller, 2006). Percolation is an application of the Soxhlet principle to batch 
extraction. This involves the circulation of solvent through a bed of biomass contained 
in a percolator vessel. A rich miscella is obtained which is then concentrated by 
external evaporators to recover solvents for recycling (Bart and Pilz, 2011). Tonk et al. 
found that Soxhlet extraction had the best performance of the alternative methods they 
evaluated for the extraction of the larvicidal components of A. annua (Tonk et al., 
2006). 
Ultrasound assisted extraction (UAE) uses sound waves of above 20 kHz to cause 
mechanical vibration in biomass and solvent through expansion and compression 
cycles. The resulting mechanical effect allows a greater penetration of solvent into the 
biomass thereby improving mass transfer. Industrial application of this method, 
involves the use of ultrasonic baths or ultrasonic hom transducers fitted to closed 
extractors (Wang and Weller, 2006). Briars and Paniwnyk have suggested viable 
industrial scale up of their ultrasonic method for the extraction of artemisinin (Briars 
and Paniwnyk, 2013). 
1.5.2 Microwave assisted extraction (MAE) 
This method delivers microwave energy (0.3 - 300 GHz) to both solvent and plant 
matrix, which results in heating of the solvent and biomass efficiently and 
homogeneously. Cell disruption is achieved by superheated endogenous water in the 
plant matrix caused by the absorbed electromagnetic radiation. The resulting disruptive 
changes in plant tissue could lead to a comparative increase in yield of extract and 
migration of dissolved ions could also enhance solvent penetration into biomass matrix 
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and the release of target metabolites. Effective application of MAE however, depends 
on the dielectric susceptibility of both the extraction solvent and the plant matrix 
(Wang and Weller, 2006, Christen and Veuthey, 2001). Comparing MAE with 
commonly used extraction methods for artemisinin, Hao et at. reported shorter 
extraction time and higher extraction rate for MAE over Soxhlet and supercritical CO2 
extractions, however the later produced a cleaner extract than the other two methods 
(Hao et at., 2002). 
1.5.3 Supercriticatjluid extraction 
Raising the temperature and pressure of a substance above its critical value brings it to 
a supercritical state having the characteristic of both a gas and a liquid. The advantages 
of using such fluids over conventional solvents include the ability to adjust the 
dissolving power of the fluid through the manipulation of the pressure and/or 
temperature parameters. Supercritical fluids also exhibit several advantageous solvent 
characteristics (e.g. higher diffusing coefficient, lower viscosity and surface tension, 
etc) over conventional solvents and therefore better mass transfer (Wang and Weller, 
2006). 
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Figure 1-5. Schematics of a supercritical fluid extraction design (Wang and Weller, 
2006). 
The biomass is placed into the extraction vessel (extractor, Figure 1.5) maintained at 
desired temperature and pressure through associated control valves. Fluid is pumped 
into the extractor holding the biomass, which facilitates the partitioning of the analytes 
in the fluid. The fluid and dissolved analytes are transported to the separator chamber, 
(Figure 1.5) and by manipulation of the pressure and/or temperature, the solvation 
power of the fluid is decreased to sweep out the analytes which are then collected. The 
fluid is regenerated in a condenser and recycled for the next round of extraction 
(Christen and Veuthey, 2001, Wang and Weller, 2006). 
Successful implementation of the technology requires careful selection of fluid to suit 
the type of analyte to be extracted. Carbon-dioxide, CO2 is the most common of fluids 
used for extraction of metabolites in A. annua however hydro-fluorocarbon HFC-134a 
(1,1,1,2-tetrafluoroethane) has also been employed (Lapkin et aI., 2006, Kohler et aI., 
1997a). 
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1.5.4 Accelerated solvent extraction 
In accelerated solvent extraction, organic solvents (or pressurized hot water) are used 
at high pressure (10 -15 MPa) and temperature above the solvent boiling point (50 -200 
0c). Although solvents are pressurized similar to SFE however, the solvents are still 
below their critical values in this employment. Increased temperature increases the 
kinetic energy of solvent molecules and interaction with the biomass, while increased 
pressure helps to maintain the solvent in a liquid state (Richter et al., 1996, Wang and 
Weller, 2006). 
Pump 
Solvent 
Nitrogen 
Pump Valve 
Purge 
Valve 
Oven 
Extraction Cell 
Static 
Valve 
Collection Vial 
Figure 1-6. Schematic diagram of an accelerated solvent extraction design. Reproduced 
from Richter et al. (Richter et al., 1996) 
Figure 1.6 show a typical ASE setup. The extractor is placed in a thermostated oven. 
The extraction solvent is pumped into the extraction cell at an appropriate flow rate 
and the cell kept at the ideal temperature and pressure. The sample is collected in the 
collection vial. Christen and Veuthey used a similar setup to extract artemisinin and 
artemisinic acid from A. annua leaves with a favourable result (Christen and Veuthey, 
2001). 
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The various methods discussed above are suited for both single and mUlti-compound 
extraction schemes. In the majority of A. annua extraction for example, the isolation 
of artemisinin, the main active principle is the focus. However targeted multi-
component extraction paradigms are re-emerging with a range of industrial 
applications including, pharmaceutical, nutraceutical and biomaterials for chemical 
industry to name a few. Multi-component extractions for medicinal use are common in 
folk and herbal medicines, for example the use of Artemisia tea in parts of Asia and 
Africa as a self mediated therapy for malaria and other ailments. 
1.6 Artemisia Tea 
1.6.1 Extraction of Artemisia tea 
Several methods are described in ancient Chinese texts for the extraction of Qing Hao 
(A. annua) for medicinal purposes. Two of these involve either soaking followed by 
wringing or pounding followed by squeezing the fresh herb (Hsu, 2006b, Wright et at., 
2010, Hsu, 2006a). 
In their study Rath et at. used three methods of tea preparation using 5 and 9 grams of 
dried leaves for each preparation, Table 1.1 (Rath et at., 2004). In a method (A), 
boiling water was added to leaves and left to cool to room temperature and then 
filtered. In another preparation (B) leaves were boiled in water for 30 min then allowed 
to cool to room temperature and subsequently filtered. The third method (C) had 
boiling water added to the leaves and the mixture briefly stirred and covered for 10 
min followed by filtration and gentle squeezing of the leaves to release residual water. 
The efficiency of extraction, Table 1.1, was between 86 % and 30 % of the total 
artemisinin in biomass. 
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Mueller et al. compared two methods of Artemisia tea preparations (Mueller et al., 
2000). In one method, boiling water was added to leaves, stirred and left to cool for 15 
min and in the second, the extract was kept boiling for 5 min and later filtered. The 
extraction efficiencies obtained were between 42 and 25 %. 
Table 1-1. Efficiencies of aqueous artemisinin extraction from Rath et aL (Rath et aL, 
2004). 
Preparation AmountofA. Artemisinin Efficiency of 
method annua (g) concentration extraction 
in Tea (mg L-1) (%) 
A 5.0 57.5 83 
9.0 88.2 71 
B 5.0 36.5 53 
9.0 37.8 30 
C 5.0 60.0 86 
9.0 94.5 76 
From these results, adding boiled water to dried leaves gave the best efficiency while 
cooking reduces the yield considerably. De Ridder et al. suggested possible reasons for 
the differences in results obtained in these two experiments including differences in 
cultivation and the harvesting of the leaves of Artemisia plant used in these trials (De 
Ridder et al., 2008). 
Vander Kooy and Verpoorte also quantified artemisinin in tea prepared by different 
methods (Van der Kooy and Verpoorte, 2011). They observed that the extraction 
efficiency is temperature sensitive and efficiencies of above 90 % are obtainable. They 
also concluded that the solubility of artemisinin is not improved by other components 
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in the extract and obtained aqueous solubility for pure artemisinin in the range of 50 
1.6.2 Metabolites in Artemisia tea 
Table 1.2 shows components in Artemisia tea analysed by Cabonara et al. by HPLC-
ELSD (Carbonara et al., 2012). The analysed teas were prepared from A. annua leaves 
by infusion in water for 1, 24 and 48 hours. Interestingly on reconstitution of the same 
extracts in less polar or apolar solvents a different composition with no phenolic 
compounds and a much lower concentration of artemisinin resulted. 
Table 1-2. Components of Artemisia tea. Reproduced from Cabonara et aL (Carbonara et 
al.,2012). 
Peaks R,(min) mgfgdw 
Ih 24h 48h 
I 3.(affeoylquinic uid 4.23 1.14±0.01 1.1HO.Ol 121.0.01 
2 5.(affeoylquinic uid 5.76 7.81 %0.02 9.11 .0.02 9.97.0.03 
3 4-Caffeoylquinic uid 6.54 1.2HO.~ 1.40 ± 0.02 1.58 ± 0.03 
4 3-Feruloylquninic acid 7.93 0.70±0.02 O.74±O,Ol 0.86 ± 0.02 
5 TetramethoxyfLwanone 9.01 0.89±0.06 O.42±O.o1 G.29.0.01 
6[7 4-Ftruloylquinic acid 11.95 0.28 ± 0.01 0.32:1:0.01 0.29 ± 0.02 
8 Caffeic acid 14.85 3.11 ±0.02 3.12:<0.03 4.10 :tO.06 
9 5.Feruloylquininc acid 16.01 0.71 ±0.02 0.78 ± 0.01 0.71 ± 0.04 
10 6.(.arabinosyl·8.(·&!ucosyl api&enin 19.35 0.49 ± 0.01 0.48 ± 0.01 052 ± 0.02 
11 6.(·glucosyl·8.(·arabinosyl api&enin 20.91 0.45 ± 0.01 0.4510.03 0.45 ± 0.02 
12 Trimetiloxycoumarin 37.69 1.31 ±0.09 1.11±0.09 1.68.0.10 
13 CIuysoerioi rutinoside 45.17 0.96 ± 0.06 0.9I±O.o2 1.05±O,OS 
15 Vitexin (8.(.,lucosyl api&enin) 52.41 0.80±0.03 0.7410.01 1.04.0,02 
16 Patulelindycoside 54.79 0.69:1:0.02 0.72 ± 0.01 0.70 ± 0.02 
17 Isovitexin (6C.&!ucosyl apigenin) 56.00 1.14:1:0.01 0.89 ± 0.07 0.8H0,02 
18 3.4-Dlcaffeoylqulnic acid 57.33 1026 ± 0.02 8.98±0.02 12.16 ± 0.06 
19 3,5·Dicaffeoylquinic acid 58.07 3.15±0,04 2.98±0'03 3.11 ± 0.07 
20 Luteolin-74i1ucoside 59.00 1.88.0.14 
22 4.5·Dicaffeoylqulnic acid 61.56 2.oo±o'06 125.0.06 3.141 0.06 
23 3.4-Dileruloylquinic acid 65.43 0.39:1:0.01 0.34±O.o1 0.60 ± 0.07 
24 3,5.Dileruloylquinic acid 6624 0.47±O.o2 0.44±0,04 0.72.0,04 
28 4,5·Diferuloylquinic acid 68.48 0.58.0,04 0.50 ± 0.03 0.50 :to.OS 
29 3,5.(affeoylleruloylqulnic acid 72.74 0'90±0'04 0.73.0.01 058 ± 0.06 
31 4-Caffeoyl.3.5-disuccinoylquinic uid 75.96 0.78±0,02 O.81±O,Ol 0.86 ± 0.02 
32 Eryodictiol 77.77 0.90±0.02 0.88 ± 0.01 0.86 ± 0,02 
33 ]aceidln 83.92 1.11 ±O.o2 1.15±0.03 1.13 ± 0.05 
34 Cirsilineol 86.68 0,06±0,02 O.OS±O.o1 0.06 ± 0.02 
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1.6.3 Bioactivity of major (~2 mg/g) components of Artemisia tea 
The major components identified by Carbonara et al. are a series of caffeoyl and 
feruloyl-quinic acids (chlorogenic acids) and some flavonoids (Carbonara et al., 2012). 
Chi orogenic acids refer to a related family of esters of hydroxycinnamic acids (caffeic, 
ferulic, etc) with quinic acid (Scheme 1.8). These compounds possess a broad 
spectrum of pharmacological properties, including antioxidant, hepato-protectant, 
antibacterial, antihistiminic, chemo-preventive and other biological effects (Belkaid et 
al., 2006, Zhang et al., 2008, Feng et al., 2005, Miketova et al., 1999). 
HO Quinic substituent 
HO <: )r CH-OOOH Rl R2 R3 
3-caffeoylquinic acid CA H H 
I 
CatTeoyl group (CA) 4-caffeoylquinic acid H CA H 
caffeic acid 5-caffeoylquinic acid H H CA 
:Q:oH 3,4-di-caffeoylquinic acid CA CA H 
3,5-di-caffeoylquinic acid CA H CA 
R3 OR} 
4,5-di-caffeoylquinic acid H CA CA 
ORz 
quinic acid 3,4,5-tri-caffeoylquinic acid CA CA CA 
Scheme 1.8. Mono, di and tri-caffeoyl-quinic acids in Artemisia tea. 
1.6.3.1 5-caffeoylquinic acid and caffeic acid 
Park in his studies shows that 5-caffeoylquinic acid (Scheme 1.8) and caffeic acid 
orally administered are absorbed and able to suppress P-selectin expression on platelets 
via inhibiting COX enzymes (Park, 2009). He concluded that these compounds have 
beneficial effects on cardiovascular diseases by suppressing P-selectin expression on 
platelets. Jin et al. isolated 5-caffeoylquinic acid from methanol extracts prepared from 
stem barks of Euonymus alatus, which showed a strong inhibitory effect on matrix 
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metalloproteinase (MMP)-9 activity and therefore responsible for anti-MMP-9, known 
to be involved in tumor cell invasion and metastasis (Jin et ai., 2005). 
1.6.3.2 3,4-Dicaffeoylquinic acid 
Takemura et ai. in an in vivo trial found that Brazilian green propolis water extract 
-(PWE) and its chemical components, caffeoylquinic acids, such as 3,4-dicaffeoylquinic 
acid (Scheme 1.8) act against the influenza A virus (IA V) without influencing the viral 
components (Takemura et al., 2012). Chikaraishi et al. showed both in vitro and in 
vivo that the chief chemical constituent of propolis, 3,4-di-caffeoylquinic acid collected 
from plant by honeybees, has several pharmacological actions, such as anti-tumor and 
anti-inflammatory effects (Chikaraishi et ai., 2010). 
1.6.3.3 3,5-Dicaffeoylquinic acid 
Kim et al. showed that 3,5-dicaffeoylquinic acid, (Scheme 1.8) might be a potential 
therapeutic agent for treating or preventing neurodegenerative diseases associated with 
oxidative stress (Kim et ai., 2005). Zha et ai. also showed that the acid displayed anti-
oxidative and anti-apoptotic activities in human dermal micro-vascular endothelial 
cells (HMEC-l) due to scavenging of intracellular ROS induced by Lipo-
polysaccharide (LPS), and the suppression of caspase-3 activity (Zha et ai., 2007). 
1.6.3.4 4,5-Dicaffeoyiquinic acid 
Robinson, et ai. showed that 4,5-dicaffeoylquinic acid and two other analogues were 
potent and selective inhibitors of HIV -I in vitro (Robinson Jr et al., 1996). The 
antioxidant activity of the acid has been demonstrated by Chuda et al. (Chuda et ai., 
1996). 
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1.6.4 Anti-plasmodial activity oj Artemisia tea 
Historically, Artemisia aqueous extracts have been used in treating fevers and 
associated ailments in folk Chinese medicine for millennia. Only recently however is 
the scientific study of the extract and its activity undertaken. 
The study by Rath et ai. was designed to evaluate artemisinin plasma concentration 
after oral intake of the tea preparation (Rath et ai., 2004). In one preparation made 
from 9 grams of Artemisia leaves, 94.5 milligrams of artemisinin was obtained which 
corresponded to about 19% of the recommended daily dose. Tea was absorbed quickly 
with maximum blood concentration reached in 30 minutes compared to pure 
artemisinin at 2.3 hours. Bioavailability was similar for both tea and artemisinin in 
capsules. They also observed that the concentration of artemisinin in the blood after 
intake of the tea are sufficient for clinical effects, however higher recrudescence was 
observed for this group than was the case for modem artemisinin based combination 
therapy. Similarly Mueller et al. investigated the efficacy and safety of traditional 
Artemisia tea preparations in the treatment of uncomplicated malaria (Mueller et al., 
2004). Treatment resulted in a quick resolution of parasitaemia and of clinical 
symptoms. After 7 day of medication, cure rates were about 74% for the tea treatment 
compared with 91 % for quinine. They also found as did Rath et al. that recrudescence 
rates were high in the tea group (Rath et al., 2004). 
Hirt and Lindsey (reference from Willcox et al. (Willcox et al., 2004» in a trial in the 
Democratic Republic of Congo reported a 93% parasite clearance rate in 254 patients 
who had taken a 7 day medication of Artemisia tea, mainly for P. Jalciparum malaria. 
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A subset of 31 patients from the larger group was followed long-term and the 
recrudescence rate was 13% after 1 month. 
Wright et al. used juice squeezed out from Artemisia leaves soaked in water and found 
that the anti-plasmodial ICso values were 6 to 18 times lower than was expected based 
. 
on their artemisinin content (Wright et al., 2010). This juice also suppressed 
parasitaemia by 95% in mice infected with Plasmodium berghei against a 88% 
suppression of parasitaemia obtained when mice were administered 30 mg kg-' single 
dose artemisinin suggesting that compounds in the juice enhanced the action of 
artemisinin (Rasoanaivo et al., 2011). 
In an in vitro trial using both chloroquine sensitive and resistant strains, De Donno et 
al. confIrmed the improved effIcacy of tea over artemisinin and suggested that because 
the concentration of artemisinin in tea was far too low, it could not be wholly 
responsible for the anti-malarial activity (De Donno et al., 2012). Rather, artemisinin 
may be acting in synergy with other ingredients in the extract, which might have 
intrinsic anti-plasmodial activity or may potentiate artemisinin's activity by enhancing 
its solubility. They also stressed the need for targeted research to elucidate the 
interaction between artemisinin and co-metabolites in the extract. 
1.6.5 Anti-plasmodial interactions between components of Artemisia tea 
Limited work has been done to elucidate the nature of the interaction between 
artemisinin and other ingredients in tea. Apart from artemisinin there are other 28 
sesquiterpenes identifIed in the plant and 36 flavonoids some of which have shown 
limited anti-malarial activity (Willcox et al., 2004). Elford et al. showed that 
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methoxylated flavonoids - artemetin, chrysoplentin, chrysosplenol-D and cirsilineol 
enhanced the potency of artemisinin in a combination with each of the flavonoids, see 
Table 1.3 (Elford et al., 1987). Interestingly they did not observe any potentiating 
effect with chloroquine by the flavonoids. 
Table 1-3. Inhibitory effects of flavonoids alone or with artemisinin against P.falciparum 
(Elford et al., 1987). 
IC50 
Flavonoid alone Artemisinin (M x 10.8) 
(M xlO·5) + Flavonoid (5 ~M) 
Artemisinin 3.3 
Artemetin 2.6 2.6 
Casticin 2.4 2.6 
Chrysoplenetin 2.3 2.25 
Chrysosplenol-D 3.2 1.5 
Cirsilineol 3.6 1.6 
EU]2atorin 6.5 3 
Weathers et al. reported that the above methoxylated flavonoids are poorly extracted 
and are unstable in aqueous tea extract (Weathers and Towler, 2012). Therefore the 
improvements in potency of aqueous tea extract over equivalent artemisinin dosage 
will most likely be due to compounds other than these flavonoids in Artemisia tea. 
Literature on the interactions of artemisinin with other metabolites in A. annua besides 
the polymethoxylated flavonoids is lacking. This highlights the need for further 
research in this area. However multi-component interactions are complex to study and 
appropriate methods must be chosen to elucidate these interactions and associated 
mechanisms. 
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1.7 Methods for evaluating multi-component interactions 
The observed improvement in efficacy of the whole extract over an equivalent quantity 
of the single active ingredient underlines synergistic or multi-factorial effect of herbal 
medicine. Synergy defmes the phenomenon where two or more components act 
together to produce an effect greater than the predicted effect from the sum of 
-
individual contributions. When the effect is less than would be predicted, the 
interaction is antagonistic (Williamson, 2001). An additive effect does not necessarily 
implies simply adding up the effect of individual components or an assumption of a 
linear dose response curve which may lead to erroneous results (Kortenkamp and 
Altenburger, 1998). 
Because of the inherent complex nature of phyto-medicines, synergy is difficult to 
prove since to do so it would necessitate the testing of each individual constituent and 
comparing the activity with an equivalent dose in the mixture (Williamson, 2001). 
Several methodologies exist for the evaluation of the nature of component interactions. 
These methods include, isobologram, combination index and curve shift analysis to 
mention a few. These methods are a derivative of the Loewe additivity model (Loewe 
and Muischnek, 1926) that assumes that a drug cannot interact with itself. The isobole 
(or iso-effect) method proposed by Berenbaum (Berenbaum, 1989) is considered one 
of the most practical experimentally and the most demonstrative method for the proof 
of synergy effects (Wagner and Ulrich-Merzenich, 2009). 
This method provides a graphic presentation of the nature of interaction of two drugs. 
The lineally arranged x and y axis reflects the dose rates of single individual 
components - drug (dose) A and drug (dose) B required to produce a fix effect, for 
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example, 50% inhibition (i.e. ICso,A ,ICso,B when x=50%) when used as a single agent. 
The line of additivity is constructed by joining point ICso,A to ICso,B. The 
concentrations of A and B in different combinations that provides the same x=50% 
effect (CAX, CBX) are plotted on the graph as in Figure 1.7 below: 
DrugB 
Drug A 
Figure 1-7. Isobologram for zero-interaction (additivity), synergism and antagonism. 
In a zero or additive interaction as shown by the line in Figure 1.7 the effect of the 
combination of two substances is a pure summation effect (Equation I). For 
interactions that are antagonistic, the overall effect is less than the summation of the 
individual effect (Equation 2). For synergistic interactions, the overall effect of the 
combination is larger than expected from the summation of separate effects of 
components (Equation 3). These interactions is represented equation in the following 
equations (Wagner and Ulrich-Merzenich, 2009): 
E(da, db) = E (daJ + E (db) ............ (1) 
E(da, db) < E (daJ + E (db) .............. (2) 
34 
E(da, db) > E (daJ + E (db) ............... (3) 
where: 
E = observed effect 
da, = dose of component a 
db = dose of component b 
. 
From the above, synergistic interactions necessities therefore a lower amount of the 
combining compounds (a and b) to achieve the desired effect. 
One of the first experiments that conclusively demonstrated synergy between two 
natural products occurring in the same extract was conducted by Wagner and Ulrich-
Merzenich using isobole method to show positive interactions between ginkgolide A 
and B in a thrombocyte aggregation inhibitory assay (Wagner and Ulrich-Merzenich, 
2009). 
Ginkgolide A (JJ.M] 
12 
10 
Glnkgolide B [JJ.M] 
0.5 1 1.5 2 2.S 3 3.S 
GA:GB IC50 Utg/mll Glnkgollde A UtM] Glnkgollde B UtM] 
3 : 1 2.40 4.41 1.42 
2 : 1 2.20 3.60 1.72 
1 : 1 1.80 2.21 2.12 
1 : 2 1.55 1.27 2.43 
1 : 3 1.40 0.88 2.57 
1: 10 1.30 0.29 2.79 
Figure 1-8. Isobologram and table showing synergistic interaction between ginkgolide A 
and B on PAF-induced platelet aggregation. Points on graph show tested combinations 
that produced 50% inhibition of PAF-induced platelet aggregation. Reproduced from 
(Wagner and U1rich-Merzenich, 2009). 
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Due to its inherent limitation the isobolographic method can only deal with the 
interactions between 2-3 components at a single time. 
1.8 Mechanisms of interactions between components 
The Isobel method is independent of the mechanism(s) behind the interactions and 
therefore unable to elucidate on the same for the purpose of predicting the clinical 
significance of such interactions. Several authors have identified some mechanistic 
pathways for interactions in multi-component remedies. In her review, Williamson 
described pharmacokinetic and pharmacodynamic effects as the two broad 
mechanisms for multi-component interactions (Williamson, 2011). Pharmacokinetic 
interactions are processes based on enhanced bioavailability, resorption rate and 
improved solubility. This is one component or ingredient affecting the other 
component's absorption, distribution, metabolism or excretion. This is the most 
common way of interaction in herbal medicinal. Pharmacodynamic process describes 
the effect of two or more compounds on the same receptor, enzyme or biological 
system. This describes each drug's effect on the body and will include example such 
as a single compound interacting with multiple targets or several compounds with a 
single target and mUltiple compounds interacting with multiple targets, see Figure 1.9. 
Because these interactions do not only describe synergistic but includes both additive 
and antagonistic effects they are therefore broadly referred to as multi-factorial (or 
polyvalent) effects. 
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Figure 1-9. Graphical description of single and multi-target effects of agents in an 
extract. 
Wagner and Ulrich-Merzenich suggested other mechanisms of multi-component 
interactions to include the inhibition of parasite resistance network by a synergist 
(compound) and thereby enhancing the effect of the main drug. Improvement in 
efficacy could also come from the elimination or neutralization of the negative or 
adverse side effects of a drug by agents contained in the extracts (Wagner and Ulrich-
Merzenich, 2009). 
1.9 Project aims and objectives 
The key to successful design of multi-component medicinal extracts with improved 
efficacy involves identification and quantification of the components responsible for 
the bioactivity of the extracts. The intrinsic activity and activity in combination with 
other agents in specialised bioassays will lead to the elucidation of the mechanisms 
underpinning multi-component interactions. Using metabolites in A. annua as a model, 
this projects seeks to: 
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1. To develop and validate a quick, sensitive and robust all in one method for the 
determination of artemisinin and other related metabolites in the plant extract. 
2. To study the science and mechanisms of the interactions ofartemisinin with co-
metabolites in the plant extract on anti-plasmodial and anti-proliferation 
activities (potency) of artemisinin. This knowledge hopefully could help in the 
design of new mUlti-component therapies with improved potency and less 
susceptible to parasite resistance. 
3. To identify the cause(s) for and solution(s) to the variable and poor 
extraction/processing efficiencies obtained industrially in the purification of the 
anti-malaria agent artemisinin from Artemista plant. This problem specifically 
relates to plant biomass obtained from East Africa. 
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CHAPTER 2. EXPERIMENTAL 
2.1 Introduction 
This chapter describes the materials and methods employed and it is organised into a 
general method Section (2.2) comprising methods common to most of the experiments. 
Sections 2.3 - 2.6 contains methods specific to major- experiments in suceeding 
chapters bearing the chapter titles. 
2.2 General methods 
2.2.1 Plant samples 
High-yielding A. annua biomasses were obtained from Mediplant (Switzerland), 
BIONEXX (Madagascar), REAP (Kenya), SensaPharm, (UK) CHEMO (Argentina), 
GSK (Australia) and ANAMED (Germany). Dried plant leaves were stored at -20°C. 
Mutant (glandless) A. annua plant sample was kindly provided by Prof. P. Weathers 
(Worcester Polytechnic Institute, MA USA). Hippophae rhamnoides (Sea-buckthorn) 
used as negative control was obtained from the Centre for Alternative Land Use, 
CALU, (Bangor University, Wales, UK). 
2.2.2 Acquity liquid chromatography method 
The liquid chromatography analyses were performed using an Acquity TQD (Waters 
Corp., Milford, MA, USA) coupled to an Acquity tandem quadrupole detector. The 
high-pressure liquid chromatography (HPLC) system consisted of a binary pump, a 
cooling auto-sampler set at 10°C with an injection loop of 10 J..lL. The column heater 
was set at 30°C and a Genesis® Lightn CI8 column (100 mm x 2.1 mm; 4 J..lm;) 
(Grace, IL, USA) protected by an Acquity UPLC column in-line filter unit (0.2 J..lm 
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in-line frit) was used for the separation of the metabolites. The mobile phase consisted 
of A: 0.1 % formic acid in water and B: 0.1 % formic acid in acetonitrile. 
Chromatographic separation was achieved using a linear gradient: 0-7.0 min, 25-98% 
B; 7-9.5 min, 98% B; 9.5-10 min, 98-25% B; 10-15 min, 25% B; at a flow rate of 0.4 
mL min-I. Weak wash solvent was 10 % acetonitrile. The strong and needle wash 
solvents were a mixture of acetonitrile, propan-2-01, me~anol and water (30:30:30: I 0 
v/v/v/v). 
2.2.3 Tandem mass spectrometry (MS/MS) method 
The MSIMS system was operated with an ESI interface in positive ionization mode 
(ESI+) and acquisition was performed in MRM mode. The cone and de-solvation gas 
flow rates were set at 45 L h-I and 800 L h-I, respectively while the capillary voltage, 
the source and de-solvation temperatures were similar of all analytes at 28 kV, 150°C 
and 350 °C respectively. MS parameters were automatically defined using Waters 
IntelliStart® software for the tuning and calibration of the TQD and subsequently 
manually optimized as shown in Table 2.1. Quantification was determined using 
multiple reaction-monitoring (MRM) modes for the above transitions. The dwell time 
was automatically set at 0.161 seconds. Data were acquired by MassLynx V4.1 
software and processed for quantification with QuanLynx V4.1 (Waters Corp., 
Milford, MA, USA). 
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Table 2-1. TQD parameters for MS/MS experiments. 
Cone Collision 
Metabolites Voltage Voltage MRM transitions 
(V) (V) 
Artemisinin 24 7 283-+219+229+247+265 
9-Epi-artemisinin 30 12 283 -+209+219+247+ 265 
Artemisitene 30 10 281-+217+227+245+263 
Dihydroartemisinic 32 12 237-+190+200+218 
Artemisinic acid 32 12 235-+190+200+218 
Arteannuin B 28 9 249-+189+213+221+231 
B-artemether (IS) 20 5 299-+221+249+267 
2.2.4 Dionex-RS Liquid chromatography method 
Ultra high-pressure liquid chromatography (UHPLC) was performed on a Dionex-RS 
3000 instrument. The mobile phase consisted of A: water with 0.1 % formic acid and B: 
methanol with 0.1 % formic acid. The flow rate was 0.2 mL min'l with a run time of 29 
min. The gradient was as follows: 0-10 min, isocratic 55% B; 10-15.4 min, 55% B to 
100% B; 15.4-20.4 min, isocratic 100% B; 20.4-23.4 min, 100% B to 55% B, then 
isocratic for 5 minutes before next run. Separation was achieved on a Zorbax RPC 18 
2.1xl00 mm, particle size 2.2 Jlm with 2 JlL injection volume. 
2.2.5 Q-TOF high resolution - mass spectrometry 
This was carried out on a Bruker MaXis UHR-Q-TOF mass spectrometer under the 
following conditions: ionisation mode: ESI (+); MS Scan range: 50-2500 m/z; end 
plate offset: -500 V; capillary: -3000 V. Nebulizer gas (N2): 0.4 bar; dry gas (N2): 4 L 
min'l; dry temperature: 180°C. Ion transfer conditions: funnel RF: 200 Vpp; multiple 
RF: 200 Vpp; Quadruple Low Mass: 55 m/z; Collision Energy: 5.0 ev; Collision RF: 
600 Vpp; Ion Cooler RF: 50-250 Vpp ramping. Transfer time: 121 JlS; Pre-Pulse 
Storage time: 1 JlS. Calibration was achieved before each run through a loop injector of 
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20 IlL of sodium fonnate (10 mM). 
2.3 Methods for the determination of artemisinin and its biosynthetic 
precursors in raw materials and Artemisia annua L. crude extracts 
2.3.1 Chemicals 
Artemisinin reference standard (98%) was obtained from Sigma-Aldrich (Dorset UK). 
Samples of artemisinin were also kindly provided by Neem Biotech (Newport, UK) 
Chemotechnica (Argentina), Amato, (India) REAP, (Kenya) and Chengdu (Sichuan 
Xieli Pharmaceutical Co Ltd, China). These samples were obtained following 
purification of extracts from A. annua plants cultivated in UK, India, Kenya, China and 
Argentina. Dihydroartemisinic acid (> 96%) was purchased from Apin Chemicals 
(Oxfordshire, UK). 9-epi-artemisinin (98%) was sourced from Sensapharm Ltd 
(Sunderland, UK), while arteannuin B, artemisitene and artemisinic acid were kindly 
provided by Walter Reed Anny Institute of Research (Washington USA). LC-MS 
grade fonnic acid in water, acetonitrile and HPLC grade acetonitrile were obtained 
from Fisher Scientific, UK. Purified water (~18 Mn/cm) was dispensed from a Milli Q 
system (Millipore, UK). 
2.3.2 Analytical standards 
Standard stock solutions of 1 mg mL- 1 of artemisinin, 9-epi-artemisinin, artemisitene, 
dihydroartemisinic acid, artemisinic acid and arteannuin B in acetonitrile were 
prepared. The analytical standard was a mixture of all six standards in a mobile phase 
spiked with glandless Artemisia plant matrix (section 2.1.1) in the concentration range 
between 0.15 - 10 )lg mL-1 for artemisinin, 9-epi-artemisinin, artemisitene and 
arteannuin B. For dihydroartemisinic acid and artemisinic acid the range of 3.75 - 120 
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J.lg mL"1 was used. This is to provide a similar matrix for the standards as with the 
samples minimizing any possible effect due to ion suppression or enhancement. 
Glandless A. annua plant is devoid of artemisinin and related metabolites (Duke et al., 
1994). Beta-artemether was used as internal standard (IS) at 5 J.lg mL"1 to adjust for 
possible fluctuations in injection volumes. Based on the response from the IS, the 
instrument QuantLynx software automatically adjust for these fluctuations making the 
method more robust and accurate. 
2.3.3 Sample extraction and preparation 
Samples were extracted using published methods (Mannan et ai., 201Ob, Lapkin et al., 
2009) with a slight modification. Briefly, 10 mL ofn-hexane containing 5% v/v ethyl 
acetate was used to extract 1 g of biomass in a sonication bath, kept cold with ice, for 
30 min. The extracts were striped of solvent in vacuo and the residue re-suspended in 2 
mL acetonitrile. This was then filtered through a 0.2 J.lm syringe filter to remove waxes 
and other un-dissolved components. An aliquot of the filtrate was dissolved in the 
mobile phase and internal standard added for LC-MS/MS analysis (see section 2.1). 
Glanded A. annua (BIONEXX, REAP, Mediplant, and ANAMED), glandless A. annua 
(matrix), and Hippophae rhamnoides (Sea buckthorn) used as negative control were all 
(see section 2.1.1) extracted using the above procedure. 
In several earlier studies (Arsenault et al., 2010, Briars and Paniwnyk, 2013, Mannan 
et al., 201Oa) solvent extraction was combined with sonication for the extraction of 
artemisinin and related compounds. Sonication provides mechanical disruption of the 
Contents of the trichomes thereby aiding in extraction. Extraction at cold temperature 
«30°C) minimizes the amount of chlorophyll and other interfering components 
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extracted. Briars and Paniwnyk also observed an increase in the amount of artemisinin 
in plant extracted using ultrasound at 25 DC compared to extraction at higher 
temperatures without ultra-sonication and conventional steeping at the same 
temperature (Briars and Paniwnyk, 2013). The use of hexane modified by 5% (v/v) 
ethyl acetate increases the solubility of artemisinin in the mixture by over 3500 % 
compared with hexane alone (Lapkin et aI., 2006). Initially we employed an additional 
sample purification step using SPE columns, however this led to significant losses for 
some of the metabolites. Therefore a limited extract purification procedure with 
acetonitrile was used in all consecutive experiments. 
Treated plant extract for high resolution ESI-MS analysis (QToF, section 2.1) was 
prepared by a 20 minutes contact of the plant extract (above) with activated carbon 
(AC) and celite at a ratio of I g each of AC and celite to 100 mL of extract. This was 
filtered in vacuo with a 0.2 J.1m MiIIipore® filter paper. 
2.4 Anti-plasmodial polyvalent interactions in Artemisia annua L. extracts -
possible synergistic and resistance mechanisms 
2.4.1 Chemicals 
Reference standards of artemisinin (98%), rosmarinic acid, caffeic acid and casticin 
were obtained from Sigma-Aldrich (Dorset, UK). Dihydroartemisinic acid (> 96%) 
was purchased from Apin Chemicals (Oxfordshire, UK). 9-Epi-artemisinin (98%) was 
sourced from Sensapharm Ltd (Sunderland, UK). Artemisitene, artemisinic acid and 
arteannuin B were kindly provided by Walter Reed Anny Institute of Research 
(Washington, DC USA). The chlorogenic acids (>99%) and isovitexin (>99%) were 
obtained from Biopurify, China. LC-MS grade fonnic acid in water, acetonitrile and 
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HPLC grade acetonitrile were obtained from Fisher Scientific, UK. Purified water (-18 
Mn cm- I ) was dispensed from a Milli Q system (Millipore, UK). 
2.4.2 Plant extracts 
Artemisia tea was prepared according to published methods with slight modification 
(Hsu, 2006a, De Donno et al., 2012). Briefly, I L of boiling water was added to 5 g of 
dried plant material (BIONEXX, section 2.1.1.), stirred and stored in the dark for I 
hour. The extract was filtered in vacuo and Iyophilised after freezing to obtain the 
dried tea extract. The ethanolic extract was obtained by sonication for 30 minutes in 
ethanol at 1: 10 (w/v) biomass to solvent ratio. The sonication bath was kept cool with 
ice and the extract was filtered and concentrated in vacuo at 30°C, and further dried 
under a gentle stream of nitrogen gas. These extracts were used in the Plasmodium 
assays and metabolite profiling. 
2.4.3 Fractionation of crude extracts 
Hexane and acetonitrile extract: 
109 of Artemisia biomass (Mediplant, see section 2.1.1) was first extracted with 150 
mL of hexane. The extract was concentrated to about 100 mL and partitioned with 100 
mL acetonitrile twice to completely remove the artemisinin, then each partition was 
concentrated in vacuo and dried in glass vial using a speed vacuum. 
Methanol, chloroform and water fractions: 
The marc from the hexane extraction was extracted with 150 mL 90% methanol. The 
extract was concentrated and suspended in water. This aqueous suspension was 
Partitioned with chloroform. The aqueous fraction was freeze dried while the crude 
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chloroform was washed with 1% NaCI water to rid it of tannins. The chloroform 
partition was concentrated to dryness in vacuo. 
2.4.4 Sample preparation for Plasmodium assay at Liverpool School of Tropical 
Medicine (LSTM) 
Equi-molar artemisinin concentration of fractions and crude extracts obtained from 
2.4.3 were prepared by determining the amount of artemisinin contained in the extracts 
and fractions and making it up to 10.00±0.5 mM with artemisinin reference standard. 
Table 2-2. Controls and treatments used in Plasmodium assay with description and 
artemisinin (nM) content of each. (Art =Artemisinin) 
Controls 
I 
2 
3 
4 
DMSO 
TEA50 
TEA25 
ART 1O.0mM 
Fractions 
5 AAN 
6 ACL50 
7 CL50 
8 AWR100 
9 AWR50 
10 AWR25 
11 WRIOO 
12 AHX33.3 
13 AHXI6.7 
14 AHX8.3 
15 HX 33.3 
Crude Extracts 
16 AEEC 
17 AHXC 
18 AMHC 
DMSO (blank) 
Artemisia Tea 50 mg (1.0 mM art) 
Artemisia Tea 25 mg (0.5 mM art) 
Art (sigma) 2.82 mg mL-! 
Acetonitrile fraction 11.2 mg (10.5 mM art) 
Art + Chloroform fraction 50.7 mg (10.0 mM art) 
Chloroform fraction 50 mg (5.8 mM art) 
Art + Water fraction 100 mg (10.0 mM art) 
Art + Water fraction 50 mg (10.0 mM art) 
Art + Water fraction 25 mg (10 mM art) 
Water fraction 100 mg (0 mM art) 
Art + Hexane fraction 33.3 mg (10.0 mM art) 
Art + Hexane fraction 16.7 mg (10.0 mM art) 
Art + Haxane fraction 8.3 mg (l0 mM art) 
Hexane fraction 33.3 mg (0.0 mM art) 
Ethyl acetate Extract 35.6 mg (10.3 mM art) 
Hexane extract 14.7 mg (10.5 mM art) 
Methanol Extract 39.5 mg (10.1 mM art) 
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2.4.5 Sample preparation - solubility studies 
The solubility of artemisinin, artemisitene and 9-epi-artemisinin in aqueous solvent at 
room temperature (22°C) was determined by the method employed by Wang et al. 
(Wang et al., 2007) with modifications. A saturated solution was prepared by 
dissolving excess amount of the pure (> 99.0%) standard of each material in 1 mL de-
ionised water (MS grade, Brucker, UK) and vortexed. This suspension was allowed to 
settle and the supernatant filtered through a 0.1 f.lm syringe filter (Fisher Scientific, 
UK). An appropriate volume of the filtrate was then diluted with mobile phase for 
mass spectrometry analysis (see Section 2.1). 
2.4.6 HPLC analysisfor artemisinin content offractions 
Chromatographic analysis of crude extracts and fractions for their artemisinin content 
was performed on a Shimadzu Prominence HPLC equipped with auto-sampler, 
degasser, photodiode array and evaporative light scattering (ELSD) detector. The 
method of Stringham et al. was used (Stringham et al., 2009b). Separation was 
achieved by a 50:50 acetonitrile/water mobile phase delivered at a flow of 1 mL min-I 
on an Eclipse Zobax column (150 x 4.6 mm, 0.5 miron). 
2.4.7 HPLC methodfor acids andjlavonoid 
Analysis of acids and flavonoid was performed on an Agilent 1100 series HPLC 
equipped with a quaternary pump, auto-sampler, photodiode (PDA) array and a 
degasser. The chromatographic method by Carbonara et al. was used in the analysis 
with slight modifications (Carbonara et aI., 2012). Briefly, the solvent system 
consisted of A (0.1 % acetic acid, brought to pH 4 with NaOH) and B (0.1 % acetic acid 
in acetonitrile) using a gradient elusion of 0-60 min: 12-25% B, 60-80 min: 25-60% B, 
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80-85 min: 60-100% B. The system was equilibrated back to 12% B for 5 minutes 
before the next run. Analytes were separated and resolved at a flow rate of 1 mL min-I 
on a Phenomenex Luna C18 column (250 mm x 4.60 mm, 5 Ilm particle size) attached 
to a C 18 guard column. Detection and quantification was at 310 nm for caffeic acid, 
chlorogenic acids and isovitexin. Rosmarinic acid was analysed at 330 nm. 
2.4.8 Plasmodium assay (George Town University, USA) 
Determination of 50% growth inhibitory concentration (lC50) values of extracts, 
compounds and combinations against CQ-sensitive (HB3) and CQ-resistant (Dd2) 
strains of P. falciparum was performed at Georgetown University, Washington, DC, 
USA, using a previously reported protocol (Bennett et aI., 2004) with minor 
modifications. Typically, test samples were dissolved in DMSO to give a stock 
solution, followed by serial dilution using complete media (RPM I 1640 supplemented 
with 10% (v/v) type-O+ human serum, 25 mM HEPES (pH 7.4), 23 mM NaHC03, 11 
mM glucose, 0.75 mM hypoxanthine, and 20 mg/L gentamicin) to generate working 
stocks. 100 fA.L of these stock solutions were transferred into pre-warmed (37°C) 96-
well plates. 100 fA.L of asynchronous parasite culture at 2% parasitemia, 4% hematocrit 
was transferred into each drug pre-loaded well, for a final 1% parasitemia, 2% 
hematocrit. Plates were transferred to a gassed (90% Nz, 5% Oz, 5% COz) airtight 
chamber and incubated at 37°C for 72 hours. Following this incubation, 50 fA.L of lOX 
SYBR Green I dye (diluted with complete media from a 10000X DMSO stock) was 
added to each well and plates incubated for an additional 1 hour at 37°C to allow DNA 
intercalation. Fluorescence was measured at 530 nm (490 excitation) on a Spectra 
GeminiEM plate reader (Molecular Devices, USA). IC50 values were obtained from 
sigmoidal fits to % parasite growth (relative to zero drug controls) vs. concentration 
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curves using SigmaPlot 10.0, and are the average of three replicates. Chloroquine (CQ) 
was included as a positive control in the assay. 
2.4.9 Plasmodium assay (LSTM) 
Plasmodiumfalciparum 3D7 parasites were maintained in continuous culture using the 
method of Jensen and Trager (Trager and Jenson, 1978). Cultures were grown in flasks 
containing human erythrocytes (2-5%) with parasitemia in the range of 1 % to 10% 
suspended in RPMI 1640 medium, supplemented with 25 mM HEPES and 32 mM 
NaHC03, and 10% human serum (complete medium). Cultures were gassed with a 
mixture of 3% O2, 4% CO2, and 93% N2. Antimalarial activity was assessed with an 
adaption of the 48-h sensitivity assay of Desjardins et al. (Desjardins et ai., 1979), 
using 3H-hypoxanthine incorporation as an assessfnent of parasite growth. Stock plant 
extracts solutions were prepared in 100% dimethyl sulfoxide (DMSO) and diluted to 
the appropriate concentration using complete medium. Assays were performed in 
sterile 96-well microtiter plates, and each plate contained 200 ~L of parasite culture 
(2% parasitemia, 0.5% haematocrit) with or without 10 ~L drug dilutions. Triplicate 
drug test was carried out and parasite growth compared to control wells (which 
constituted 100% parasite growth). After 24-h incubation at 37°C, 0.5 micro Curie 
(~Ci) hypoxanthine was added to each well. Cultures were incubated for a further 24 h 
before they were harvested onto filter-mats, dried for 1 h at 55°C, and counted using a 
Wallac 1450 Microbeta Trilux Liquid scintillation and luminescence counter. IC50 
values were calculated by interpolation of the Probit transformation of the log dose-
response curve. 
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2.4.10 Combination analysis 
Interaction between compounds were evaluated by isobologram analysis (Bray et aI., 
2005, Berenbaum, 1978). Briefly, a master stock solution is prepared for each 
compound such that its concentration following four or five twofold dilutions 
approximates the ICso. These stock solutions were mixed at ratios of 0:4, 1 :3, 1: 1, 3: 1 
and 4:0 (v/v) to give working combination stocks. Subsequently, the combination 
stocks were twofold serially diluted to generate a full dose concentration range for 
each v/v mixture, which were then analysed under standard growth inhibitory assay 
conditions (see above) to provide dose response curves and an ICso, for each 
component of each v/v mixture. 
2.4.11 Data analysis for in vitro combination studies 
ICso values for each compound alone and in the combination were used to calculate 
FICs (fractional inhibition concentrations) as described elsewhere (Vivas et aI., 2007, 
Fivelman et aI., 2004). The FICs were summated to obtain the fractional inhibition 
concentration index (FICindex) for the combination as in the equation below: 
Where: 
FIC _ ICso of Drug A in Combination 
A ICso of Drug A Alone 
IC ICso of Drug B in Combination F B--~---"'--------
ICso of Drug B Alone 
so 
The following categorization was used to detennine the type of interactions between 
compounds evaluated: synergy (FICndex <0.9), additivity (0.9<FICindex<1.5) and 
antagonism (FICindex > 1.5) (Vivas et aI., 2007, Fivelman et aI., 2004). 
2.5 Comparative cytotoxicity of artemisinin and cisplatin and their interactions 
with chlorogenic acids in MCF -7 breast cancer cells 
2.5.1 Chemicals 
Reference standards of artemisinin (98%), Dimethyl-sulphoxide (DMSO) and 
chlorogenic were obtained from Sigma-Aldrich (Dorset UK). LC-MS grade fonnic 
acid in water, acetonitrile and HPLC grade acetonitrile were obtained from Fisher 
Scientific, UK. Purified water (~18 MO cm- I ) was dispensed from a Milli Q system 
(Millipore, UK). 
2.5.2 Plant extracts 
Artemisia tea was prepared according to published methods with slight modification 
(Hsu, 2006a, De Donno et al., 2012). Briefly, 1 L of boiling water was added to 5 g of 
dried plant material (BIONIXX, see Section 2.1.1), stirred and stored in the dark for 1 
hour. The extract was filtered in vacuo and lyophilised after freezing to obtain the 
dried tea extract. The ethanolic extract was obtained by sonication for 30 minutes in 
ethanol at 1:10 (w/v) biomass to solvent ratio. The sonication bath was kept cool with 
ice and the extract was filtered and concentrated in vacuo at 30°C, and further dried 
under a gentle stream of nitrogen gas. These extracts were analysed for their 
artemisinin content by mass spectrometry (see Section 2.1) used in the anti-
proliferation assays. 
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2.5.3 Cell Culture. 
MCF7 human breast carcinoma were obtained from the European Collection of Cell 
Cultures (ECACC) and used between passages 5 and 18. The cells were grown in 
Roswell Park Memorial Institute medium (RPMI-I640), supplemented with 10 % of 
fetal calf serum, 1 % of 2 mM glutamine and 1 % penicillin/streptomycin, as adherent 
mono layers at 310 K in a 5 % CO2 humidified atmosphere and passaged at 
approximately 70-80 % confluence. 
2.5.4 In vitro growth inhibition assay. 
Briefly, 5000 cells were seeded per well in 96-well plates. The cells were pre-
incubated in drug-free media at 310 K for 48 h before adding different concentrations 
of the compounds to be tested. Stock solutions of the compounds were firstly prepared 
in 5% DMSO and a mixture 0.9% saline and medium (1:1) following serial dilutions in 
RPMI-1640. The drug exposure period was 24 h. After this, supernatants were 
removed by suction and each well was washed with PBS. A further 72 h was allowed 
for the cells to recover in drug-free medium at 310 K. The SRB assay was used to 
determine cell viability (Vichai and Kirtikara, 2006). Absorbance measurements of the 
solubilised dye (on a BioRad iMark microplate reader using a 470 nm filter) allowed 
the determination of viable treated cells compared to untreated controls using the 
inflection point of a dose-response graph. ICso values (concentrations which caused 
50% of cell death) were determined as duplicates of triplicate readings in two 
independent sets of experiments and their standard deviations were calculated. 
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2.5.5 IC50 modulation experiments. 
Experiments to investigate the effect of co-administration of artemisinin and 3CA were 
carried out as described above, with the following modifications: Cells were pre-
incubated in drug-free medium for 48 h at 310 K, before adding artemisinin together 
with 3CA. In order to prepare stock solutions of the drug, the solid artemisinin was 
dissolved first in 5% DMSO and then diluted in a 1: 1 mixture of 0.9% saline: cell 
culture medium. This stock was further diluted using RPMI-1640 until working 
concentrations were achieved. Separately, a stock solution of 3CA was prepared in a 
similar manner. Both solutions were added to each well independently, but within 5 
min of each other. Once again the drug exposure time was 24 h and the drug-free 
recovery time was 72 h. The SRB assay was used to determine cell viability. 
ICso values were determined as duplicates of triplicates in two independent sets of 
experiments and their standard deviations were calculated. 
2.6 The effect of O-methylated flavonoids and other co-metabolites on the 
crystallisation and purification of artemisinin 
2.6.1 Chemicals 
Artemisinin reference standard (~ 98%), Casticin (~ 98%), Xanthophyll and j3-carotene 
(~ 97%) were obtained from Sigma-Aldrich (Dorset UK). Retusin (~ 90%) was 
obtained from Extrasynthese (Genay, France). Artemetin was sources from APIN 
Chemicals (Oxfordshire, UK). All organic solvents used in the experiments were of 
HPLC grade from Fisher Scientific (UK). Purified water (~18 Mn em-I) was dispensed 
from a Milli Q system (Millipore, UK). 
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2.6.2 Plant extraction and treatment 
Plant leaves (see section 2.1.1 - BIOXEXX, REAP, SensaPhann Ltd, CHEMO and 
GSK) were extracted with a hexane-ethyl acetate (95:5 v/v) mixture at a ratio of 1:10 
(biomass: solvent) for 1 hour, using a sonication bath, which was kept cool with ice. 
The extract was filtered (1.0 !-lm Whiteman filter paper) to give the crude extract. This 
was then treated with activated carbon and celite, each applied at 10% w/v for 30 min. 
Celite and activated carbon were kindly provided by Chemotecnica, Argentina, and Dr. 
Guillenno Wollace, Chemotecnica, suggested the method of treatment of Artemisia 
annua raw extracts with these adsorbents. The tre~ted extract is obtained by filtrating 
over 0.45 Ilm Millipore filter paper. The treated extract is then concentrated in a rota-
evaporator to about 10% volume. 
2.6.3 Doping experiments and crystallisation 
From a single batch of the concentrated treated extract prepared as described in Section 
2.6.2, equal volumes (10 mL) were used in each of the treatments and replicates. Three 
levels of doping (0, 250 and 500 !-lg) were used for each of the three metabolites 
(casticin artemetin and retusin CAR). The dopants (CAR) due to their relatively lower 
solubility in extraction solvent were first dissolved in ethanol before introduction to the 
liquor. The control or blank was spiked with an equivalent volume of pure ethanol. The 
treatments and blank were together placed in 4 °C storage for 24 hours to crystallize 
artemisinin. Crystals were harvested from liquor in a cool room (5°C), washed with 
cold hexane, filtrated in vacuo, and dried under a gentle stream of nitrogen gas. 
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2.6.4 Artemisinin determination 
2.6.4.1 Sample preparation 
The artemisinin content of the dried crystals were determined by LC-MS/MS analysis 
(see section 2.1). The artemisinin content was determined by dissolving a weighed 
quantity of harvested crystals or a volume of extract concentrated to dryness in a 
known quantity of acetonitrile. This suspension is then filtered with a syringe filter 
(0.25 ~m Fisher, UK). The filtrate was further diluted to appropriate concentration 
with the mobile phase for analysis. 
2.6.5 HPLC method/or methoxylatedflavonoids 
The analyses were performed using an Agilent 1100 series HPLC instrument (Agilent 
Technologies, UK) equipped with a quaternary pump, auto-sampler, a degasser and a 
diode-array detector. The method of Bilia et al. was employed with some modification 
(Bilia et al., 2006). Briefly, the isocratic mobile phase consisted of water adjusted to 
pH3.2 by acetic acid (eleuent A) and acetonitrile (eluent B) operated at 50% A and 
50% B at a flow rate of ImL min-I for 30 minutes. Separation was on a Zobax Eclipse 
CI8 column (150 x 4.6 mm 5 ~m) protected by a Zobax CI8 guard column and 
detection was at 280 nm with an injection volume of 20 ~L. 
2.6.6 Wax determination 
A known amount of concentrated extract prepared as described in Section 2.3.3 was 
placed in a weighted 50 mL centrifuge tube. Acetonitrile was added at a ratio of 25 % 
v/v to extract. The mixture was thoroughly mixed together and kept in cold storage at 4 
°C for 12 hours to partition. The partitioned mixture was centrifuged at 3,000 rpm, 0 °C 
for 5 minutes. Using a pipette, the subnatant of the partition was carefully removed 
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while the vial was kept in ice. The vial was spun in the centrifuge under similar 
conditions as before. After the supernatant was removed, the residue was carefully 
washed with cold acetonitrile and dried under a gentle stream of nitrogen gas. 
2.6.7 Pigments determination 
2.6.7.1 Xanthophylls 
Crude extracts prepared as described in Section 2.3.3 were analysed for their 
xanthopyll content using a modification of the HPLC method by Rodriguez-Amaya 
and Kimura (Rodriguez-Amaya and Kimura, 20Q4). Briefly, a mobile phase of 5% 
methanol in acetonitrile (solvent A), 100% methanol (solvent B) and 0.05% 
triethylamine in ethyl acetate (solvent C) in three separate bottles was used in a 
80: 10: 10 isocratic elusion. Separation was achieved on an Eclipse Zobax C 18 column 
(150 x 4.6 mm, 5 /lm) at a flow rate of I mL min-! over a 30 min run time. Detection 
was at 470 nm on a photodiode array detector (PAD) attached to an Agilent 1100 
series HPLC with a quart-pump, auto-sampler and a degasser. 
2.6.7.2 {3-carotenoid analysis 
Treated extract prepared as described in Section 2.3.3 were analysed on a Shimadzu 
Prominence HPLC equipped with an auto-sampler, degasser, and photodiode array 
detector using the method by Kimura and Rodriguez-Amaya (Kimura and Rodriguez-
Amaya, 2003) and modified after Morinova and Ribarova (Marinova and Ribarova, 
2007). Separation was conducted on a Phasesep-Partisil C 18 (250 x 4.6 mm, 5 !-lm) 
column attached to a C 18 guard column maintained at 30 °C. A solvent system 
composed of eluent A (acetonitrile:methanol, 95:5 v/v) and eluent B 
(acetonitrile:methanol:ethylacetate, 60:20:20 v/v/v). The eluents were modified with 
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0.1 % butylated hydroxytoluene (BHT) and 0.05% triethylamine (TEA) respectively. A 
flow rate of 1 mL min-1 was used on a gradient elusion which was as follow: 100% A 
0-5 min, 100% B 13 min, 100% B 30 min, 100% A 45 min. Detection was done at 450 
nm on the PDA. 
2.6.8 Computational COSMO-RS method 
COSMO-RS is an a priori solvation model that provides for an analytical expression 
of the chemical potential of a substance in the liquid phase (Klamt et al., 2002, Klamt 
et ai., 2010). The implementation of COSMO:RS in COSMOtherm (C30_1201, 
COSMOlogic GmbH & Co. KG) was used for the calculation of solubilities. For each 
substance i the infinite dilution solubility x~ can be calculated using the difference 
between the pseudo-chemical potential of the pure substance and that of the same 
substance in its infinitely diluted dissolved state J.1; - J.1~ , according to the following 
equation (Eckert, 1999): 
where the term with the free energy change of fusion !!J.G filS is required if the state of 
the pure substance is solid at the examined temperature. Since this equation must also 
hold for any other higher concentration, an iterative process can be used to calculate 
the solubility limit by substituting J.1~ in every step by the chemical potential 
calculated at the concentration of the previous step. The concentration at the solubility 
limit x~ is thus achieved upon convergence. 
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Since artemisinin and the three flavonoids studied in this work are all solid at 293 K, 
the value of free energy change of fusion is necessary in order to carry out the 
solubility calculations. The free energy change of artemisinin upon melting has been 
recently estimated (Lapkin et ai., 2010) using the above equation and solubility data 
available from (Neau et at., 1997). 
The following equation was used to calculate the required free energy changes for 
casticin and retusin: 
whereby the melting temperature Tm and the enthalpy and constant pressure heat 
capacity change upon melting !JJ.H fIt' and !JJ.CPjilS need to be known. For casticin and 
retusin Differential Scanning Calorimetry (DSC) was used to measure the melting 
point and the enthalpy change upon melting while !JJ.Cp jilS was approximated using 
COSMOtherm with the following equation (Eckert, 1999, Neau et aI., 1997): 
!JJ.C A C' mjilS P jilS = u.J jilS = --
Tn! 
where MjilS denotes the entropy change upon melting. For artemetin the melting free 
energy was calculated by COSMO-RS using a Quantitative Structure-Property 
Relationship (QSPR) (Eckert, 1999). 
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2.6.9 Deferential Scanning Calorimetry (DSC) 
The thennal analysis of casticin and retusin were perfonned using differential scanning 
calorimetry (Mettler Toledo Star DSC l). The measurements were carried out in 
nitrogen atmosphere. The temperature was calibrated in relation to aluminum standard 
(40 flL). Casticin (2.23mg) and retusin (1.99 mg) were each in tum loaded into metal 
pans and located on the thennoelectric disc cells. A temperature range of 25 - 210°C 
was used for each scan. 
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CHAPTER 3. METHODS FOR THE DETERMINATION OF ARTEMISININ 
AND ITS BIOSYNTHETIC PRECURSORS IN RAW MATERIALS AND 
ARTEMISIA ANNUA L CRUDE EXTRACTS 
3.1 Introduction 
Malaria is a life threatening disease transmitted by mosquitoes with about half of the 
world's population at the risk of the disease (WHO, 2010). Although death from 
malaria has been decreasing globally since 2005 (WHO, 2011), there is the fear of a 
reversal due to the parasite developing resistance to traditional anti-malaria drugs. The 
discovery of artemisinin (3.1) (Scheme 3.1) three decades ago and the development of 
the artemisinin-based semi-synthetic drugs used in combination therapies (ACTs) 
backed by the World Health Organization (WHO) have provided a highly effective 
treatment againstfalciparum-type malaria in many countries (Qu et ai., 2010, Haynes, 
2006, We ina, 2008). 
HaC 
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(3.1) artemisinin (3.2) 9-epi-artemisnin (3.3) artemisitene 
H3c~~H3 
OH 
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~cd) 0 
H3CJy 
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(3.4) dihydroartemisinic acid (3.5) artemisinic acid (3.6) arteannuin B 
Scheme 3.1 Chemical structures of metabolites of interest. 
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Currently, the worldwide demand for ACT treatments is approximately 100 million 
doses annually (Qu et ai., 2010, Haynes, 2006, Weina, 2008). 
Until recently, the only commercially viable source of artemisinin was Artemisia 
(Asteraceae) plant. Artemisia annua L., Artemisia apiacea Hance, and Artemisia 
lancea Vanoit are three species in the genus Artemisia that have been reported to 
contain significant amounts of artemisinin with most of the interest focused on A. 
annua (Willcox et aI., 2004, Hsu, 2006a). Crystallization from extracts of dried plant 
biomass is the simplest method of recovery of aitemisinin and with improved plant 
breeding methods reported yields are up to about 1.5% dry weight (Covello, 2008, 
Lapkin et ai., 2006, Larson et ai., 2013). Commercial interests are also focused on 
other biosynthetic precursors that are convertible to artemisinin analogs (Ro et ai., 
2006b). 
There are several published methods for the analysis of artemisinin and other related 
sesquiterpenes including 9-epi-artemisinin (3.2), artemisitene (3.3), dihydroartemisinic 
acid (3.4), artemisinic acid (3.5), and arteannuin B (3.6). However more rapid, 
sensitive, accurate and all-in-one methods are still needed for these metabolites. 
Techniques developed and validated for analysis of artemisinin include thin layer 
chromatography (TLC) (Quennoz et ai., 2010), high performance liquid 
Chromatography with ultra violet detection (HPLC-UV) (Stringham et ai., 2009b, Tian 
et al., 2012), electrochemical detection (HPLC-ECD) (Chan et al., 1997), evaporative 
light scattering detection (HPLC-ELSD) (Lapkin et al., 2009), and refractive index 
(HPLC-RI) (Lapkin et ai., 2009). HPLC-UV is the WHO recommended method and 
the most widely used. However because artemisinin has very weak UV adsorption 
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above 210 run, the use of UV detection at the end of an HPLC separation requires very 
careful set-up and calibration, especially for analysis of extracts. An earlier method 
involved conversion of artemisinin to a UV absorbing compound Q260 to facilitate its 
detection (Wallaart et al., 2000, Qian et al., 2005, Wang and Weathers, 2007). The 
disadvantage of this method is that the derivatisation procedure from artemisinin to 
Q260 is time consuming and introduces significant experimental errors (Cheng et aI., 
2004). Other methods include gas chromatography with flame ionization (GC-FID) 
(Peng et al., 2006, Woerdenbag et al., 1991), supercritica1 fluid chromatography with 
ELSD (Christen and Veuthey, 2001), FID (Kohler et al., 1997b) and MS (Dost and 
Davidson, 2003) detection. NMR (Liu et aI., 2010) and immunoassay (He et aI., 2009) 
methods have also been reported. An excellent review of these techniques in greater 
detail was published by Christen et al. (Christen and Veuthey, 2001). 
Mass and tandem mass spectrometry based methods have the advantage of high 
sensitivity and selectivity for metabolites in plant extracts (Wang et aI., 2005). Several 
gas chromatography and liquid chromatography methods coupled to mass 
spectrometry (GC-MS (Woerdenbag et aI., 1991), LC-MS (Wang et aI., 2005, Maillard 
et al., 1993)) and tandem mass spectrometry (GC-MSIMS (Liu et aI., 2008), LC-
MS/MS (Van Nieuwerburgh et al., 2006)) have been reported for the determination of 
artemisinin and its derivatives in blood, plasma, serum and plant extracts. The MSIMS 
method developed by Van Nieuwerburgh et al. (Van Nieuwerburgh et aI., 2006) for 
the analysis of artemisinin and its biosynthetic precursors in A. annua takes about 20 
minutes to analyse four metabolites. 
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This work evaluates the levels of impurities in artemisinin raw material and describes 
an MSIMS method for the analysis of six analogues of artemisinin, including 9-epi-
artemisinin, in crude plant extract with minimal sample preparation, a simple binary 
mobile phase solvent system and a short overall analysis time, lending the method to 
high throughput (HTP) analysis with low consumables costs and a reduced 
environmental impact. 
3.2 Results and Discussion 
3.2.1 LC analysis of impurities in artemisinin raW material 
Figure 3.1 shows the UV chromatogram for impurities in artemisinin raw material. The 
quantification of these impurities was done using a regression equation from the 
calibration curve for 9-epi-artemsinin (y=657.24x+944.07 with R2 = 1) and for 
artemisitene (y=35992x09962 with R2 = 0.99742). The extinction coefficient for 
artemisitene is not linear as for 9-epi-artemisinin. A power function was used to obtain 
a 99.7% fit for the concentration range of 0 to 2.2mg mL-1• 
The term x in the equation which is the amount or concentration of impurities was 
calculated by substitution for y, the peak area. The percentage level of contamination 
Was derived from the formula: 
M =X/S*100 
where: 
M = % contaminant 
X = amount of contaminant (in mg) 
S = amount of sample assayed (in mg) 
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Figure 3-1. UV Chromatogram of artemisinin raw material. 
Table 3.1 shows values obtained using the above calculations for estimating 
artemisitene and 9-epi-artemisinin in artemisinin raw material analysed. These values 
are similar to those obtained by Stringham et al. who employed a conversion factor for 
calculating the concentration of artemisitene. The above calculation had no need for 
the determination of a conversion factor; which is dependent on absorption wavelength 
and other variables (Stringham et al. , 2009a). 
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Table 3-1. Percentage of9-epi-artemisinin and artemisitene per weight of artemis in in 
raw material. 
% impurity per weight of raw material 
Source of raw material 9-epi-art artemisitene 
Amato-India 0.29 0.04 
Chemotecnica-Argentina 0.38 0.08 
SensaPharm (UK) 0.32 0.04 
NeeemBiotech (UK) 0.36 0.03 
India 0.10 0.04 
Kenya 0.49 0.02 
Chengdu-China 0.11 0.02 
China 2 0.07 0.03 
Vietnam 1 0.44 0.05 
Vietnam 2 0.54 0.03 
Stringham et al. obtained between 0.17-0.30% for levels of 9-epi-artemisinin and 
between 0.03 -0.08% for artemisitene in raw materials originating from China 
(Stringham et aI., 2009a). The Kenyan materials they analysed had 0.07 - 0.73% for 9-
epi-artemsinin and the quantity of artemisitene was between 0.04-0.06%. An Indian 
sample had 0.50 and 0.01% of 9-epi-artemsinin and artemisitene respectively and 
collaborated the tabulated values Table 3.1. The levels of 9-epi-artemsinin and 
artemisitene in the raw material were within the WHO guideline of not exceeding 1.00 
and 0.15% respectively (WHO, 2011). 
The wide range reported (Stringham et ai., 2009a) in the levels of these impurities 
between and within countries, may be due to the purification processes used and does 
not seem to be dependent on the geography of the growth location of the plant 
material. 
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Figure 3-2. Total ion current chromatography (TIC) with retention times for all 
metabolites of interest and the internal standard (~-artemether). The chromatograms 
were acquired by multiple reaction monitoring (MRM) in positive electro-spray mode 
Using analytical standards at a concentration of 5 p.g mL-1 for all analytes and internal 
standard except for artemisinic acid af.ld dihydroartemisinic acid which were determined 
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3.2.2 LC-MS chromatography 
The quantification of artemisinin and its biosynthetic precursors in complex plant 
matrixes necessitated the development of fast sensitive and robust LCMS based 
method for which ordinary HPLC is not adequate. In the development of the MS 
protocol, gradient and isocratic LC methods were tested to optimize the conditions for 
resolution of all the metabolites and the internal standard. A buffered system similar to 
those employed by Van Nieuwerburgh et al. was also tested (Van Nieuwerburgh et al., 
2006). The best resolution was obtained with the method described in Section 2.5. All 
metabolites and internal standard were successfurry resolved in the first 6 minutes of 
run time. Figure 3.2 shows the total ion current chromatogram (TIC) for all the 
analysed compounds. 
3.2.3 Recovery 
The recovery was assessed using ten equal samples of 1 g of dried A. annua 
(Madagascar variety). Six of these extracts were not spiked while four were spiked 
with a mixture of each analyte to give the fmal concentration in the prepared extract of 
2.5 ~g mL-! for artemisinin, 5.0 ~g mL-! for 9-epi-artemisinin, artemisitene and 
arteannuin B, 30 ~g mL-! for dihydroartemisinic acid and artemisinic acid. Table 3.2 
shows a recovery of between 98.44 and 105.54% was obtained for the analytes 
investigated. 
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Table 3-2. Recovery of artemisinin and analogues (rom A. annua. 
Spiked analyte quantities /lg mL-1 Artemisinin* 9-Epi-artemisin * Artemisitene Dihydroartemisinic* Artemisinic Arteannuin B 
acid acid 
Mean quantity in un-spiked samplea 7.49 0.13 0.05 18.15 0.00 0.39 
Spiked quantitl 2.50 5.00 5.00 30.00 30.00 2.50 
Total quantity in spiked samplec 9.99 5.13 5.05 48.15 30.00 2.89 
Recovered quantities (/lg mL-1) 
Spiked Sample 1 d 10.24 (102.50010) 5.08 (99.03%) 5.08 (100.59%) 52.14 (108.28%) 28.65 (95.50%) 3.06 (105.88%) 
Spikes Sample 2d 10 .60 (106.11 %) 5.24 (102.14%) 4.97 (98.41 %) 47.84 (99.36%) 30.62 (102.06%) 2.82 (97.58%) 
Spiked Sample 3d 10.38 (103.90%) 4.92 (95.91%) 5.38 (106.53%) 51.87 (107.72%) 28.30 (94.33%) 3.09 (106.92%) 
Spiked Sample 4d 9.97 (99.80%) 4.98 (97.08%) 5.46 (108.12%) 47.53 (98.71%) 31.31 (104.36%) 2.96 (102.42%) 
Mean spiked sample (Ilg mL-1) 10.30 (103.10010) 5.05 (98.44%) 5.22 (103.37%) 49.85 (103.53%) 
.\ 
29.72 (99.07%) 3.05 (105.54%) 
Standard deviation (/lg mL-1) 0.23 (2.30%) 0.12 (2.34%) 0.21 (4.16%) 2.16 (4.49%) 1.27 (4.23%) 0.11 (3.79%) 
Ten equal samples ofl g dried MadagascanA. annua leaves were extracted and prepared for analysis. a Six of these extracts were un-spiked while 4 
were spiked at indicated levelsb, The total quantityc ofanalyte in samples is calculated as tbe sum oftbe mean quantities in six un-spiked sample and 
the spiked quantity, Analyte levels in individual spiked samples were determinedd and absolute and percentage (in bracket) recoveries presented. * 
Quantitative values corrected for percentage purity 
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3.2.4 Specificity 
Figure 3.3 shows the possible MRM transitions for artemisinin. Three or four 
transitions were monitored for the MS/MS experiment to identify and quantify each 
metabolite. The sum of combined transitions gave the total ion current (MRM) data 
while the signal with the highest mlz value was used for the quantification of each 
analyte. 
MS/MS based assay are inherently specific. However to investigate the specificity of 
the method further, extracts of glandless A. annua and Hippophae rhamnoides (Sea-
buckthorn) were analysed. In these negative control extracts we found no components 
of interest in the chromatograms from the MS/MS experiments. The result for the 
presence of trace level of artemisinin in the glandless biomass was not conclusive and 
this is being investigated further. 
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Figure 3-3. Multiple reaction monitoring (MRM) chromatogram of standard 
artemisinin (5 J.l.g mL-1) showing the four transitions selected, their intensities and 
chemical formulae. 
3.2.5 Ion suppression or enhancement (matrix effect) 
Quantitative analysis of plant and biological samples with positive electro-spray 
ionization coupled to tandem mass spectrometry is compounded by the presence of 
matrix components, which can interfere with the analysis hence resulting in ion 
suppression or enhancement effects. The common methods for the assessment of ion 
sUppression are the post-column infusion method (Bonfiglio et al. , 1999) and the 
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post-extraction spike method (Matuszewski et a/., 2003). The spike method was used 
in our determination and this was assessed by comparing the response of the analyte 
in plant matrix to the response of the analyte spiked into a blank matrix (mobile 
phase) sample that has gone through the sample preparation process (Van Eeckhaut et 
al., 2009). Signals from three samples for each analyte prepared in the mobile phase 
(25% formic (0.1%) acetonitrile in 0.1% formic acid) were compared with the similar 
concentration in the plant matrix. Table 3.3 below shows the values obtained for each 
of the analytes. 
There was a negligible (0.3%) enhancement of artemisinin signals resulting from the 
plant matrix compared with the blank (mobile phase). Other metabolites showed some 
evidence of ion enhancement due to the plant matrix. Less than 15% of enhancement 
was observed in all analytes determined. The widest range was between about -2.0 to 
14.13% for artemisinic acid. The supression (-2.0%) was within the margin of error 
(5.02%) for the determination. Similarly, a slight supression (-2.58%) was observed 
for one of the determinations of 9-epi-artemisinin; this was also within the margin of 
error. An average enhancement for all the determined compounds was between 0.3% 
for artemisinin to 8.06% for artemisinic acid. 
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Table 3-3. Ion suppression due toA. annua plant matrix. 
Artemisinin 9-Epi- Artemisitene Dihydroartemisinic Artemsininic Arteannuin B 
Jlg mL-1 artemisninin Jlg mL-1 acid (DHAA) acid Jlg mL-1 
I:!gmL-1 I:!gmL-1 I:!gmL-1 
Mean quantity spiked into 2.50 5.05 5.08 32.72 30.88 2.49 
plant matrixa 
Quantities in blank matrix b 
Sample 1 2.49(-0.22%) 4.92(-2.58%) 5.49(7.95%) 32.86(0.42%) 35.24(14.13%) 2.61(5.03%) 
Sample 2 2.52(0.85%) 5.58(9.62%) 5.70(12.14%) 36.17(9.54%) 34.57(11.94%) 2.49 (0.0%) 
Sample 3 2.51(0.28%) 5.54(8.67%) 5.46(7.37%) 34.20(4.32%) 30 .30(-1.89%) 2.55(2.48%) 
Mean 2.51(0.30%) 5.35«5.30%) 5.58(6.83%) 34.41(4.76%) 33.37(8.06%) 2.55(2.48%) 
Standard error (SE) 0.04(0.24%) 0.21(3.95%) 0.08(1.50%) 0.96(2.64%) 1.54(5.02%) 0.04(1.47%) 
a mean of three determinations of spiked standards at 2.5 JIg mL-1 for artemisinin and arteannuin B, 5 JIg mL-1 for 9-epi-artemisinin and 
artemisitene. Dihydroartemisinic acid and artemisinic acid were spiked at 30 Ilg mL-1 each. b 3 determination of spiked standards in blank matrix 
(mobile phase of 0.1 % formic: 0.1 % formic in acetonitrile, 75:25) at similar concentration spiked into plant matrix. Percentage suppression or 
enhancement shown in brackets. 
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3.2.6 Limit of detection (LOD), Lower limit of quantification (LLOQ), and precision 
The guideline by the international conference on hannonization (ICH) (I.C.H.H.T, 
2005) for bio-analytical method validation were adopted for the defmition and 
determination of precision, LOD and LLOQ. The limit of detection is defmed as the 
lowest amount of analyte in a sample, which can be detected but not necessarily 
quantitated while lower quantification limit is the lowest amount of analyte in a 
sample, which can be quantitatively determined with suitable precision and accuracy. 
Both limits were calculated from the calibration curve following Miller and Miller 
(Miller and Miller, 2005). Injection precision (repeatability) was calculated with at 
least six determination of each analyte in a single day. The coefficient of variation 
(CV) for these determinations is below 10 % for all metabolites investigated (Table 
3.4). 
Within-day precision was determined for six concentration levels covering the analyte 
calibration range and making a total of 12-17 analyses on a single day. Between-day 
precision was calculated for the same calibration range on three different days spread 
over a month, resulting in a total of 32-40 determinations. The range for the accuracy 
for both within and between day precision determinations was from 81.42 - 118.81% 
while the coefficient of variance in both was less than 8.5% (Table 3.4). 
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Table 3-4. LOD, LLOQ, injection precision, within-day and between-day precisions. 
Artemisinin 9-Epi-artemisinin Artemisitene DHAA Artemisinic acid Arteannuin B 
LOD ()lg mL-1) a 1.3x10""4 l.OxlO-J 2.8xlO""4 2.0 xlO-1 3.3xlO-1 1.2x 1 0006 
LLOQ ()lg mL·1) b 4.lx10-4 3.0 xlO-J 8.4xI0-4 6.0xI0-1 9.9 xlO-' 3.5xlO-6 
Regression equation C y=857.32x+ 163.1 y=344x-35.84 y ==388.54x-21.01 y= 13 .98x+54.l6 y=21.64x +71.47 y=96645x+5947.7 
R2 value 0.99396 0.99623 0.99562 0.99408 0.99803 0.99547 
Injection precision d 
Mean ()lg mL-1) 5.67 (n=lO) 0.13 (n=8) 0.24 (n=7) 19.54 (n=6) nJa 0.32 (n=6) 
CV(%) 4.48 4.54 6.24 6.20 nJa 9.89 
Within and Between-day precision e 
Within day range (%) 93.22 - 114.20 83.09-106.61 86.04 - 116.35 87.26 -111.75 92.73 -118.81 82.32 -112.69 
(n==12) (n==16) (n=17) (n=14) (n=13) (n=15) 
CV(%) 7.26 5.92 7.60 7.96 7.10 7.70 
Between day range (%) 82.78-117.88 83.09 - 109.07 81.65 - 116.35 81.42 - 114.33 92.32-118.81 82.32 - 119.98 
(n=36) (n=37) (n=40) (n=38) (n=32) (n=37) 
CV(%) 7.86 6.47 7.37 8.30 ., 6.26 8.26 
a,b,c Calculation based on 12 point calibration graph and the following formulas LOD=¥B+3SB and LLQD=3LOD. Where ¥B is the signal equal to the 
blank signal (the y intercept), SB is standard deviation of the blank (the random error in the y-direction) (Miller and Miller, 2005). dInjection 
precision was assessed by n determination at 100% concentration. e Within and between-day precisions were determined over 6 concentration levels 
covering tbe calibration range for botb precisions. ilia - undetermined values below method's LLOQ. 
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3.2.7 Regression indices and dynamic range 
Good linearity (,z > 0.99) of the calibration curves for all the analytes of interest in 
both the mobile phase and the mobile phase spiked with the matrix is indicative of the 
robustness of the method (Table 3.4). The regression and sensitivity indices in Table 
3.4 are for the standards prepared in the mobile phase spiked with extracts of the 
glandless plant. The method is highly sensitivity for most of the analytes. LLOQ for 
arteannuin B is about 3.5 pg mL-1• However for dihydroartemisinic acid and 
artemisinic acid, the LLOQ is much higher at 0.6 and 1.0 J.lg mL-1 respectively. The 
dynamic ranges for these compounds reflect the same pattern with a lower range (0.15 
- 10 J.lg mL- 1) for all analytes except dihydroartemisinic acid and artemisinic acid 
with a range of3.75 - 120 J.lg mL-1• 
3.2.8 A rtemisinin, 9-epi-artemisinin and artemisitene 
Transitions used for the MSIMS analysis of artemisinin and 9-epi-artemisinin were 
2837219 + 229 + 247 + 265 and 283 -+ 209 + 219 + 247 + 265 respectively (Table 
2.1). The two analytes were differentiated based on their retention times as shown in 
Figure 3.4. We report here for the fIrst time the detection of 9-epi-artemisinin in a 
plant extract. The presence of 9-epi-artemisinin and artemisitene has been reported as 
impurities in artemisinin raw material (Stringham et ai., 2011, Stringham et ai., 
2009b, WHO, 2011). 
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Figure 3-4. Top - MRM chromatogram for 9-epi-artemisinin in A. annua extract also 
showing artemisinin content. Bottom - chromatogram of the same extract spiked at 5 ILg 
mL' \ of9-epi-artemisinin. 
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WHO has guidelines and recommendations for concentration limits for this isomer 
and other impurities in the raw material (WHO, 2011). However the source of the 
impurity has never been established. To verify the detection of the isomer in a plant 
extract by our method we employed a high-resolution mass accuracy approach using a 
Q-ToF instrument to examine the compound in the plant extract. Figure 3.5 shows 
extracted chromatograms, EIC (A and B) and high resolution MS, HRMS (C and D) 
data for the crude (untreated) extract and 9-epi-artemisinin standard at mlz 283. 
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Figure 3-5. Panels (A) and (B) are EIC for extracts and 9-epi-artemisinin standard 
respectively. Below panels are HRMS data for extract (C) and standard (D). 
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A comparison of the EIC chromatograms and the HRMS simulated spectrum for both 
extract and standard show a peak in the extract with the identical retention time as the 
9-epi-artemisinin standard and an HRMS data difference between both peaks of less 
than 2 ppm. This confIrms and validates the MRM results and establishes the 
presence of 9-epi-artemisinin in A. annua raw extracts. 
Acton and Klyman (Acton and Klayman, 1987), fIrst reported the isolation of 
artemisitene from plant extracts and its possible role in the biosynthetic pathway of 
... 
artemisinin has been suggested (Brown, 2010, Weathers et al., 2011). Acton and 
Klyman have also demonstrated the conversion of artemisinin into iso-artemisitene 
and 9-epi-artemisinin (Acton and Klayman, 1987). Table 3.5 shows the levels of 
artemisinin (3.1) and the related metabolites in four A. annua biomasses analysed by 
our method. The level of 9-epi-artemisinin in the analysed extracts was about tenfold 
lower than the detected levels of artemisitene in the extracts. 
Table 3-5. Levels of metabolites in four Artemisia biomasses. 
Artemisinin 9-Epi- Artemisitene DHAA Arteannuin 
Source of artemisinin B Biomass (mg g-l) (~g g-I) (~g g-I) (mg g-l) (~g g-I) 
BIONEXX 10.00 ±0.03 23.80±0.12 290.0±1.0 58.15±1.52 81.1O±1.05 
(Madagascar) 
Mediplant 1O.63±O.l1 12.70±0.07 389.0±4.0 67.38±1.22 168.60±2.l1 
(Switzerland) 
REAP 1O.66±0.01 12.40±0.06 11O.0±1.0 68.33±2.64 20.70±0.07 
(Kenya) 
ANAMED 6.45±0.08 1.60±0.0 64.0±4.0 37.71±1.01 2.30±0.0 
.LGerman~} 
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3.2.9 Dihydroartemisinic and artemisinic acids 
In our method, the MRM for dihydroartemisinic acid ([M+Ht = 237) and artemisinic 
acid ([M+Ht = 235) are similar (237/235 7 190 + 200 + 218, see Table 2.1). Three 
main peaks were observed in A. annua plant extracts for these transitions Figure 3.6). 
The standard peak for dihydroartemisinic acid (DHAA) in Figure 3.6, matched one of 
the main peaks while an impurity in the DHAA standard matched the second peak. 
We were unable to confIrm the composition of this impurity. The standard artemisinic 
acid peak at 5.86 minutes did not match any of the major peaks. A small peak in the 
plant extract with similar retention time to artemisinic acid standard was below the 
method's quantifIcation limit for the same (Table 3.4). This is consistent with work by 
Brown and Sy (Brown, 2010, Brown and Sy, 2004, Dhingra and Lakshmi Narasu, 
2001), who have shown that dihydroartemisinic acid rather than artemisinic acid is the 
true late-stage precursor to artemisinin in some A. annua chemotypes. 
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Figure 3-6. Panel (A) is MRM TIC chromatogram for A. annua plant extract monitored 
for artem isinic acid (235-+190+200+218). Panel (B) is MRM chromatogram for 
artemisinic acid standard at 40 p.g mL- t • Panel. (C) is MRM of plant extract monitored 
for DHAA (237-+190+200+218) and panel (D) shows MRM ofDHAA standard at 10 p.g 
L -t m . 
We also verified this result on the high resolution and mass accuracy Q-ToF 
instrument. The extracted ion chromatograms from the Q-ToF for A. annua extract, 
artemisinic acid standard and DHAA standard at mlz 235 and 237 respectively are 
shown in Figure 3.7 (left) with corresponding high resolution MS data (right). A 
small peak in both treated and untreated extract matched the retention time of the 
standard peak for artemisinic acid and a relatively larger peak in the extracts matched 
the standard peak for DHAA, confirming the results from the MRM based assay. 
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Figure 3·7. EIC at mlz 235 (artemisinic acid) and 237 (DHAA) showing EIC of extracts 
and standards (left) and HRMS data (right). 
Figures 3.5 and 3.6 shows peaks other than dihydroartemisinic acid and artemisinic 
acid in the extracts. The largest peak in Figure 3.5 C and D is likely a degradation 
product of dihydroartemisinic acid or an intermediate in the conversion of 
dihydroartemisinic acid to artemisinin, which we also observed in the stressed 
dihydroartemisinic acid reference standard. 
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3.3 Conclusions 
In this study we evaluated the levels of impurities in artemisinin raw material as 
possible markers for traceability. The impurities seem to be purification process 
dependent rather than geography dependent. We also reported the development and 
validation of a fast, simple, sensitive and selective analytical HPLC-MSIMS-ESI 
MRM method for the determination of artemisinin, 9-epi-artemisinin, artemisitene, 
dihydroartemisinic acid (DHAA), artemisinic acid and arteannuin B in A. annua crude 
extracts. Using this method we report for the first time the presence of 9-epi-
artemisinin in A. annua extracts. Validation indices evaluated were satisfactory. 
Linearity (..z) in native matrix were> 0.99 for all analytes while the LOD was at least 
0.3 j..tg mL-1 for artemisinic acid and sensitivity as high as 1.2 pg mL-1 was obtained 
for arteannuin B. LLOQ was between 1 j..tg mL-1 for artemisinic acid and 3.5 pg mL-1 
for arteannuin B and a dynamic range of 0.15 -10 j..tg mL-1 for all the analytes except 
DHAA and artemisinic acid with a range of 3.75 -120 j..tg mL- I . The accuracy was 
between 82.32% and 116.35% and the within day and between day variation for 
determinations covering the calibration range for all metabolites was < 19%. 
Therefore showing the method to be robust, quick, sensitive and adequate for a range 
of applications including high throughput (HTP) analysis. 
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CHAPTER 4. ANTI-PLASMODIAL POLYVALENT INTERACTIONS IN 
ARTEMISIA ANNUA L. EXTRACTS - POSSIBLE SYNERGISTIC AND 
RESISTANCE MECHANISMS 
4.1 Introduction 
The use of Artemisia annua (Qing Hao) in traditional Chinese phannacopeia includes 
the treatment of fevers and chills (Hsu, 2006a, Wright et al., 2010). In the 1970s the 
active principle in the extract was isolated and identified as artemisinin (4.1, scheme 
4.1), a sesquiterpene lactone. Artemisinin and its derivatives have now been 
established in various combination therapies (ACTs) as effective anti-malarial 
treatments against multi drug-resistant P. Jalciparum infection (Haynes, 2006, Weina, 
2008). In some parts of Asia and Africa, a hot water infusion (tea) of the plant is used 
as a self-medication for malaria. The use of tea in this way has raised concern of the 
possible development of parasite resistance as a result of un-standardized use of 
artemisinin in these tea preparations (Jansen, 2006). 
The recipes in ancient Chinese texts for preparing Qing Hao extracts for the treatment 
of fevers include soaking, followed by wringing or pounding, followed by squeezing 
the fresh herb (Wright et al., 2010, Hsu, 2006a, Hsu, 2006b). In their study, Rath et 
al. (Rath et al., 2004) found that adding boiling water to the leaves, stirring briefly 
and leaving covered for 10 min, and filtering and gently squeezing the leaves to 
release residual water gave the best extraction efficiency (86%) for artemisinin in the 
preparation, relative to the total amount of the compound in leaves. In the literature, a 
range of aqueous extraction efficiencies (25-90%) has been reported for artemisinin 
(Rath et al., 2004, De Ridder et al., 2008, Van der Kooy and Verpoorte, 2011). Due to 
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the differences in the content of artemisinin in tea preparation, Vander Kooy and 
Verpoorte (Vander Kooy and Verpoorte, 2011) quantified artemisinin in tea prepared 
by different methods. 
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Scheme 4.1. Structures of some artemisinin related compounds, flavonoids and acids 
identified in A. annua extract. 
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They observed that extraction efficiency was temperature-sensitive and that 
efficiencies of above 90% were attainable. Regardless, the amount of artemisinin in 
these extracts cannot fully account for its effectiveness against Plasmodium parasites 
in vitro and in vivo (Jansen, 2006, Rath et al., 2004). Apart from artemisinin, there are 
around 30 other sesquiterpenes and over 36 flavonoids identified in the plant (Scheme 
4.1), some of which have shown limited anti-malarial properties (Willcox et aI., 
2004). Five flavonoids, including casticin (4.7), have been shown to potentiate the 
activity of artemisinin (Liu et al., 1992, Elford et al., 1987). Interestingly, the 
potentiating effect of these flavonoids was not observed with chloroquine. Billia et al. 
(Bilia et al., 2002) observed that although these flavonoids have no effect on hemin 
(chloroferriprotoporphyrin) themselves, they do catalyze a reaction between 
artemisinin and hemin. 
Weathers and Towler (Weathers and Towler, 2012) have shown that poly-
methoxylated flavonoids like casticin are poorly extracted and unstable in the aqueous 
tea infusion. This suggests that compounds other than this class of flavonoids are 
likely responsible for the reported improvement in the potency of artemisinin in tea 
infusion. A recent analysis by Cabonara et ai. (Carbonara et aI., 2012) of tea prepared 
from A. annua leaves by infusion in hot water for I, 24 and 48 hours, identified a 
series of caffeoyl and feruloyl-quinic acids as main components of the infusion, 
together with some flavonoids. Chlorogenic or caffeoylquinic acids (CQAs) are 
esters of caffeic and quinic acids (Scheme 4.1). They possess a broad spectrum of 
pharmacological properties, including antioxidant, hepato-protectant, antibacterial, 
anti-histaminic, chemo-preventive and other biological effects (Belkaid et ai., 2006, 
Zhang et ai., 2008, Feng et ai., 2005, Miketova et ai., 1999). 
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To our knowledge, only the interactions of artemisinin with the poorly extracted poly-
methoxylated flavonoids found in Artemisia tea have been studied. This study 
therefore aims at the understanding of other possible interactions and mechanisms 
involved in artemisinin activity in the plant extracts, and the effects of these 
interactions on parasite resistance to artemisinin. 
4.2 Results and discussions 
Two sets of in vitro experiments were carried out. The initial anti-plasmodial 
evaluation of Artemisia extracts was carried out in Liverpool School of Tropical 
Medicine using products of sequential extraction in various polarity of solvents. 
Based on the results of this a follow-on analysis was done at the Centre for Infectious 
Diseases, George Town University, USA. 
4.2.1 Fractionation and extraction yield 
Figure 4.1 shows the extraction and fractionation scheme employed and the 
corresponding percentage yield obtained. Methanol (13.4%) was the best extractant 
of all the three organic solvents used in crude extraction. The yield from tea 
preparation was 23.4%, although a comparatively larger volume of liquid (lliter) was 
employed in this extraction. 
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Figure 4-1. Fractionation scheme for A. annua plant extracts used in P./aiciparum 
assay. 
The artemisinin content of the fractionated and the crude extracts are shown in Table 
4-1. Artemisinin was effectively partitioned into acetonitrile from the hexane extract; 
however de-fatting with hexane did not totally extract all the artemsinin in the 
biomass. The residual amount left in the marc was carried over into the methanol 
extraction and portioned into chloroform. The water fraction was also artemsinin free. 
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Methanol proved to be the best extractant for artemisinin (9.72mg g-! of biomass) of 
all the solvents used. 
Table 4-1. Artemisinin in fractionated and crude extracts. 
Fractions Amtof Total artemisinin 
artemisinin mg mg 
(per 100mg) (per 109 biomass) 
Acetonitrile 26.4 31.2 
Hexane 0.0 0.0 
Chloroform 3.3 12.7 
Water 0.0 0.0 
Crude Extracts ... 
Hexane 20.1 66.8 
Ethy 1 acetate 8.2 80.2 
Methanol 7.2 97.2 
Water (Tea) 0.58 13.5 
4.2.2 Metabolite profile of Artemisia extract 
The metabolites in the aqueous extract analysed by both MSIMS and HPLC methods 
and their quantities in milligrams per litre of extract is shown in Table 4.2. The 
compounds analysed were based on the in extenso analysis by Carbonara et ai. 
(Carbonara et ai., 2012), who showed them to be the major metabolites 
(quantitatively) in Artemisia tea infusions. In addition, artemisinin related 
compounds, which we have previously detected in such extracts, were also included. 
The level of artemisinin reported (Vander Kooy and Verpoorte, 2011, Rath et al., 
2004, Carbonara et al., 2012, De Magalhaes et al., 2012, Wright et al., 2010) for tea 
extract is varied and the values obtained in this study (47.5 mg L-!) are within the 
reported range of artemisinin content. These differences could be due to tea 
preparation methods and the biomass cultivar used. Carbonara et al. (Carbonara et 
al., 2012) used a solvent to biomass ratio of 26:1 (v/w), while this study, as well as 
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others (Van der Kooy and Verpoorte, 20 II, Rath et al., 2004), employed the 
therapeutically recommended ratio (200:1, v/w or 5 g L-1) (Willcox, 2009). 
Table 4-2. Metabolites in the aqueous Artemisia extract analysed by both MS/MS and 
HPLC methods quantified as milligrams per litre of tea. 
Amount 
Compound 
(mg L-1 oftea) 
Artemisinin 47.5±0.8 
Arteannuin B 1.3±0.0 
Dihydroartemisinic acid 70.0±0.3 
Caffeic acid 0.8±0.00 
3,5-Di-caffeoylquinic acid 57.0±1.7 
3-Caffeoylquinic acid 72.0±1.6 
4-Caffeoylquinic acid 20.4±1.6 
4,5-Di-caffeoylquinic acid 31.6±4.0 
5-Caffeoylquinic acid 9.0±0.7 
Isovitexin 105.0±7.2 
Rosmarinic acid l.l±O.O 
Dihydroartemisinic acid (4.4) (70 mg L- 1) and arteannuin B (4.5) (1.3 mg L-1) are the 
only biosynthetic precursors of artemisinin detected in the tea extract using our 
method. Therefore artemisinin is the only compound among the metabolites we 
analysed in the tea with significant (ICso <I ~M) anti-plasmodial activity (Table 4.3). 
3-Caffeoylquinic acid (4.11) was found to be the most abundant (72 mg L-1) of the 
caffeic acid derivatives (4.11-4.17) in the analysed extract, followed by 3,5-di-
caffeoylquinic acid (4.15) (57 mg L-1). Caffeic acid (4.10) was the least abundant (0.8 
mg L-1) of the evaluated acids. Isovitexin (4.8) was the only flavonoid analysed (l05 
mg L-1), being relatively abundant in our extract. Some classes of flavonoids have 
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poor aqueous solubility and limited profiles of these compounds in aqueous extract 
have been reported (Weathers and Towler, 2012, Carbonara et al., 2012). Lower level 
of rosmarinic acid (4.9) (1.1 mg L -I) was detected in our samples, compared to the 
levels found by De Magalhaes et al. (De Magalhaes et ai., 2012). However, they 
reported widely different concentrations in the cultivars and samples they analysed 
and this acid was not detected at all in the analysis by Carbonara et ai. (Carbonara et 
ai., 2012). Van der Kooy and Verpoorte have also shown that the method employed in 
preparing the hot water infusion does affect the amount of artemisinin and therefore 
other co-metabolites extracted (Van der I('ooy and Verpoorte, 2011). These 
differences in profiles and concentration levels of metabolites seem to suggest that 
composition of prepared tea infusions differ and is significantly influenced by 
geography of growth area and the Artemisia cultivar used. 
4.2.3 Activities of A. annua extract fractions in choroqine (CQ) sensitive parasites 
The half-maximal response data (IC50) of fractionated and crude extracts in a 
plasmodium assay are shown in Figures 4.2, 4.3 and 4.4. Pure artemisinin and 
artesunate, a more bio-available analogue of artemisinin were positive controls. A 
solvent control was employed and Artemisia tea with reported (De Donno et ai., 
2012) synergistic anti-plasmodial effect was used both as control and as a treatment. 
Figure 4.2 and 4.3 shows the IC50 for tea infusion at 50 mg mL-1 (TEA50) and 25 mg 
mL-1 (TEA25) and suggests that the tea extracts were about 3.8 times and 2.2 times 
more potent than pure artemisinin respectively. 
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Figure 4-2. Dose-response curve for fractionated and crude extracts. TEA 25, 50 = 25 
and 50mg mL-1 Artemisia tea. Art = artemisinin, AAN = artemisinin + acetonitrile 
fraction, ACL50 = artemisinin + 50 mg mL-1 chloroform fraction. CL50 = 50 mg mL-1 
chloroform fraction. A WR50 = artemisinin + 50mg mL-1 water fraction. 
The fIrst set of results obtained fonn the plasmodium assay (Figure 4.3) shows the 
ICso of most of the fractions was similar (7.1 - 8.5 nM) to pure artemisinin (8.03 nM), 
the exception being the chlorofonn (CL50 - ICso = 1O.5nM) fraction with 
comparatively lower level of artemisinin. Among the crude extracts, hexane (HXC) 
had signifIcantly lower ICso of 4.7 nM while ethyl acetate and methanol had ICso 
comparable to that of pure artemisinin. 
91 
12 
.-. 
10 
= .... r 
= .... 8 I III 
·s 
<iI 
1:: 6 
rei 
...... 
~ 4 
= 0 U'l 
~ 
- 2 
0 
c:> lJ') ~ Z c:> c:> c:> c:> lJ') ~ r-. M ~ ~ ~ V) lJ') N :! lJ') lJ') c:> lJ') N M Il5 ex) ~ :z:: ~ < < < ...:l ...:l ,... ~ c:x:: M ,... >< ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ < < < E- E- < < < < 
Figure 4-3. IC50 for artemisinin and extract fractions (first data set). TEA 25, 50 = 25 
and 50 mg mL-1 Artemisia tea. Art = artemisinin, AAN = artemisinin + acetonitrile 
fraction, ACL50 = artemisinin + 50 mg mL- t. chloroform fraction. CL50 = 50 mg mL- t 
chloroform fraction. A WR 25, 50 andl00 = artemisinin + 25, 50 and 100 mg mL-1 water 
fraction. AHX 8.3, 16.7 and 33.3 = artemisinin + 8.3, 16.7 and 33.3 mg mL-1 hexane 
fraction. AEEC = artemisinin + Ethyl acetate crude extract. AHXC = artemisinin + 
hexane crude extract. AMHC = artemisinin + methanolic crude extract. ARTES = 
artesunate 
A second analysis (Figure 4-4) of the same fractionated extract shows a similar pattern 
but with improved ICso for the crude extracts (5.1 -5.3 nM) compared to pure 
artemisinin (6.5nM). The improvement observed for crude extracts compared to 
artemisinin were not significant due to the relatively large variation within treatments. 
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Figure 4-4. ICso for artemisinin and extract fractions (second data set). TEA 25, 50 = 25 
and 50 mg mL-1 Artemisia tea, Art = artemisinin, AAN = artemisinin + acetonitrile 
fraction, ACL50 = artemisinin + 50 mg mL-1 chloroform fraction, CL50 = 50 mg mL-1 
chloroform fraction, A WR 25,50 and100 = artemisinin + 25, 50 and 100 mg mL-1 water 
fraction, AHX 8.3, 16.7 and 33.3 = artemisinin + 8.3, 16.7 and 33.3 mg mL-1 hexane 
fraction, AEEC = artemisinin + ethyl acetate crude extract. AHXC = artemisinin + 
hexane crude extract. AMHC = artemisinin + methanolic crude extract, ARTES = 
artesunate. 
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4.2.4 Activities of A. annua extracts and compounds in chloroquine resistant (CQR, 
Dd2) and sensitive (CQS, Hb3) parasites 
Table 4.3 shows ICso anti-plasmodial values for pure compounds and extracts of 
Artemisia plant. An approximate seven-fold and two-fold potentiation of artemisinin's 
activity was observed in Artemisia aqueous (tea) and ethanolic extracts respectively, 
in both parasite strains. Only artemisitene (4.3) (ICso, 114.0/95.0 nM, Hb31Dd2) and 
9-epi-artemisinin (4.2) (ICso, 61.0/63.5 nM, Hb31Dd2) showed significant anti-
plasmodial activities (ICso <1 JlM) among the artemisinin biosynthetic precursors 
evaluated. 9-epi-artemisinin and artemisitene ""respectively showed about one third 
and one fifth of the activity of artemisinin. Acton et al. observed a similarly reduced 
activity for 9-epi-artemisinin and artemisitene, compared to artemisinin in D6 and W2 
strains of P. falciparum (Acton and Klayman, 1987, Acton and Klayman, 2007). 
Artemisinin has a chiral molecular structure and the bioactivity of the molecule is 
influenced by its absolute configuration. 
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Table 4-3. ICso of extracts and components of A. annua in CQ-sensitive (HB3) and 
resistant (Dd2) strains. 
ICso (oM) 
Compound/extracts Hb3 strain Dd2 strain 
Chloroquine (CQ) 23.3 205.1 
Artemisinin 21.7 20.3 
Artesunate 8.5 4.6 
Artemisitene 114.0 95.0 
9-epi -artemisinin 61.0 63.5 
Artemisia aqueous extract 3.1 3.2 
Artemisia ethanol extract 8.8 11.4 
ICso (f.1M) 
Artemisinic acid 74.8 39.1 
Arteannuin B 3.4 6.6 
Dihydroartemisinic acid 31.3 33.6 
Caffeic acid 59.4 35.6 
3-Caffeoylquinic acid 102.9 124.1 
4-Caffeoylquinic acid 113.2 41.6 
5-Caffeoylquinic acid 151.9 93.6 
3,4-Caffeoylquinic acid 33.4 36.1 
4,5-Caffeoylquinic acid 34.0 36.7 
3,4,5-Caffeoylquinic acid 185.6 99.6 
Rosmarinic acid 84.7 50.2 
Isovitexin 84.7 50.2 
Casticin 10.0 13.5 
To investigate if solubility of these artemisinin analogues could be partially 
responsible for the reduced activity, we determined the aqueous solubility of 
artemisinin, artemisitene and 9-epi-artemisnin. 
Table 4.4 shows the solubility of these compounds at experimental conditions. 
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Under these conditions, 9-epi-artemisinin has a higher solubility, about twice that of 
artemisinin or artemisitene. The lower bioactivity could not be explained based on the 
solubility data alone, although the experimental data were obtained at 22°C. 
Table 4-4. Solubility in mg L-1 of artemisinin, artemisitene and 9-epi-artemisinin in 
water at 22°C and atmospheric pressure. 
Compound 
Artemisinin 
Artemisitene 
9-Epi-artemisinin 
Solubility / mg L-1 at 22°C 
74.27±2.l0 
74.2l±2.99 
133.08±5.44 
Woerdenbag et al. observed that the anti-cancer activity of ll-hydroxy-ll-epi-
artemisinin (CII in older and C9 in newer references for the structure) was about 
threefold less than the conformer (Woerdenbag et al., 1993b), which is the same 
threefold difference we observed in anti-malarial activity for epimerisation at C9 
(Table 4.4). If the threefold activity difference is consistent regardless of the 
differences in molecular targets and effect, this may suggest a common upstream 
differentiation point of molecule activation. The lower activity of 9-epi-artemsinin 
may therefore be due in part to a structural conformation that is relatively more 
difficult to activate compared to artemisinin. 
4.2.5 Antagonism of artemisinin with biosynthetic precursors 
Figure 4.5 shows the interaction of artemisitene and 9-epi-artemisinin with 
artemisinin and artesunate (4.6). These biosynthetic precursors of artemisinin have 
significant anti-malarial activities (Table 4.3). The interaction of artemisinin with 9-
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epi-artemisinin and artemisitene was antagonistic, but the interaction of these 
compounds with artesunate was additive in both chloroquine sensitive (Hb3) and 
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Figure 4-5. Isobologram of 9-epi-artemisinin and artemisitene with artemisinin (top) 
and artesunate (bottom) in CQS (HB3 (Jeft) and CQR (Dd2) (right) strains. ART = 
artemisinin, ATSU = artesunate, EPI = 9-epi-artemisinin, ATENE = artemisitene. 
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The reason for the observed antagonistic interaction with artemisinin at the 
combinations investigated is unclear. Structurally, artemisinin, 9-epi-artemisinin and 
artemisitene are differentiated at C9. The difference from artemisinin is epimerisation 
of the methyl group for 9-epi-artemisinin and a methylene group attached instead for 
artemisitene (Scheme 4.1). Given the minor structural differences, it is likely that 
these compounds have identical molecular targets and therefore possibly compete for 
these when combined. Conversely, due to the relatively larger difference in structure 
and mass of artesunate and 9-epi-artemisinin or artemisitene, these compounds, when 
combined, may act on the same targets as wellas on different molecular targets with 
the possibility of positive polyvalent interaction. Similarly, Wagner (Wagner and 
Ulrich-Merzenich, 2009, Wagner, 2011, Wagner, 2005) has reported an in vitro 
synergistic inhibitory effect upon combining ginkgolides A and B from Ginkgo bi/oba 
extract for PAF-induced thrombocyte-aggregation. The difference between ginkgolide 
A and B is an oxygen atom (16 Da). 
4.2.6 Pharmacokinetic interactions responsible for potentiation of extracts 
The above result showing that the two other compounds in the extract with significant 
anti-plasmodial activity (lC50 <1 IlM) interact antagonistically with artemisinin 
suggests that the in vitro anti-malarial potency enhancement for aqueous (tea) and 
ethanolic extracts is probably due to interaction between artemisinin and some other 
compound(s) in the extracts. Pharmacokinetic interactions are improvements due to 
increased solubility, re-sorption rate and/or enhanced bioavailability (Wagner and 
Ulrich-Merzenich, 2009, Williamson, 2001). 
98 
4.2.7 Other combination analysis 
Table 4.5 shows the interaction of co-metabolites in Artemisia extracts with 
artemisinin. In the CQ-sensitive (HB3) strain, 3-caffeoylquinic acid (3CA) showed 
additive interaction at 1:3 (v/v), which became synergistic at higher ratio of the acid 
to artemisinin (l: 10, 1: 100 v/v). For casticin, the interaction at 1:3 (artemisinin to 
casticin, v/v) is antagonistic. Synergistic interaction is however reported (Elford et al., 
1987, Liu et al., 1992) for combination ratios at the range of 1:10-1000 (artemisinin to 
casticin, v/v). 
Therefore, using the FIC index of casticin (1.9) as a benchmark for potential positive 
interactions, compounds like isovitexin, caffeic acid and dihydroartemisinic acid that 
show antagonistic interactions at 1:3 may also, like casticin, interact synergistically at 
a higher ratio. Rosmarinic acid was synergistic at a 1:3 combination with artemisinin 
(v/v) and some chlorogenic acids were additive at this combination also. These 
compounds showing positive interactions with artemisinin may collectively be 
responsible for the potentiation of artemisinin in the tea extract. Arteannuin B and 
artemisinic acid are poorly extracted in the aqueous extract, but may contribute to the 
synergy observed in the alcoholic extract. 
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Table 4-S. Anti-plasmodial interactions of co-metabolites with artemisinin in CQ-
sensitive (HB3) and CQ-resistant (Dd2) strains. Art = artemisinin, CA = caffeic acid, 
3CA = 3-caffeoylquinic acid, 4CA = 4-caffeoylquinic acid, SCA = S-caffeoylquinic acid, 
3,4 CA = 3,4-di-caffeoylquinic acid, 3,SCA = 3,S-di-caffeoylquinic acid, 4,SCA = 4,S-di-
caffeoylquinic acid, TCA = 3,4,S-tri-caffeoylquinic acid, ISO = siovitexin, CAS = 
casticin, ATCID = artemisinic acid, ARTB = arteannuin B, RA = rosmarinic acid, 
DHAA = dihydroartemisinic acid, ARTENE = artemisitene. 
ICJO (~"') HB3 Dd2 
Combination ComDound H83 Dd2 FIC .... FIC ••• FIC , .. Inte raction FIC~ Flbt. FlCm- Interaction 
1:3 ART 0.0172 0.0294 0.411 1.160 1.570 AntagonsUe 0.748 3.298 4.046 AnlagontSbe ART:CA CA 68.9 117.4 
1:3 ART 0.0143 0.0283 0.341 0.831 1.172 Additive 0.720 1.367 2.088 Anlagolll be ART: 3CA 3CA 85.5 169.7 
1:10 ART 0.0044 0.0081 0.105 0.580 0.685 Synorglstle 0.206 0.881 1.087 Additive ART:3CA 3CA 59.7 109.3 
1:100 AIlT ~ OJ)004 I 0.0007 0.010 0.772 0.781 Synergl,tlc 0.018 1.160 1.177 Additive ART:3CA 3CA 79.4 143.9 
1:3 ART ·0.0164 0.0303 0.391 0.696 1.088 Additive 0.771 3.495 4.266 Anlagonlsbe ART:4CA 4CA 78.8 145.4 
1:3 ART 0.0139 0.0259 0.332 0.596 0.928 Additive 0.659 1.801 2.460 Anlagonsbc ART:SCA SCA 90.5 168.6 
1:3 ART 0.0269 0.0601 0.642 1.611 2.253 AntagoniStic 1.529 3.332 4.862 AntagontSue ART:34CA 34CA 53.8 120.3 
1:3 ART 0.028 0.0594 0.668 1.644 2.312 Antagonl~tie 1.511 3.237 4.749 AnlagonlSbe ART:35CA 3SCA 55.9 118.8 
1:3 ART 0.0264 0.06 0.630 1.685 2.315 Antagon tic 1.527 3.318 4.844 Anlagon! tiC ART:45CA ' SeA 52.9 120.1 
1:3 ART 0.0313 0.0568. 0.747 0.473 1.220 Additive 1.445 1.595 3.041 AnlagMsbc ART:TCA TCA 87.7 158.9 
1:3 ART 0.0259 0.0567 0.618 0.916 1.534 Anlagonl tic 1.443 3.386 4.829 Anlagonlsbe ART:ISO ISO 77.6 170 
1:3 ART 0.0143 0.0284 0.341 1.580 1.921 Antagon tic 0.723 2.311 3.034 Antagonisbc ART:CAS CAS 15.8 31.2 
1:3 ART 0.0162 00271 0.387 1.080 1.467 Additive 0.690 3.463 4.152 Anlagonlsuc ART:ATCID ATCIO 80.8 135.4 
1:3 ART 0.0143 0.0039 0.341 0.909 1.250 Additive 0.099 0.242 0.342 Syn rgls~c ART:ARTS ARTB 3.09 1.6 
1:3 
.ART ... o.olAl ,..0.0315 0.356 0.535 0.890 Syn rglstle 0.802 4.150 4.952 AntagonlsbC ART:RA RA 74.3 151.3 
1:3 ART i 0.0182 00392 0.434 1.366 1.801 AntagOOisUe 0.997 1.863 2.861 AnlagOntSbc ART:OHAA OHAA 29.1 62.6 
1:3 ART 0.0356 0.0643 0.850 2.631 3.480 Antagon$tle 1.636 5.366 7.002 Anlagonsbc ART:ATENE ATENE 0.2136 03858 
ART 0.0419 00393 1 1 . 
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Casticin and 3-caffeoylquinic acid (3CA) are polyphenolic compounds that are 
natural anti-oxidants. Endogenous anti-oxidants at cellular redox sites are 
considered a "double edge sword" able to act either as anti-oxidant or pro-oxidant 
depending on conditions such as dosage levels and presence of metal ions (Y ordi 
et al., 2012, Nemeikaite-Ceniene et al., 2005). This "double edge sword" 
characteristic of anti-oxidant polyphenols could help explain our observation. At a 
lower combination with artemisinin, casticin and 3CA were anti-oxidative 
towards the ROS and carbon-centred radicals formed from artemisinin activation 
and, as a result, countered artemisinin activity in vitro. Conversely, at a higher 
concentration ratio to artemisinin, casticin and 3CA were pro-oxidative, 
enhancing the oxidative stress resulting from the activation of artemisinin and 
leading to improvement in potency for artemisinin. A schematic isobologram to 
describe the interaction between an active pharmaceutical ingredient (API) like 
artemisinin (A) and synergists like casticin and 3CA (B, non-API) is shown in 
Figure 4.6. 
Substance A 
(API) 
Anatgonism at lower 
B concentration 
Synergy at higer 
B concentration 
Substance B 
(Non-API) 
Figure 4-6. A schematic isobologram of the observed interactions. 
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4.2.8 Possible role of anti-oxidant defence network in resistance 
Rosmarinic acid at the combination ratio evaluated had a potentiating effect (FICindex 
0.89) on artemisinin in CQ-sensitive (HB3) strain (Table 4.5) but this effect was not 
reproduced in the resistant (Dd2) strain; rather a strong antagonistic effect (FICindex 
4.95) was observed. The effect of rosmarinic acid on the ability artemisinin to 
mitigate the resistance mechanism of the parasite could be partly explained by the 
fmding of CuI et al and others who observed that in vitro resistance in P. falciparum 
is associated with increased pfmdr-l copy number and anti-oxidant activity (Cui et 
al., 2012,Sidhu et al., 2006). Some experiments with rosmarinic acid have reported 
strong anti-oxidant activity for the compound that is over three times that of trolox 
(Erkan et al., 2008, Petersen and Simmonds, 2003, Tepe et al., 2007). In the presence 
of rosmarinic acid, anti-oxidant activity may further be elevated thereby promoting 
increased resistance. A similar trend of activity in sensitive and resistant strains in 
combination with artemisinin was observed for caffeic acid, 4-caffeoyl-quinic acid 
(4.12) and isovitexin with reported anti-oxidant properties (GUl9in, 2006, Xu et al., 
2012, Cao et al., 2011). This seems to confmns the possible role of the anti-oxidant 
defence network in parasite resistance to artemisinin (Bozdech and Ginsburg, 2004). 
4.2.9 Arteannuin B selectively potentiates the activity of artemisinin against 
parasite defence system 
Arteannuin B at 3:1 (v/v) combination with artemisinin showed additive or no 
interaction (FICindex 1.25) in the CQ-sensitive strain and a synergistic interaction 
(FICindex 0.34) in the resistant parasite strain (Table 4.5). This is about a three-fold 
improvement in artemisinin's potency against CQ-resistant P. falciparum. This is not 
reproduced in the CQ-sensitive strain. The potentiation of artemisinin by arteannuin 
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B seems to be selectively directed at the parasites' chloroquine resistance mechanism. 
This combination could therefore help to better understand the mechanism(s) 
involved in parasite defence against artemisinin analogues and other anti-malarials. 
Reproducing this three-fold improvement in potency with other artemisinin analogues 
could help in the development of therapeutics effective against emerging drug-
resistant strains. 
Arteannuin B is an unusual a-methylene-y-lactone, transfused via a tertiary hydroxyl 
group (Agrawal et al., 1991). This strUcture could account for its easy 
fragmentation/ionisation observed in mass spectrometry and reported facile 
rearrangement in acidic conditions (Lansbury and Mojica, 1986, Suberu et al., 
20 13 a). 
4.3 Conclusions 
In this study we examine interactions between artemisinin and co-metabolites found 
in A. annua plant extracts for chloroquine sensitive (CQS; HB3) and resistant (CQR; 
Dd2) P. falciparum malarial parasites. Potentiation of artemisinin anti-malarial 
activity was observed in the plant extracts. The aqueous extract showed 
comparatively superior potentiation (about seven-fold) over the ethanolic extract 
(about two-fold). When pure compounds were combined, 9-epi-artemisinin and 
artemisitene interacted antagonistically with artemisinin at the combinations 
evaluated. 9-epi-artemisinin and artemisitene were the only artemisinin-related 
metabolites with significant anti-plasmodial activity (ICso <1 !J.M) among those 
evaluated.· 
103 
In CQ-sensitive parasites, caffeic acids and their chlorogenic acid derivatives showed 
additive interactions with artemisinin at the combination ratio evaluated. 3-
Caffeoylquinic acid's interaction with artemisinin turned synergistic with the 
increased ratio of the former in the combination. Rosmarinic acid showed synergistic 
interaction with artemisinin in the drug sensitive strain but the interaction with 
artemisinin in the drug resistant strain was strongly antagonistic at the same level of 
combination. This antagonistic interaction in CQ-resistant parasites was also 
observed for caffeic acid and some of its derivatives known to have anti-oxidant 
properties. The observation seems to confrrm"literature evidence (Cui et at., 2012, 
Sidhu et at., 2006) for a potential role of anti-oxidants in parasite drug resistance. 
Therefore the effect of dietary anti-oxidants on artemisinin combination therapies 
used in the management of drug resistant P. Jalciparium malaria may need to be 
further investigated. 
Arteannuin B was found to selectively potentiate the activity of artemisinin in Dd2 
parasites, suggesting some interaction with the CQR mechanism, since the 
potentiation of artemisinin by arteannuin B was not reproduced in CQS parasites. As 
a result of this specificity, arteanniun B could potentially be used as a probe to better 
understand parasite drug resistance mechanisms and the combination might prove 
useful for treating CQR strains of malaria. 
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CHAPTER 5. COMPARATIVE CYTOTOXICITY OF ARTEMISININ AND 
CISPLATIN AND THEIR INTERACTIONS WITH CHLOROGENIC 
ACID IN MCF7 BREAST CANCER CELLS. 
5.1 Introduction 
Cancer is a major public health problem with about 7.6 million deaths in 2008 and 
projected to increase to over 13 million in 2030 (Ferlay et ai., 2010). Although a 
range of treatment options are available in many cases these therapies are fraught with 
significant levels of toxicity to healthy cells and in some treatment regimes drug-
resistance is emerging (Crespo-Ortiz and Wei, 2011, Hsiao and Liu, 2010). To reduce 
the current cancer burden, drug discovery is being directed at developing highly 
effective and potent medications with considerably lower side effects. 
The role of natural products as a rich source of new bioactive molecules and the 
properties and mechanism of action of anti-malaria agent artemisinin has been 
discussed in Chapter 4. 
The in vitro cytotoxic activity of artemisinin (5.1, Scheme 5.1) and its derivatives 
have been reported in different cancer cell lines including drug-resistant cell lines 
(Gravett et ai., 2011, Singh and Lai, 2004, Sadava et ai., 2002, Efferth et al., 2004). 
Sigh and Lai showed that a combination of dihydroartemisinin (5.5) and halo-
transferin effectively killed radiation resistant breast cancer cells (Singh and Lai, 
2004), while artemisinin pretreated with holo-transferin was also found to be effective 
on both the drug sensitive and multi-drug resistant human lung carcinoma (SCLC) 
cells (Sadava et al., 2002). Artesunate (5.6) inhibited the growth of highly angiogenic 
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Kaposi sarcoma cells showing the anti-angiogenesis effect of artemisinins (Dell' Eva 
et al., 2004). 
(5.1) artemisinin 
~rf a"b>?;cHa 
o 
(5.4) arteannuin B 
(5.7) cisplatin 
Cafl'eoyJ group (CA) 
(5.10) caffeic acid 
(5.11-5.17) quinic acid 
o 
"~D5 0 HJC~ 
HO 
(5.2) artemisitene (5.3) dihyroartemisinic acid 
H,m' 
""trpvCy" 
OH CH, 0 
(5.5) dihydroartemisinin (5.6) artesunate 
OH ~I 
""'" 
H e
OH 
I 
OH 
H~O""'" 0 OH 
H~ 
OH 
(5.8) isovitexin (5.9) rosmarinic acid 
R\ R2 R3 
(5.11) 3-caffeoylquinic acid CA H H 
(5.12) 4-caffeoylquinic acid H CA H 
(5.13) 5-caffeoylquinic acid H H CA 
(5.14) 3,4-di-caffeoylquinic acid CA CA H 
(5.15) 3,5-di-caffeoylquinic acid CA H CA 
(5.16) 4,5-di-caffeoylquinic acid H CA CA 
(5.17) 3,4,5-tri-caffeoylquinic acid CA CA CA 
Scheme 5.1. Some compounds found in Artemisia aqueous extract (Tea) and cisplatin. 
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The in vivo anti-proliferative bioactivities of artemisinins have also been reported. 
Chen et al. implanted nude mice with human ovarian cancer cells and found that 
artesunate decreased tumour growth and significantly lowered vascular endothelial 
growth factor (VEGF) expression in the cells (Chen et al., 2004). The potential of 
artemisinin to prevent the development of breast cancer in rats treated with a known 
carcinogen (7,12 dimethylbenz [a] anthracene, DMBA) has been reported (Lai and 
Singh, 2006). Artesunate has also been successfully used in combination to standard 
chemotherapy to treat metastatic melanoma in human subjects after standard 
chemotherapy alone was ineffective in stopping tumour growth (Berger et al., 2005). 
Several workers have investigated the mechanisms of the selective cytotoxicity of 
artemisinin and its derivatives against neoplastic cells. Mercer et al. showed that 
selective activation of the trioxane bridge via carbon centred radicals occurs in rapidly 
dividing or susceptible cells (Mercer et al., 2007). This then results in mitochondrial 
membrane depolarization leading to induction of apoptosis by the chemical stress 
pathway and the activation of caspase-3 and caspase-7 in HL-60 cells resulting in 
degraded DNA or hypodiploidy. Li et al. also showed that artemisinin derivatives 
induce apoptosis mainly in G 1 phase of cell cycle. G 1 phase has been associated with 
the increased iron intake and transferin receptor expression. Down regulation of anti-
apoptotic bel-2 proteins and up regulation of pro-apoptotic bax proteins have been 
associated with the artesunate-treated human vein endothelial cells (Li et aI., 2001). 
Artemisinins have also been associated with lowered vascular endothelial growth 
factor (VEGF) expression. VEGF are potent angiogenic factors (Wu et al., 2004). 
These studies suggest that the mechanism(s) for the cyto-toxicicty of artemisinins 
involves many different pathways. 
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In comparison, cisplatin (5.7) (cis-diamminedichloroplatinum, II), a platinum-based 
drug used in the treatment of a range of solid tumours exerts its cytotoxic effect 
through multiple mechanisms of which the most important and the better understood 
mode of action involves interaction with DNA to form DNA lesions, leading to 
activation of several signal transduction pathways and culminating in the induction of 
mitochondrial apoptosis (Siddik, 2003). Consistent rates of initial responses have 
been obtained by cisplatin treatment. However, this often results in the development 
of chemo-resistance and therapeutic failure (Galluzzi et al., 2011). Combination of 
cisplatin with a chemosensitizer or a synergist can potentially improve efficacy and 
restore sensitivity to cisplatin (Chirnomas et al., 2006). 
Artemisinin and its derivatives have also been used as chemosensitizers to 
conventional treatments in drug resistant cancer cell lines (Reungpatthanaphong and 
Mankhetkom, 2002, Liu et al., 2011). Synergistic interaction of dihydroartemisinin 
with gemcitabine, a cancer drug, showed a 45% enhancement of tumour growth 
inhibition compared with the drug alone (Wang et al., 201 Ob). The improved efficacy 
of mUlti-component combinations involving artemisinin in cancer treatment has 
encouraged some researchers to look at other compounds in the plant besides 
artemisinin that may exhibit cytotoxic activities and potential artemisinin synergists in 
the crude extract. Two artemisinin related compounds, artemisitene (5.2) and 
arteannuin B (5.4), and two unrelated ones, scopoletin and 1,8-cineole, showed anti-
proliferative activities (Efferth et al., 2011). No cross-resistance to artemisinin with 
any of these actives was observed, thus showing a potential for use in combination to 
treat drug resistant tumours. 
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Cabonara et al. observed that chorogenic acids (5.11-5.17) are major constituents of 
the Artemisia tea they analysed (Carbonara et at., 2012). They also detected a number 
of feruloyl-quinic acids together with some flavonoids in the extract. Chlorogenic or 
caffeoylquinic acids (CQAs) are esters of caffeic (5.10) and quinic acids. The 
pharmacological properties of these catechols includes antioxidant, hepato-protectant, 
antibacterial, anti-histaminic, chemo-preventive and other biological effects (Belkaid 
et at., 2006, Zhang et at., 2008, Feng et at., 2005, Miketova et at., 1999). 
Lee and Zhu have shown that chlorogenic acids and other catechols-containing 
dietary polyphenols can inhibit in vitro the methylation of synthetic DNA substrates 
and in human breast cancer cells inhibit the methylation of the promoter region of the 
RAj3 gene which are normally hyper-methylated in neoplastic cells (Lee and Zhu, 
2006, Sirchia et at., 2000) In their study, Noratto et at. showed the chemo-preventive 
potential of dietary chlorogenic and neo-chlorogenic acids (Noratto et at., 2009). 
These compounds exerted a relatively high growth inhibition on the estrogen-
independent breast cancer cell line and low toxicity in the normal cells. Chlorogenic 
acid derivatives were also found to inhibit hepatocellular carcinoma cell line 
proliferation and induced apoptosis in leukemia cell lines (Jin et at., 2005, 
Bandyopadhyay et at., 2004). 
Combinations of caffeic and chlorogenic acid with chemotherapeutic agents as 
chemo-sensitisers have been reported. An increased sensitivity of multidrug-resistant 
breast cancer cells (MCF-7/Dox) to doxorubicin was observed with caffeic acid (Ahn 
et at., 1997). A US patent for the use of chI orogenic acid as sensitizers for 
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chemotherapeutic agents, reported a 30 % reduction in the viability of cancer cells 
sensitized by chlorogenic acids to doxorubicin compared with cells administered with 
doxorubicin alone (Kim, 2010). 
This study therefore attempts to evaluate the in vitro cytotoxicity on breast cancer 
cells of artemisinin in combination with co-metabolites in Artemisia tea extract. It 
specifically looks at the interaction of artemisinin with chlorogenic acid (3 
caffeoylquinic acid), a major metabolite in Artemisia tea and compares this with 
cisplatin's interaction with the acid in other to better understand the cyto-toxic 
mechanism of action of artemisinin and possible implications for the use of Artemisia 
tea in cancer therapies. 
5.2 Result and discussion 
5.2.1 Composition of Artemisia tea 
The profile of metabolites in the aqueous extract and their quantities in milligrams per 
litre of extract is shown in Table 5.1. These were analysed by both MSIMS and HPLC 
methods. The profiling is based on the earlier in extenso analysis by Carbonara et ai. 
who showed these compounds to be the major metabolites (quantitatively) in 
Artemisia tea infusions (Carbonara et ai., 2012). Based on the earlier work (Suberu et 
ai., 2013a), several artemisinin-related compounds were also analysed in the extracts. 
The levels of artemisinin reported in tea extract are varied and the values obtained in 
this study (47.5 mg L-') are within the range (Van der Kooy and Verpoorte, 2011, 
Rath et ai., 2004, Carbonara et al., 2012, De Magalhaes et ai., 2012, Wright et ai., 
2010). Quantitative differences could be due to variation in biomass and tea 
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preparation methods especially biomass-to-solvent ratio used. Van der Kooy and 
V erpoorte (Van der Kooy and Verpoorte, 2011) have shown that the method 
employed in preparing the hot water infusion does affect the amount of artemisinin 
and other co-metabolites extracted. This study, as well as others (Van der Kooy and 
Verpoorte, 2011, Rath et al., 2004), employed the therapeutically recommended ratio 
of200:1, v/w or 5 g L-1, (Willcox, 2009). 
Table 5-1. Metabolites in the aqueous Artemisia extract analysed by both MSIMS and 
HPLC methods quantified as milligrams per Iit~ of tea. 
Compound Amount 
(mg L-1 of tea) 
Artemisinin 47.5±0.8 
Arteannuin B 1.3±0.0 
Dihydroartemisinic acid 70.0±0.3 
Caffeic acid 0.8±0.00 
3,5-Di-caffeoylquinic acid 57.0±1.7 
3-Caffeoylquinic acid 72.0±1.6 
4-Caffeoylquinic acid 20.4±1.6 
4,5-Di-caffeoylquinic acid 31.6±4.0 
5-Caffeoylquinic acid 9.0±0.7 
Isovitexin 105.0±7.2 
Rosmarinic acid 1.1±0.0 
Dihydroartemisinic acid (5.4) (70 mg L-1) and arteannuin B (5.5) (1.3 mg L-1) are the 
only biosynthetic precursors of artemisinin detected in the tea extract using our 
method (Suberu et al., 20 13 a). 
The most abundant of the caffeic derivatives (5.11-5.17) was 3-caffeoylquinic acid 
(5.11) (72 mg L-1) in the analysed extract, followed by 3,5-di-caffeoylquinic acid 
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(5.15) (57 mg L-'). A comparatively lower profile (0.8 mg L-') was observed for 
caffeic acid (5.10). The only flavonoid analysed was isovitexin (5.8) (l05 mg L-') and 
was relatively abundant in our extract. Rosmarinic acid (5.9) was lower (1.1 mg L-') 
in our samples compared to the levels found by De Magalhaes et al. (De Magalhaes et 
al., 2012). 
5.2.2 Cytotoxicity of cisplatin, artem is in in, and 3-caffeoylquinic acid (3CA) 
Table 5.2 shows the 50% inhibitory concentration (lC50) for artemisinin, cisplatin and 
3CA in MCF7 breast cancer cells. ThiS" cell line is derived from breast 
adenocarcinoma tissues and are a common model employed in carcinogenesis and 
chemo-preventive studies (Paluszczak et al., 2010). 
Table 5-2. IC50 values for artemisinin, cisplatin and 3CA in MCF7 cells. 
Compounds 
Artemisinin 
Cisplatin 
3-Caffeoylguinic acid (3CA) 
5.2.3 Cytotoxicity of artemisinin 
Average IC50 (IlM) 
38.44±0.41 
4.44±0.07 
1 54.27±0.82 
The cytotoxicity ofartemisinin (Table 5.2 and Figure 5.1) in the MCF7 cells shows its 
potency against invasive breast ductal carcinoma that is oestrogen sensitive. The IC50 
values obtained for the compound (38.44±0.41 f..tM) are within range of values (lC50; 
0.17 - 87.1 0 f..tM) reported by Efferth and Oesch for artemisinin and its derivatives 
determined for the tumour panel of 60 cell lines in the National Cancer Institute (NCI) 
screening programme (Efferth and Oesch, 2004). Artemisinin had the highest IC50 
(least potent) of all the related derivatives reported (Efferth and Oesch, 2004). 
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Figure 5-1. Dose response curve for artemisinin in MCF7 cells calculated based on 
percentage cell survival in the presence of graded concentration of the compound. Each 
data point was derived from duplicate determination of a triplicate measurement. 
5.2.4 Activity of cisplatin 
Cisplatin showed superior cytotoxicity in MCF7 cells compared to artemisinin, see 
Table 5.2 and Figure 5.2. The mean IC50 value obtained here (4.4 f.A.M) is similar to 
values reported by Isikdag et al. (IC5o 8.6 f.A.M) using the similar MCF7 cells and the 
same length of drug exposure (Isikdag et aI. , 2011). Although cisplatin is very 
effective with solid type carcinoma, drug resistance and toxic side effects have also 
been reported (Tegze et al., 2012, Florea and Blisselberg, 2011). 
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Figure 5-2. ICso curve for cisplatin in MCF7 cells calculated based on percentage cell 
survival in the presence of graded concentration of the compound. Each data point was 
derived from duplicate determination of a triplicate measurement. 
5.2.5 Cytotoxicity of3-caffeoylquinic acid (3CA) 
The ICso (154.27 ± 0.82 flM) in MCF-7 cells for 3CA was highest among the three 
single agents tested (Figure 5.3). The relatively higher ICso shows that 3CA's 
cytotoxicity occurs at relatively higher concentration. This is similar to the 
observation by Lee et al. who reported that the growth inhibition of MCF-7 cells by 
3CA was insignificant up to 20 flM and only inhibited by about 15% at 50 flM 
concentration (Lee and Zhu, 2006). Therefore a 50% growth inhibition at about 150 
flM concentration which we obtained is in the range of the reported values. The 
cherno-preventive and anti-proliferation effects of 3-caffeoylquinic acid along with 
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other dietary derivates have also been reported by others (Noratto et ai., 2009, Jin et 
al., 2005, Bandyopadhyay et aI., 2004). 
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5.2.6 Cytotoxic combination studies 
The cytotoxicity of Artemisia tea was investigated to assess its possible role in cancer 
therapy. Consequently the combinations of artemisinin and 3CA, a major metabolite 
in tea was carried out to elucidate and explain observations from the tea test. The 
resulting drastic modification of artemisinin' s activity with 3CA, led to the 
investigation of the interaction of 3CA with cisplatin to see if the same effect is 
reproduced in another anti-cancer drug in the hope of possible elucidation of the 
mechanism of the interactions observed. 
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5.2.6.1 Cytotoxicity of Artemisia tea 
The ICso values obtained for Artemisia tea were not reproducible. In one result, the 
ICso, was similar to that of pure artemisinin, see Table 5.2. However in a second 
repeat analysis values above 200 "",M was obtained. The inconsistency observed and 
the complex composition of the components of tea necessitated examination of 
interactions on a smaller scale. The combination of artemisinin with 3CA was 
subsequently investigated. In our analysis of the tea, 3CA was one of the most 
abundant component second only to isovitexin, see Table 5.1. Our choice of 3CA 
was also infonned by its prominent dietary pro tie. 
5.2.6.2 Artemisinin combination with 3CA 
The dose response curve for the combination of artemisinin and 3CA at a I to 1 ratio 
(v/v) is shown in Figure 5.4. The calculated ICso in MCF-7 cells for the combination 
is 255.67 mM. This is about 6,500-fold deterioration in artemisinin activity and 
represents a complete loss of cytotoxicity for the compound in the presence of 3CA, 
Table 5.2. A similar loss of activity was observed in combinations involving lower 
3CA concentrations with artemisinin (art to 3CA, 1 to 0.5 and 1 to 0.01). 3-
Caffeoylquinic acid also lost its mild cytotoxic activity in the presence of artemisinin, 
Table 5.2. This suggests an antagonistic interaction between artemisinin and 3CA 
when equally combined (v/v) and may partly explain the high ICso value (Section 
5.2.6.1) observed for tea in one of the tests. 
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Figure 5-4. Dose-response curve for artemisinin and 3-caffeoylquinic acid. Mean values 
of duplicate determinations oftriplicate measurements are plotted. 
The cytotoxicity of 3CA like many other anti-oxidant compounds is dose 
(concentration) dependent and observable only above certain concentration (Lee and 
Zhu, 2006). Controversial and conflicting experimental results have been observed 
(Yordi et al., 2012, Nemeikaite-Ceniene et al., 2005) in trials involving endogenous 
anti-oxidants such as 3CA because of their "double edge sword" effect at cellular 
redox sites. Depending on the dosage level and the in situ matrix, these compounds 
can either be pro-oxidative or anti-oxidative. As a result, factors like the batch 
variation in crude extracts along with the dose and matrix dependent activity of the 
compounds such as 3CA could partly explain the conflicting and irreproducible result 
observed for Artemisia tea, see Section 5.2.6.1. 
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5.2.6.3 Cisplatin combination with 3CA 
To investigate whether the strong antagonistic interaction observed for artemisinin 
and 3CA is reproduced in other anti-cancer agents, an equimolar combination of 
cisplatin and 3CA was tested. An ICso value of 3.6 f-tM was obtained from the dose-
response curve, Figure 5.5. This represents a 13 % improvement in the potency 
compared to cisplatin alone, Table 5.2. Kim et al. have reported the chemo-sensitizing 
effect of chlorogenic acids and up to 30% improvement in activity of doxorubicin was 
observed when combined with chlorogenic acid in a range of combinations (Kim, 
2010). 
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Figure 5-5. Dose-response curve for equimolar combination of cisplatin and 3CA. 
Plotted values are means of duplicated measurements. 
The mechanism for the interaction of 3CA in MCF7 cells with artemisinin 
(antagonism) and cisplatin (potentiation) seem to be pharmacokinetic in nature. The 
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observed effect of the combination in each case seem to be a result of 3CA 
modification of the activities of cisplatin and artemisinin and less likely due to 
pharmacodynamic effect where the intrinsic cytotoxicity of 3CA is a major factor in 
the interaction (Williamson, 2011). 
The activation of artemisinin and the cleavage of the endoperoxide bridge to form 
carbon centered radical and/or reactive oxygen species (ROS) is a key to the 
compound's cytotocity and anti-plasmodial activities. This activation has been 
suggested to be initiated by endogenous iron which is relatively abundant in actively 
dividing cells compared to normal cells (Efferth et al., 2004). Efferth et al. reported 
that 3CA has iron chelating properties and forms a complex with the metal (Kono et 
al., 1998). In a combination with artemisinin, 3CA may chelate and complex with 
endogenous iron and as a result depletes the iron pool available for the artemisinin 
activation. This effect will be more prominent in cytotoxic activity of artemisinin 
compared to its anti-plasmodial activity because the hemoglobin iron pool is more 
abundant (multiple fold) than the neoplastic cell iron pool (Kono et al., 1998) 
This is consistent with our observations for the combination in both anti-plasmodial 
and cytotoxic assays. In the previous work, a mild antagonism was observed for the 
anti-plasmodial activity of 3CA and artemisinin combination (Suberu et al., 2013b). 
In the above cytotoxic assay, a strong antagonism (or a loss of activity) was observed, 
see Figure 5.4. An activation site for the anti-malaria activity of artemisinin is in the 
parasites' food vacuole, which contains ingested hemoglobin. Activation of 
artemisinin for cytotoxicity is suggested to take place in neoplastic or cancer cells 
(Kono et al., 1998). 
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In contrast, cisplatin is activated in the cell by aquation of the molecule resulting in 
the loss of one or both of its chloride ions. The activation is enhanced by a lower 
endo-cellular chloride ion concentration compared to extracellular concentration of 
the ion (Florea and BUsselberg, 2011). Metal ions does not seem to play any role in 
cisplatin activation and thus unaffected by metal chelating properties of 3CA. 
5.3 Conclusions 
This study investigated in vitro the use of Artemisia tea as a chemotherapeutic agent 
using MCF-7 cells. The erratic and high ICs; observed for the tea extract, led to the 
investigation of the combinations of 3-caffeoylquinic acid (3CA), a major component 
of tea, with artemisinin, the main active ingredient in the extract. The combination 
showed a near total loss (strong antagonism) of cytotoxicity. This was in contrast to a 
13% improvement observed when 3CA was combined with cisplatin, another anti-
cancer agent. A mechanistic explanation was suggested for these observations and 
also a possible reason was advanced for the difference in anti-plasmodial and 
cytotoxicity of 3CA combination with artemisinin via endogenous iron-mediated 
activation of artemisinin molecule. 
Based on these results, the use of Artemisia tea in cancer therapeutics seem at best 
unpredictable and at worst ineffective. Further in vivo and in vitro investigation of the 
interactions between artemisinin with 3CA and other dietary antioxidants is 
imperative to any recommendation for the use of artemisinin and it derivatives as anti-
proliferative drugs with the possible avoidance of anti-oxidant food and drink 
immediately before and after intake of the drug in single or combination therapies. 
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CHAPTER 6. THE EFFECT OF CO-METABOLITES ON THE 
CRYSTALLISATION AND PURIFICATION OF ARTEMISININ 
6.1 Introduction 
The isolation of the anti-malaria agent artemisinin from the Chinese medicinal plant 
Qinghao (Artemisia annua. L) in the 1970s provided a new class of anti-malaria drugs 
effective against chloroquine resistant plasmodium parasites. Artemisinin is a 
sesquiterpene lactone with a unique endo-peroxide bridge, which is key to its 
bioactivity (Qu et al., 2010, O'Neill et al., 2010b, Meshnick et ai., 1996, Haynes and 
Krishna, 2004, Meshnick, 2002, Webster and Lehnert, 1994). In 2002, the World 
Health Organization (WHO) recommended the use of artemisinin in a combination 
therapy (ACT) as a ftrst-line treatment for uncomplicated malaria (Qu et al., 2010, 
Shretta and Yadav, 2012). Since then, the global delivery of ACT treatment courses to 
the public and private sectors has been increasing and rose sharply from II million in 
2005 to 278 million doses in 2011 (WHO, 2012). This trend is projected to continue 
against the challenge of demand and supply imbalances resulting from widespread 
fluctuations in price and global ACT shortages in some cases (Shretta and Yadav, 
2012). 
In 1987, Arvey et al. discovered the total synthesis of artemisinin (A very et al., 1987) 
and seven years ago, researchers at the University of California, Berkeley, USA, 
successfully inserted the engineered artemisinin metabolic pathway into microbes to 
produce artemisinic acid, the biosynthetic precursor to artemisinin (Withers and 
Keasling, 2007, Ro et al., 2006a). A semi-synthetic complement for the conversion of 
artemisinic acid to artemisinin was also recently discovered by Levesque and 
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Seeberger (Levesque and Seeberger, 2012). The announcement in 2012 by Sanofi of 
the first industrial-scale bio-engineered production of artemisinic acid that could be 
converted to over 40 million treatment courses via the Berkeley process will help to 
ease shortages but also could add to the problem of fluctuation in price for the 
growers of the plant (Peplow, 2013). Presently the bulk of artemisinin used in ACT 
and other treatments is of plant origin. East Asia (mainly China and Vietnam) 
cultivated approximately 80% of the global output in 2012 while 20% came from East 
Africa and Madagascar, Figure 6.l(CutIer, 2011). 
East Africa 
and 
Madagascar 
20% 
China and 
Vietnam 80% 
Figure 6-1 Global distribution of A. annua production for artemisinin extraction 
(Shretta and Yadav, 2012, Cutler, 2011). 
This is an increase over the previous year for Madagascar and East Africa, when it 
contributed just only 9% or 15 metric tonnes to the global output (A2S2, 2011). This 
trend is significant in the light of the reported problem of variable recovery rates in 
the processing of the East African biomass into the active ingredient (Henfrey, 2013). 
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Production of artemisinin from the plant is a multi-step process starting with the 
drying of the plant parts, in most cases the leaves and the shoots. This is followed by 
extraction, which on a commercial scale involves soaking, percolation or continuous 
flow in warm (30 - 40°C) organic solvents of low polarity like hexane, toluene, 
petroleum ether, etc (EISohly et al., 1990, Lapkin et al., 2006, Haynes, 2006). To 
improve solubility of artemisinin in the extractant, a modifier like ethyl acetate is 
sometimes used. Up to three to four extraction cycles may be employed in the batch 
process and each cycle takes between 10 - 48 hours (Lapkin et al., 2006). 
Simultaneously, extraction of essential oils, fffivonoids, waxes and pigments occurs in 
the process, necessitating the separation of artemisinin from the raw extract by 
sequential crystallisation from ethanol (Malwade et al., 2013, Qu et al., 2009). To our 
knowledge, literature evidence on the effect of these co-extracted metabolites on 
solubility of artemisinin in the extraction liquor and its crystallisation and processing 
is lacking. However, Lapkin et al. have reported the effect of eight co-metabolites in 
Artemisia plant extract on the solubility of artemisinin based on ab initio 
computational screening (Lapkin et al., 2010). They found that some co-metabolites 
increased the solubility of artemisinin in the extraction by up to 7.5%. At a given 
concentration, casticin and its glycosylated form had the greatest impact on the 
solubility of artemisinin among the metabolites tested. These data complement the 
anecdotal evidence from commercial extractors that recovery of artemisinin is 
strongly dependent on the 'quality of the plant', the latter being a technically 
undetermined characteristic. 
Casticin is one of a group of o-methylated flavonoids found in A. annua (Baeva et al., 
1988). There are over 17-reported methoxylated flavonoids found in the plant (Shilin 
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et al., 1989, Bhakuni et al., 2001, Ferreira et al., 2010). The major ones are artemetin, 
casticin, chrysoplenetin, chrysosplenol-D, cirsilineol, eupatorin and retusin (Liu et aI., 
1992). Methoxylated flavonoids are low molecular weight bioactive polyphenolics 
based on a CI5 (C6-C3-C6) carbon skeleton containing two aromatic rings (A and B) 
linked by a chroman ring (C), Scheme 6.1 (Sisa et al., 2010). In plants O-methylated 
(methoxylated) flavonoids are more widely distributed than c-methylated compounds 
and the methoxy groups may be present on the flavone nucleus in positions 2', 3', 4', 
5',3,5,6, 7, and 8 (Bandyukova and Avanesov, 1971). 
artemisinin methoxylated flavonoids 
Compounds 
Substituent on rings 
R3 R5 ~ R7 Rs R2, R3, ~, R5, ~, 
Artemetin OCH3 OH OCH3 OCH3 H H OCH3 OCH3 H H 
Casticin OCH3 OH OCH3 OCH3 H H OH OCH3 H H 
Chrysoplenetin OCH3 OH OCH3 OCH3 H H OCH3 OH H H 
Chrysosplenol-D OCH3 OH OCH3 OCH3 H H OH OH H H 
Cirsilineol H OH OCH3 OCH3 H H OCH3 OH H H 
Eupatorin H OH OCH3 OCH3 H H OH OCH3 H H 
Retusin OCH3 OH H OCH3 H H OCH3 OCH3 H H 
Scheme 6.1. Chemical structures of artemisinin and some methoxylated flavonoids of A. 
annua L. extract. 
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The maximum number of methoxy groups is seven with the molecule generally 
containing hydroxyl groups also. Methoxylated flavonoids are often present as 0-
glycosides or C-glycosides with the O-binding more abundant in plants (Bandyukova 
and Avanesov, 1971, de Rijke et ai., 2006). The substituent sugar (commonly 
arabinose, galactose, glucose or rhamnose) of the O-glycosides usually binds to the 
OH of the aglycone at position 3 or 7 while in the C-glycosides this is usually with the 
carbon of the aglycone at 6 or 8 (de Rijke et aI., 2006). 
Bio-medical research shows that O-methyfated flavonoids are promising cancer 
chemo-preventive agents in cell culture studies (Wen and Walle, 2006, Walle, 2007, 
Xiao et al., 2009). O-methylated flavonoids in particular exhibited a superior 
anticancer activity than their corresponding hydroxylated derivatives. They are more 
resistant to metabolism and are better absorbed in the intestines (Bernini et at., 2011, 
Walle, 2009). However O-methylation of the hydroxyl substitutions has been shown 
to inactivate both the antioxidant and the pro-oxidant activities of the flavonoid (Cao 
et al., 1997). Other biological effects includes anti-inflammatory (You et al., 1999) 
anti-viral (Conti et al., 1998) and low level antibacterial (Oksuz et al., 1984) 
activities. 
In the plant, methoxylated flavonoids are considered to participate in chemical 
defense due to the particular structural and absorptive feature. They also participate in 
stress protection and as plant development regulators (Sisa et ai., 2010). One major 
role proposed for these compounds and some other flavonoids is as absorbent and as 
natural filters or screens for solar UV radiation. This is supported by observation that 
exposure to UV radiation induces higher levels of flavonoids content in plants. One 
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such example is the work of Cadwell which showed that Alpine plants at high altitude 
and tropical plants from region of intense UV radiation have higher flavonoid content 
than plants from other regions (Caldwell, 1971). Cuadra et al. (Cuadra and Harborne, 
1996) obtained over a 40 % increase in the amount of UV absorbing flavonoids 
between control and the UV irradiated Gnaphalium plants. 
Consequently, we suspect that the levels of flavonoids in the various A. annua 
biomass will differ according to the climatic geography of the growth location and 
therefore be partly or wholly responsible for the differences observed in processibility 
due to elevated levels of these metabolites in some plant extracts and specifically in 
the East African ones. The wax and pigment content in the plants have also been 
suggested as possible reasons for poor artemisinin crystallisation through verbal 
communications within the artemisinin community. 
The aim of this work therefore, is to identify differences in metabolite profiles of four 
A. annua biomasses of the same genotype but grown in different parts of the world, 
including the problematic East African stock and attempt to isolate the possible co-
metabolites of artemisinin which might exert this effect. This knowledge will allow 
the design of better purification technologies for the isolation of this important 
biomedical molecule. 
6.2 Results and Discussion 
6.2.1 The level of artemisinin 
The level of artemisinin in the East African samples were similar to levels reported by 
Assured Artemisinin Supply Systems (A2S2) (A2S2, 2013), this being the highest 
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concentration, Table 6.1, within the group of biomass samples tested. The level of 
artemisinin was similar for the Australian and Argentinean biomasses. The UK 
biomass had the lowest content ofartemisinin of the group, Table 6.1. 
Table 6-1. Levels of wax, pigments and artemisinin in A. annua biomasses. 
Argentina Australia East Africa UK 
Artemisinin (% dry weight) 0.74 0.78 1.00 0.60 
Wax (% dry weight) 2.16 ±0.07 1.47±0.15 2.08±0.11 1.65±0.05 
Xanthophylls (~g go!) 2.63±0.04 3.67±O.08 3.38±0.O7 1.29±0.03 
~-carotene (~g go!) ~ 4.9±0.00 150.0±1.04 30.0±0.04 4.10±0.20 
6.2.2 Estimate o/percentage wax 
The biomass sourced from Argentina had the highest quantity (3.6 %) of precipitated 
waxes determined (Table 6.1), while the Australian biomass had the lowest (1.0 %) 
The East African and UK biomasses had 2.6 and 2.8 % waxes respectively. Based on 
this result, there seem to be no obvious pattern to suggest that the level of wax content 
in these plants is responsible for the relatively poorer crystallisation performance of 
the East African feedstock. 
6.2.3 Levels o/pigments 
Suggestions from producers and processors that some of the crude extracts that 
process poorly for artemisinin seem to show comparatively more pigmentation, led us 
to undertake the analysis of the xanthophyll and carotenoid content in the samples. 
Table 3 shows that the Australian biomass had a marginally higher (3.67 ~g go!) 
content ofxanthophylls than the East African (3.38 ~g go!) biomass. The UK biomass 
(1.29 ~g go!) had the lowest level of the pigment and the Argentinean stock about 
doubled that content (2.63 ~g go!). Relatively larger differences in the ~-carotene 
127 
levels were observed in the group (Table 6.1), with the Australian leaves having about 
five times more ~-carotene than the East Africa and 30 times more than the UK and 
the Argentina material. 
6.2.4 Effect of {3-carotene on artemisinin crystalisation 
The effect of ~-carotene was evaluated by spiking treated extracts from which 
pigments has been removed with graded levels of ~-carotene (0, 0.018, 0.18, 1.8 and 
5.4 mg) to evaluate impact on crystallisation. This represents a level of inclusion of 0 
---. 
to 30 fold of the level (0.18 mg mL-1 extract) of the compound found in the biomass 
used in the experiment. 
Figure 6.2 shows the amount of crystallised artemisinin and the percentage purity of 
the crystals obtained from each treatment. The fractions from flash chromatographic 
separation of Artemisia extract were used to spike T2 and T3. These fractions are 
devoid of artemisinin. The rest of the treatments apart from Tl were spiked with /3-
carotene reference standard. The difference in the amount of artemisinin crystallised 
was very small and ranged from 30.6 mg for Tl, which had no ~-carotene to 36.5 mg 
for T7 with the highest inclusion of the spike compound. This result seems to suggest 
that ~-carotene have not negative impact on the crystallisation of arteinisinin but seem 
rather to slightly enhance it. 
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Figure 6-2. Crystallisation liquor of Artemisia extract spiked with various quantities of 
Jl-carotene. Treatments were spiked with 1ml of the following - T1 = hexane, T2 = 
fractions 1-3 from the flash chromatography of Artemisia extract (clear fraction 
containing no pigment), T3 = fractions 4-7 (the combined fractions contains an 
equivalent of 0.18 mg of Jl-carotene pigment), T4 = 0.018 mg of JJ-carotene standard, T5 
= 0.18 JJ-carotene standard, T6 = 1.8 of JJ-carotene standard, T7 = 5.4 JJ-carotene 
standard. 
However when the raw crystal (solid) were analysed before the artemisinin content 
was determined, the percentage purity of the harvested solids deteriorated (Figure 6.2) 
with the increased inclusion of p-carotene. 
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6.2.5 Effect a/treatment with adsorbent on crystallisation 
Figure 6.3 shows crystallised solids containing artemisinin obtained from the 
concentrated extract of a high yielding A. annua plant treated with celite and activated 
carbon as in section 2.6.2 (left). On the right is an equal volume of the same extract 
untreated. Both were kept in cool (4°C) storage for 24 hours prior to crystalisation. 
Based on the above observation we hypothesized that some compounds in the crude 
extracts that interfere with the crystallisation of artemisinin in the extraction solvent 
are removed by the treatment thereby promoting crystallisation of artemisinin in 
treated extracts as compared to the untreated ones. 
Figure 6-3. Concentrated extracts treated (left) and untreated (right) showing 
artemisinin crystalising out of treated extract from which metabolites have been 
removed. 
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6.2.6 The effect of treatment on metabolite profile of extract 
The metabolite profiles for the treated (see section 2.6.2) and un-treated (crude) 
extracts were determined and the total ion count (TIC) chromatogram for both 
extracts showed visible differences (Figure 6-4). 
Figure 6-4 Extracted Ion chromatography (EIC)of crude and treated extracts 
To elucidate the difference we super-imposed the two chromatograms in Figure 6.5, 
to accentuate diminished or removed peaks due to treatment. 
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Figure 6-5. Superimposed chromatograms of crude (red) and treated (blue) extracts 
between retention time 9 -18 minutes. 
Peak A, B and C were found only in the crude extract. The high-resolution MS 
(HRMS) data for these peaks were determined (scheme 6.2) and coupled with 
literature and library searches, a positive identification for A, B and C was obtained as 
casticin, artemetin and retusin respectively (Scheme 6.2). These compounds are 0-
methylated flavonoids earlier reported in A. annua (Bhakuni et al., 2001). 
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Compound A: 
Chemical Formula: C19H1BOB 
Exact mass: 374.1002 
Nomenclature: Casticin, 
CompoundB: 
Chemical Formula: C20H200 B 
Exact mass: 388.1158 
Nomenclature: Artemetin 
CompoundC: 
Chemical Formula: C19H1B07 
Exact mass: 358.1053 
Nomenclature: Retusin, 
OH 
I 
o 
Scheme 6.2. Identity of peaks A, Band C in the untreated extract. 
6.2.7 Quantification ofO-methylatedflavonoids in extracts 
Quantitative analysis of the three methoxylated flavonoids was carried out in five 
biomasses from different parts of the world to evaluate the effect of geography on 
these metabolites and to identify possible target compounds that might be responsible 
for the variable (poorer) crystallisation reported (Henfrey, 2013) in the East African 
(Kenyan) sample. 
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Figure 6-6. Chromatogram of the O-methylated flavonoids in A. annua crude extract. 
Figure 6.5 is an HPLC chromatogram of a crude A. annua extract showing peaks of 
all flavonoids of interest while the relative quantities of the metabolites are given in 
Table 6.2. 
Table 6-2. O-methylated flavonoids in A. annua biomasses. 
Casticin Artemetin Retusin 
Source of Biomass 
mgg-' mgg-' mg g-' 
Argentina 1.48 ±O.1l O.O6±O.OO O.17±O.O2 
Australia 1.8l±O.13 O.O9±O.OO O.39±O.O2 
East Africa (Kenya) 1.45±O.O8 O.22±O.Ol O.49±O.O2 
Madagascar 1.73±O.O6 O.O8±O.OO O.4O±O.O3 
United Kingdom O.42±O.O2 O.O3±O.Ol O.O9±O.Ol 
Mean values of triplicate determinations with ± SEM 
The determined flavonoid profile for the Australian and Madagascan biomasses are 
very similar. This is likely to be due to their common latitudinal geography and thus 
receiving approximately similar intensity of the sun's ultra violet (UV) radiation. 
Similarly, due to its geography, United Kingdom receives comparatively lower sun 
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intensity and, hence, the UK-grown sample of A. annua has a comparatively low level 
of these flavonoids in the plant (Harborne and Williams, 2000). This might explain 
the reason for the lower values obtained for all three metabolites in the UK-grown 
biomass. Apart from the UK-grown biomass, the level of casticin in the plants is 
relatively high, up to 0.2% of dry weight, with less than 20 % difference in 
concentration between the different biomasses tested 
The biomass grown in Argentina had significantly lower levels of retusin compared to 
the other biomasses except the UK, which is consistently low. An interesting pattern 
was observed for artemetin levels in the biomasses. The East African (Kenyan) 
biomass had elevated levels (- 60%) of the metabolite compared to any of the other 
biomasses. This is in contrast to the relatively smaller differences in concentration 
levels of casticin (- 4%) and retusin (- 20%) in the biomasses studied. 
6.2.8 The effect ofO-methylatedflavonoids on artemisinin crystallisation 
Figure 6.6 shows the mean from replicated treatments of crystallised artemisinin and 
percentage purity of crystals harvested obtained from concentrated extract of A. 
annua spiked with flavonoids at different concentrations (0, 25 and 50 f,1g mL-1) 
individually and in a combination of all three. The amount of artemisinin crystallised 
was calculated from the percentage purity of the weighed crystallized solids. 
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Figure 6-7. The amount of artemisinin (mg) per treatment crystallised from 10 mL of 
concentrated extract containing 9.5 g biomass. 
The percentage purity of harvested crystals followed a pattern similar to the amount 
of artemisinin crystallised. Spiking with retusin at 25 and 50 ~g mL-1 seem to have no 
effect on the crystallisation of artemisinin from the liquor. There was an increase in 
the amount of artemisinin crystallised compared to the blank un-spiked extract, 
however the increase was statistically insignificant (p > 0.05). Conversely, the 
extracts spiked with casticin and artemetin showed relatively poor crystallisation of 
artemisinin compared to control. For both flavonoids crystallisation deteriorated with 
increased level of spiking. 
Casticin depressed (up to about 18%) the crystallisation of artemisinin from the 
concentrated extract, Table 6.3 . The effect on crystallisation was significant (p < 0.05) 
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at both levels compared to the un-spiked samples. The mean amount of crystallised 
artemisinin obtained from treatment with artemetin spiked at 25 Ilg mL-1 was 
comparable to the result for casticin at a similar level but was not significant due to 
the relatively larger variation. 
Inclusion at 50 Ilg mL-1 of artemetin in the extracts produced the poorest 
crystallisation of all the single-agent doping tests. A mean reduction in crystallised 
artemisinin of about 61 % was obtained with a relatively larger variation among 
replicates compared to other treatments. "'The impact on crystallisation and the 
variability of such effect is consistent with the observation reported (Henfrey, 2013) 
with the East African feedstock. The East African biomass had a disproportionately 
high level of artemetin of all the biomasses studied (Table 6.2). 
Table 6-3. The effect of casticin, artemetin and retusin on artemisinin crystallisation. 
Treatments 
(4 replicates per 
treatment) 
Casticin 
C25 
C50 
Artemetin 
A25 
A50 
Retusin 
R25 
R50 
Combined 
CAR25 
CAR50 
Amount spiked Mean % Artemisinin 
(mg) crystallised compared to control 
0.25 - 12.25 
0.50 - 18.26 
0.25 - 10.29 
0.50 - 60.73 
0.25 +15.50 
0.50 +15.78 
0.25 each + 26.55 
0.50 each - 97.87 
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The combination treatment at 2S Jlg mL-1 each of the three dopants resulted in an 
increase (~27%) in the crystallised artemisinin. However, the effect of inclusion at SO 
Jlg mL-1 of all three compounds was a near total failure (~98%) of crystallisation. This 
trend is difficult to interpret. However it seems the enhancing effect of retusin 
dominated the other two metabolites at the low level of spiking, while at the higher 
level of spiking the combined negative effect of artemetin and casticin reduced the 
crystallization significantly. 
On a structural level, the number and positi~ning of the O-methylated and hydroxyl 
groups on the flavonoid could help explain some of our observations. Casticin has 
four methoxylated groups at C 3, 6, 7 and 4' with 2 hydroxyl groups at C 3' and S 
Scheme 2. Artemetin has methoxylated groups as in casticin with one extra at CS' and 
only one hydroxyl group at CS. Retusin is similar to artemetin but has no 
methoxylated group at C6 (Schemes 6.1 and 6.2). 
The experimental results also seem to suggest that increasing methoxylation of the 
substituent on the flavonoid skeleton is associated with reduction in the amount of 
crystalised artemisinin from the mother liquor. An extra -OH group of casticin over 
retusin lead to a maginal reduction in the amount of artemisinin crystallised. However 
from these results, methoxylated groups seem to do this better than hydroxyl group as 
in artemetin compared to casticin. The mechanism(s) driving crystallisation is a 
complexity of physico-chemical processes (Song and Colfen, 2011, Gou et ai., 2012). 
There is literature evidence (Lapkin et ai., 2010, Elford et ai., 1987) for the effect of 
flavonoids on the solubility of artemisinin. To investigate the effect of casticin, 
artemetin and retusin on artemisinin's solubility, we employed a predictive 
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computational approach using a conductor-like screening model for realistic solvation 
(COSMO-RS) to compare with the experimental results. 
6.2.9 Predictive computational analysis using COSMO-RS 
The temperature and energy values for the compounds obtained from calculations in 
section 2.6.8 are given in Table 6.4. Additionally, the free energy change of melting 
approximated by the QSPR is given for comparison. 
Table 6-4. Thermodynamic data used forsolubility calculations 
Melting l1GQSPR l1GJus m fus Jus (kJ Substance Temperature (kJ mor l ) (kJ mor (K) mor l ) I) 
Artemisinin 7.16 11.83 
Artemetin 5.30 5.30 
Casticin 458.15 41.32 6.73 11.81 
Retusin 430.15 44.56 5.34 11.65 
Table 6.5 shows the predicted effect of methoxylated flavonoids on the solubility of 
artemisinin at 293 K in a solvent mixture of 5% ethyl acetate in n-hexane. Based on 
this analysis, casticin had the most impact (2.7%) on the solubility of artemisinin in 
the solvent mixture while artemetin had the least impact (1.1%). The combination of 
all three flavonoids had about 5.2%, corresponding approximately to the sum of their 
individual effects. 
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Table 6-5. The effect of co-metabolites on the solubility of artemisinin in n-hexane-ethyl 
acetate solvent mixture at 293 K. 
Co-metabolite 
Artemisinin 
Artemetin 
Casticin 
Retusin 
Combination (CAR) 
Artemisinin solubility at 
293K 
(mol fraction X 10-3) 
1.2145 
1.2277 
1.2471 
1.2333 
Increase in artemisinin 
solubility (%) 
1.1 
2.7. 
1.6 
5.2 
The predicted increases in solubility ofartemisinin in the presence of these flavonoids 
by COSMO-RS were marginal compared to the experimental results in Table 6.3. 
This may suggest that mechanisms other than the influence on solubility of 
artemisinin are responsible for how these flavonoids impact the crystallisation process 
of artemisinin from the mother liquor containing these metabolites. Other factors that 
may influence crystalisation have been suggested by others (Gou et al., 2012, Song 
and Coif en, 2011). 
6.3 Conclusions 
In this study we identified co-metabolites in A. annua extract that potentially impact 
the crystallisation of artemisinin from the mother liquor. Comparison of the spectra of 
treated extracts that readily crystallises artemisinin with untreated extracts, which do 
not readily crystallize artemisinin, identified methoxylated flavonoids, casticin, 
artemetin and retusin as potential causes. Analysis of biomass from Argentina, 
Australia, East Africa, Madagascar and United Kingdom showed the East African 
stock had a higher level (about 60%) of artemetin compared to other biomasses. 
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Concentrated treated A. annua doped with the three O-methylated flavonoids at 0, 25, 
50 f..tg mL-1 singularly and a combination of all three was used to investigate the effect 
on artemisinin crystallisation. Spiking with retusin seems to have no effect on the 
crystallisation of artemisinin from the liquor. A non-statistically significant (p > 0.05) 
improvement was observed compared to un-spiked samples. Casticin and artemetin 
inclusion showed reduction in the yield of artemisinin crystallised compared to 
control with the efficiency of crystallisation declining with an increasing level of 
spiking. A reduction of up to about 18% in the yield of artemisinin crystallised was 
observed for the range of inclusion of casticin in the mother liquor. Inclusion of 
artemetin at the investigated levels in the treated extracts led to a reduction of up to 61 
% compared to blank. The combination of the three methoxylated flavonoids at the 
higher level reduced the yield of artemisinin crystallized from the liquor by about 98 
%, representing a near total failure of crystallisation. This seems to suggest that the 
combined effect of methoxylated flavonoids in the un-treated concentrated extract 
may be responsible for holding back crystallisation of artemisinin and removal by 
treatment readily enhances crystallisation of artemisinin as in Figure 6.3. Artemetin 
seem to have the greatest singular impact among the investigated flavonoids and its 
elevated presence in the East African stock could account for the observed difficulty 
with processing and purification of artemisinin from biomass (Hen frey, 2013). 
The levels of waxes and pigments were also evaluated in the different biomasses but 
no association was observed that suggests these may interfere with artemisinin 
crystallisation. A computation analysis using COSMO-RS analysis to evaluate the 
effect on solubility of artemisinin for the inclusion of casticin, artemetin and retusin in 
the extraction solvent suggests only a marginal improvement (1.1 - 2.7% for single 
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and 5.2% for combined agents). Because of the complexity of the crystallisation 
process, the effect on solubility of artemisinin by these methoxylated flavonoids may 
playa lesser role in the mechanism (s) by which these compounds impact artemisinin 
crystallisation process. This marginal difference in solubility of artemisinin does not 
however explain the strong effect of artemetin and the combination of methoxylated 
flavonoids on artemisinin crystallisation. 
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CHAPTER 7. GENERAL CONCLUSIONS 
7.1 Introduction 
The imperative for the scientific investigation of polyvalent interactions in natural 
product extracts stems from the need for the development of new treatments for 
emerging diseases and the challenge of emerging resistance, whilst delivering 
improved efficacy and low cost benefits. This study attempts to enhance our 
understanding of polyvalent interactions in plant extracts and with the knowledge 
tools can hopefully provide design platforms for effective therapies from natural 
products of low environmental and cost implications. The study also looked at the 
effect of interactions of plant metabolites on the processing and purification of active 
pharmaceutical ingredients (APls) to address industrial purification problems. 
Starting with a method developed for the identification and quantification of plant 
metabolites, the following sections summarises and brings together the main 
achievements of the project. 
7.2 A new method for metabolites analysis developed 
A quick, robust and sensitive method for the detection and analysis of plant 
metabolites to support the study of the interactions between metabolites was 
developed. In the HPLC-MSIMS-ESI MRM method, six artemisinin-related 
metabolites were determined in six minutes of run time. 9-Epi-artemisinin was 
reported for the first time in crude extracts of A. annua. Plant biomasses from 
different geographical regions were analysed for their metabolites based on the 
method. The satisfactory validation indices obtained, confirmed the suitability of the 
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developed method for a wide range of applications including high throughput (HTP) 
analysis. 
This method has been published: Suberu J, et al. (2013) A rapid method for the 
determination of artemisinin and its biosynthetic precursors in Artemisia annua L. 
crude extracts. Journal of Pharmaceutical and Biomedical Analysis 84: 269-277. 
http://dx.doi.org/10.1 0 16/j .jpba.20 13.06.025 
The methods of analysis developed in this "'study was used to determine metabolic 
profiles of Artemisia annua grown in five different geographical regions and 
contributed to the paper submitted to publication: Alexei Lapkin, Eba Adou, Benhilda 
N. Mlambo, Smain Chemat, John Suberu Alana E. C. Collis, Andrew Clark, Guy 
Barker (2013) Integrating medicinal plants extraction into a high-value biorefmery: an 
example of Artemisia annua L. submitted to Comptes Rendus de Chimie. 
7.3 Polyvalent interactions and the design of more potent anti-malarials 
This study focused on the interactions in medicinal plants extracts and used the anti-
plasmodial activities of component in A. annua as a model to fmd positive 
interactions and mechanisms of therapeutic value. Analysis of Artemisia aqueous 
extracts revealed a prominent profile for chi orogenic acids, flavonoids and 
artemisinin-related metabolites. Using the isobolographic approach, the following 
interactions in the extract were identified. 
Antagonistic interactions occurred between artemisinin and related metabolites found 
in the plant having significant (lCso <l/lM) anti-plasmodium activity. The nature of 
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the interactions of artemisinin with chlorogenic acids and other metabolites with anti-
oxidative properties seem to be dependent on the concentration of these anti-oxidants 
and was explained by the "double edge sword" principle. At lower concentration to 
artemisinin a general antagonistic interaction is observed. The antagonism observed 
for these anti-oxidants is stronger in chloroquine resistant parasite strain than for the 
sensitive one, which might be due in part to the anti-oxidant defence strategy 
suggested for resistant parasite. At a higher (greater than three fold) concentration to 
artemisinin, an additive or synergistic interaction develops. A lO-fold concentration 
above that of artemisinin produced the b~st synergy with 3CA for anti-malaria 
activity. 
A synergistic interaction (of about three-fold improvement) was observed for the 
combination of artemisinin and arteannuin B in chloroquine resistant parasite strain. 
This was not reproduced in parasite strain sensitive to chloroquine, suggesting that 
arteannuin B potentiation of artemisinin is selectively targeted at the parasites' 
defence network. Based on further experimental confIrmation and possible 
improvement, this result suggests a possible therapeutic platform for the combination 
of artemisinin and arteannuin B in the treatment of chloroquine and multi-drug 
resistant plasmodium infection. 
This study has been submitted to publication. Suberu JO, Gorka AP, Jacobs L, Roepe 
PD, Sullivan N, Barker, G and Lapkin, A. (2013) Anti-plasmodial polyvalent 
interactions in Artemisia annua L. aqueous extract - possible synergistic and 
resistance mechanisms. PLOS ONE. 
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7.4 Interactions in tea and the implications for use in anti-cancer therapy 
The cytotoxicity of artemisinin and combinations with co-metabolites was 
investigated and the therapeutic use of Artemisia tea for malignancy was also 
examined. The observed cytotoxicity of tea in breast MCF-7 cancer cells was 
contradictory and irreproducible. Initial analysis gave an ICso similar to that of 
artemisinin, however a repeat analysis gave results of above 200 ~M. The interactions 
in tea were investigated further on a smaller scale of two component metabolites, 
artemisinin and 3CA. The result showed a strong antagonistic interaction, resulting in 
loss of artemisinin' s cytotoxicity. 
The metal and iron-chelating characteristic of 3CA was proposed for the loss in 
cytotoxicity of artemisinin. Artemisinin is suggested to be activated by endogenous 
iron. This "depletion of iron" hypothesis, seem to be re-enforced by the observation 
that the antagonism is not reproduced in cisplatin another anti-cancer drug, activated 
by a route that is not dependent on cellular iron or metal pool. The strong negative 
interactions observed in components of tea would suggest that the extract is not 
suitable for use in cancer treatments, however further investigations both in vitro and 
in vivo are needed to establish this assertion. 
This study is being drafted for pUblication: Suberu, J; Romero, I; Saddler, P; 
Sulluvan, N; Lapkin, A. and Barker, G. - Comparative cytotoxicity of artemisinin and 
cisplatin and their interactions with chi orogenic acids in MCF7 breast cancer cells. 
Suggested Journal- Journal of Medicinal Chemistry. 
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7.5 Application of polyvalent interactions to industrial purification problem 
The knowledge of plant metabolite interactions is applicable also to extraction and 
purification problems. Spectra subtraction of purified extracts that crystallises 
artemisinin from those of untreated extract that does not, revealed the absence of 
some methoxylated flavonoids' peaks in the treated extract. The doping of treated 
Artemisia extract with these flavonoids confirmed the negative impact on 
crystallisation of some of these compounds. Artemetin had the greatest effect and 
doping a combination of artemetin, casticin and retusin into treated extracts caused a 
near total failure of crystallisation of artemisinin from the crystallisation liquor. 
Metabolic profile analysis of biomass from different region showed that the levels of 
methoxylated flavonoids in A. annua biomass seem geography dependent and 
interestingly artemetin had an elevated profile in the problematic East African 
biomass compared to other regions. The use of solid adsorbents to treat and remove 
these methoxylated flavonoids from the crude extract prior to crystallisation was 
employed in the investigation with success. 
This study has been submitted for publication: Suberu J.O; Yamin, P; Leonhard, K; 
Song, L; Sullivan, L; Barker, G and Lapkin, A. (2013) The effect of O-methylated 
flavonoids and other co-metabolites on the crystallisation and purification of 
artemisinin, Separation and Purification Technology. 
7.6 Technology transfer and industrial application of project outcomes: 
The application of the developed purification strategy utilising low-cost technology 
method of activated carbon and celite as solid adsorbents in the purification of 
artemisinin raw material from the plant extract is easily transferable to developing 
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countries and of relative economic and environmental benefit, compared to alternative 
purification strategies. In fact, we believe that Botanical Extracts Ltd in Kenya is 
presently using the method. The present system of bulk purchased biomass at 
fluctuating prices from growers in developing countries being transported over long 
distances to extraction and purification sites in China, Europe and India is inefficient, 
unstable for growers and represents considerable environmental impact. The 
implementation of low-cost and simple purification methods, such as employed here, 
has many benefits for local purification of artemisinin by ensuring more stable 
pricing, technological leapfrogging for artemisinin grower communities and a more 
environmentally friendly artemisinin supply chain. 
The adoption of new analytical protocols developed in this study requires significant 
investment in advanced instrumentation, which is only viable for well-funded 
laboratories and larger companies. However, the high-throughput nature of the 
methodology should allow central laboratories to support a large number of end-users, 
which justifies the use of expensive instrumentation. 
7.7 Suggestions for further work 
The following are suggested areas for further research. 
7.7.1 Identification of other artemisinin related metabolites in A. annua extracts 
The analysis of biosynthetic precursor in A. annua crude extract revealed the presence 
of other artemisinin related metabolites of prominent profile quantitatively. The 
identification of these metabolites will help in furthering current understanding in the 
biosynthesis of artemisinin especially at the fmal stages and these metabolites may 
also provide a bio-refmery platform for increased revenue from the biomass. 
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7.7.2 Is the production of artemisinin limited to GST alone? 
In the analysis of glandless (mutant) A. annua biomass using the method we 
developed, low levels of artemisinin were detected in the sample but the fmding was 
not conclusive as biomass might have been contaminated from source. The glandless 
biomass have been reported to be artemisinin-free due to the lack of glandular 
secreting trichomes (OST) where artemisinin is believed to be synthesized and stored 
(Duke et al., 1994). Further research with glandless biomass for artemisinin content 
will help to clarify if other sites for artemiS1nin production in the plant exist outside 
the OST. 
7.7.3 In vivo anti-plasmodium trials for artemisinin combination with co-
metabolites 
The inherent limitation of in vitro trial makes it a relatively poor mimic of normal 
environment for the study of synergistic interactions. An in vivo trial opens up other 
possible route for metabolite interactions. The investigation of artemisinin 
combination with co-metabolites in animal models (P. berghei) will help to better 
qualify the nature of these interactions and to delineate those interactions with 
possible therapeutic applications. 
7.7.4 In vivo and in vitro cyto-toxic activity of artemisinin combination with other 
metabolites 
The in vitro investigation of artemisinin combinations with co-metabolites was 
limited to 3CA alone due to time constraint. Interactions with other major 
metabolites like isovitexin, rosmarinic acid etc, in the extract both in vitro and in vivo 
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will further our understanding of cytotoxic polyvalent interactions in herbal 
medications and specifically help to assess the nutritional and pharmacological impact 
of these interactions. This will have a wider implication on drug design including 
increased efficacy and reduced cost. 
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A rapid high-pressure liquid chromatography (HPLC) tandem mass spectrometry (TQD) method for 
the determination of artemisinin, 9-epi-artemisinin, artemisitene. dihydroartemisinic acid, artemisinic 
acid and arteannuin B in Artemisia annua extracts is described. Detection and quantification of 9-epi-
artemisinin in crude extracts are reported for the first time. In this method all six metabolites are resolved 
and eluted within 6 min with minimal sample preparation. A recovery of between 96.25% and 103.59% was 
obtained for all metabolites analysed and the standard curves were linear (r" >0.99) over the concentra-
tion range of 0.15- 1 0 jJ.g mL - 1 for artemisinin, 9-epi-artemisinin, artemisitene and arteannuin B, and the 
range of 3.75- 120 jJ.g mL - 1 for dihydroartemisinic acid and artemisinic acid. All validation indices were 
satisfactory. showing the method to be robust. quick. sensitive and adequate for a range of applications 
including high throughput (HTP) analysis. 
1. Introduction 
Malaria is a life threatening disease transmitted by mosquitoes 
with about half of the world's population at the risk of the dis-
ease [1]. Although death from malaria has been decreasing globally 
since 2005 [2]. there is the fear of a reversal due to the parasite 
developing resistance to traditional anti-malaria drugs. The discov-
ery of artemisinin (1) three decades ago and the development of 
the artemisinin-based semi-synthetic drugs used in combination 
therapies (Acrs) backed by the World Health Organization (WHO) 
have provided a highly effective treatment againstfalciparum-type 
malaria in many countries [3- 5]. Currently. the worldwide demand 
for Acr treatments is approximately 100 million doses annually 
[3- 5]. 
Until recently. the only commercially viable source of (1) was 
Artemisia (Asteraceae) plant. Artemisia annua L.. Artemisia apiacea 
Hance. and Artemisia lancea Vanoit are the three species in the 
genus Artemisia that have been reported to contain significant 
amounts of (1) with most of the interest focused on A. annua [6.7] . 
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Crystallization from extracts of dried plant biomass is the sim-
plest method of recovery of (1) and with improved plant breeding 
methods reported yields are up to about 1.5% dry weight [8- 10]. 
Commercial interests are also focused on other biosynthetic pre-
cursors that are convertible to artemisinin analogues [11]. 
There are several published methods for the analysis of (1) 
and other related sesquiterpenes including 9-epi-artemisinin (2). 
artemisitene (3). dihydroartemisinic acid (4), artemisinic acid (5). 
and arteannuin B (6). However more rapid. sensitive. accurate 
and all-in-one methods are still needed for these metabolites 
(Scheme 1). 
Techniques developed and validated for analysis of artemisinin 
include thin layer chromatography (TLC) [12]. high performance 
liquid chromatography with ultra violet detection (HPLC-UV) 
[13 .14]. electrochemical detection (HPLC-ECD) [1 5]. evaporative 
light scattering detection (HPLC-ELSD) [16]. and refractive index 
(HPLC-Rl) [16]. HPLC-UV is the WHO recommended method and 
the most widely used. However because (1) has very weak UV 
adsorption above 210nm. the use of UV detection at the end of 
an HPLC separation requires very careful set-up and calibration. 
especially for analysis of extracts [1 5]. An earlier method involved 
conversion of (1) to a UV absorbing compound Q260 to facili-
tate its detection [17-19]. The disadvantage of this method is that 
the derivatization procedure from (1) to Q260 is time consuming 
and introduces significant experimental errors [20]. Other methods 
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Scheme 1. Chemical structures of metabolites of interest. 
include gas chromatography with flame ionization (GC-FIO) 
[21,22), supercritical fluid chromatography with ELSD (23), FlO (24) 
and MS (25) detection. NMR (26) and immunoassay (27) methods 
have also been reported. An excellent review of these techniques 
in greater detail was published by Christen and Veuthey (23). 
Mass and tandem mass spectrometry based methods have the 
advantage of high sensitivity and selectivity for metabolites in 
Plant extracts (28). Several gas chromatography and liquid chro-
matography methods coupled to mass spectrometry (GC-MS (22), 
LC-MS [28,29)) and tandem mass spectrometry (GC-MS/MS (30), 
lC-MS/MS (31)) have been reported for the determination of(1) 
and its derivatives in blood, plasma, serum and plant extracts. The 
MS/MS method developed by Van Nieuwerburgh et al. (31) for the 
analysis of (1) and its biosynthetic precursors in A. annua takes 
about 20 min to analyse four metabolites. 
Here we describe an MS/MS method for the analysis of six 
analogues of (1), including (2), in crude plant extract with min-
imal sample preparation, a simple binary mobile phase solvent 
sYstem and a short overall analysis time, lending the method to 
high throughput (HTP) analysis with low consumables costs and a 
reduced environmental impact. 
2. Experimental 
2.1. Chemicals 
Artemisinin reference standard (98%) was obtained from 
Sigma-Aldrich (Dorset, UK). Samples of artemisinin were also 
kindly provided by Neem Biotech (Newport, UK), Chemotech-
nica (Argentina) and Chengdu (Sichuan Xieli Pharmaceutical Co. 
l~d., China). These samples were obtained following purifica-
bon of extracts from A. annua plants cultivated in UK, China 
and Argentina. Dihydroartemisinic acid (> 99.8%) was gifted by 
ROdger Stringham (Clinton Foundation, USA). 9-Epi-artemisinin 
(98%) was sourced from Sensapharm Ltd. (Sunderland, UK), while 
arteannuin B, artemisitene and artemisinic acid were kindly pro-
vided by Walter Reed Army Institute of Research (Washington, 
USA). LC-MS grade formic acid in water, acetonitrile and HPLC 
grade acetonitrile were obtained from Fisher Scientific, UK. Purified 
water (~1 8 MQ/cm) was dispensed from a Milli-Q system (Milli-
pore, UK). 
2.2. Plant samples 
High-yielding A. annua biomass samples were obtained from 
Mediplant (Switzerland), BlONEXX (Madagascar), REAP (Kenya) 
and ANAMED (Germany). Dried plant leaves were stored at -20°C. 
Mutant (glandless) A annua plant samples were kindly provided 
by Prof. P. Weathers (Worcester Polytechnic Institute, MA, USA). 
Hippophae rhamnoides L. (Elaeagnaceae) (Sea-buckthorn) used as a 
negative control was obtained from the Centre for Alternative Land 
Use, CALU (Bangor University, Wales, UK). 
2.3. Analytical standards 
Standard stock solutions of 1 mgmL-I of artemisinin (1), 9-
epi-artemisinin (2), artemisitene (3), dihydroartemisinic acid (4), 
artemisinic acid (5) and arteannuin B (6) in acetonitrile were pre-
pared. The analytical standard was a mixture of all six standards 
in a mobile phase spiked with glandless Artemisia plant matrix in 
the concentration range between 0.15 and 10 ILgmL -I for (1), (2), 
(3) and (6). For (4) and (5) the range of 3.75-120ILgmL-:I was 
used. This was to provide a similar matrix for the standards as 
with the samples minimizing any possible effect due to ion sup-
pression or enhancement. Glandless A. annua plant is devoid of 
artemisinin and related metabolites (32). ~-Artemether was used 
as internal standard (IS) at 5 ILg mL -I to adjust for possible fluc-
tuations in injection volumes. Based on the response from the IS, 
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Table 1 
TQD parameters for MS/MS experiments. 
Artemisinin (1) 
9-Epi-artemisinin (2) 
Artemisitene (3) 
Dihydroartemisinic acid (4) 
Artemisinic acid (5) 
Arteannuin B (6) 
~-Artemether (IS) 
Cone voltage (V) 
24 
30 
30 
32 
32 
28 
20 
the instrument QuantLynx software automatically adjust for these 
fluctuations making the method more robust and accurate. 
2.4. Sample extraction and preparation 
Samples were extracted using published methods [16,33) with 
a slight modification. Briefly, 10 mL of n-hexane containing 5% 
(v/v) ethyl acetate was used to extract 1 g of biomass in a sonica-
tion bath (PUL 125, Kerry Ultrasonics, UK) operated at 50Hz and 
kept cold with ice for 30 min. The extracts were striped of solvent 
in vacuo and the residue re-suspended in 2 mL acetonitrile. This 
was then filtered through a 0.2 11m syringe filter (Fisher, UK) to 
remove waxes and other un-dissolved components. An aliquot of 
the filtrate was dissolved in the mobile phase and internal stand~rd 
added for LC-MS/MS analysis. Glanded A. annua (sample), gland-
less A. annua (matrix), and H. rhamnoides (Sea-buckthorn) used as 
negative control were all extracted using the above procedure. 
In several earlier studies [34-37) solvent extraction was com-
bined with sonication for the extraction of artemisinin and related 
compounds. Sonication provides mechanical disruption of the 
contents of the trichomes thereby aiding in extraction. Extraction 
at cold temperature «30°C) minimizes the amount of chlorophyll 
and other interfering components extracted. Briars and Paniwnyk 
(37) also observed an increase in the amount of artemisinin in 
plant extracted using ultrasound at 25°C compared to extraction 
at higher temperatures without ultra-sonication and conventional 
steeping at the same temperature. The use of hexane modified 
by 5% (v/v) ethyl acetate increases the solubility of artemisinin in 
the mixture by over 3500% compared with hexane alone (9). Ini-
tially we employed an additional sample purification step using 
SPE columns, however this led to significant losses for some of 
the metabolites. Therefore a limited extract purification procedure 
with acetonitrile was used in all consecutive experiments. 
Treated plant extract for high resolution ESI-MS analysis (QT~F) 
was prepared by a 20 min contact of the plant extract (above) With 
activated carbon (AC) and celite at a ratio of 1 g each of AC and 
celite to 100 mL of extract. This was filtered in vacuo with a 0.2 11m 
Millipore® filter paper. 
2.5. Liquid chromatography method 
An Acquity liquid chromatograph coupled to a tandem 
quadrupole detector (TQD) (Waters Corp., Milford, MA, USA) was 
Used in the analysis. The liquid chromatography system consisted of 
a binary pump, a cooling auto-sampler set at 10°C with an injection 
loop of 10 11L. The column heater was set at 30°C and a Genesis® 
Lightn C18 column (100mm x 2.1 mm; 4l1m)(Grace,IL, USA) pro-
tected by an Acquity column in-line filter unit was used for the 
separation of the metabolites. The mobile phase consisted of A: 
0.1% formic acid in water and B: 0.1% formic acid in acetonitrile. 
Chromatographic separation was achieved using a linear gradi-
ent: 0-7.0min, 25-98% B; 7-9.5 min, 98% B; 9.5-10min, 98-25% 
B; 10-15 min, 25% B; at a flow rate ofO.4mLmin-1• Weak wash 
Solvent was 10% acetonitrile. The strong and needle wash solvents 
Collision voltage (V) 
7 
12 
10 
12 
12 
9 
5 
MRM transitions 
283 ..... 219+229+ 247 +265 
283 ..... 209 + 219 + 247 + 265 
281 ..... 217+227+245+263 
237 ..... 190+200+218 
235 ..... 190+200+218 
249 ..... 189+213+221 +231 
299 ..... 221 + 249 + 267 
were a mixture of acetonitrile, propan-2-ol, methanol and water 
(30:30:30:10, v/v/v/v). 
2.6. Multiple reaction monitoring (MRM) method 
The MS/MS system was operated with an ESI interface in posi-
tive ionization mode (ESI+) and acquisition was performed in MRM 
mode. The cone and de-solvation gas flow rates were set at 45 L h-1 
and 800 L h-1, respectively while the capillary voltage, the source 
and de-solvation temperatures were similar for all analytes at 
28 kV, 150°C and 350 °C respectively. MS parameters were auto-
matically defined using Waters IntelliStart® software for the tuning 
and calibration of the TQD and subsequently manually optimized 
as shown in Table 1. Quantification was determined using multiple 
reaction-monitoring (MRM) modes for the above transitions. The 
dwell time was automatically set at 0.161 s. Data were acquired 
by MassLynx V4.1 software and processed for quantification with 
QuanLynx V4.1 (Waters Corp., Milford, MA, USA). 
2.7. Dionex RS 3000 method 
A Dionex RS 3000 instrument coupled to a Bruker MaXis high-
resolution Q-ToF mass spectrometer was used to confirm results 
obtained from the TQD instrument and obtain accurate mass mea-
surements. The mobile phase consisted of A: water with 0.1 % formic 
acid and B: methanol with 0.1% formic acid. The flow rate was 
0.2 mL min- 1 and a run time of29 min. The gradient was as follows: 
0-10min, isocratic 55% B; 10-15.4min, 55-100% B; 15.4-20.4 min, 
isocratic 100% B; 20.4-23.4 min, 100-55% B, then isocratic for 
5 min before next run. Separation was achieved on a Zorbax RPC18 
2.1 mm x 100 mm, particle size 2.2 11m with 2 I1L injection volume. 
2.B. Q-ToF high resolution - MS 
The Bruker MaXis UHR-Q-ToF mass spectrometer was operated 
under the following conditions: ionization mode: ESI (+); MS scan 
range: 50-2500 mlz; end plate offset: -500V; capillary: -3000V. 
Nebulizer gas (N2): 0.4 bar; dry gas (N2): 4 L min-1 ; dry tempera-
ture: 180°C. Ion transfer conditions: funnel RF: 200Vpp; multiple 
RF: 200 Vpp; quadruple low mass: 55 mlz; colliSion energy: 5.0 eV; 
collision RF: 6OOVpp; ion cooler RF: 50-250Vpp ramping. Trans-
fer time: 12111S; Pre-Pulse Storage time: l11S. Calibration was 
achieved before each run through a loop injector of20 I1L of sodium 
formate (10mM). 
3. Results and discussion 
3.1. Chromatography 
Gradient and isocratic LC methods were tested to optimize the 
conditions for resolution of all the metabolites and the internal 
standard. A buffered system similar to those employed by Van 
Nieuwerburgh et al. (31) was also tested. The best resolution was 
obtained with the method described in Section 2.5. All metabolites 
and internal standard were successfully resolved in the first 6 min 
272 j. Suberu et al. / Journal of Pharmaceutical and BiomedIcal Analysis 84 (2013) 269-277 
l ' MRM 013 Channels ES+ 
10~ Altemlsinle Acid 5.86 TIC (Artemlslnle ACid) 
A bllllil l 
565e4 
o I I i · 1.60 i' • 2.60 3.60 
; , 4.bO 5.bo ' j 7.bo I I I i B.bo 9.bo i I 10:00 6. 0 
1: MRM 01 3 Channels ES+ 
103 B,ta-1U1emetlltr 5.75 TIC (b-artemether) ~;b l.B6e4 i; • i 2.60 I ; , I i ' ; i i 7.bo .; i ' i· 9.bo i· . I 1.00 3.00 4.00 5.00 6. 0 B.OO 10.00 
1: MRM or 4 Channels ES+ 
10~J 4.52 TIC (Artemlslnln) 
o " " I"' , .bo 1·1 l'i60'1"I "3.bo' I i I "4.bo " ,A, " i).bo " I I I "6.bo I I I I I I I 7.bO I " I I "8.bo I I I i I '9.bo "i 10~o:2e5 
1: MRM or 4 Cllannels ES+ 
9-Epl-memlsinln 4.28 TIC (9-epl Artemlslnln) 1°3~~~~~b~I~'i~I~"~~~~1 ~b~I~~~b~I*A~II~I~~b~~~~I~b~~~~lb~1~~~I ~b'~~~~9.~OiO~' ~~~1~07.lo·701e5 
1. 0 2.00 3. 0 4. 0 5. 0 6. 0 7. a B. 0 
1: MRM or 4 CllannelS ES+ 
4 12 TIC (Artemlsltene) 10~~~I~I~I~I~~1~.b~0~~~~2T.bO~~I~I~~3~I .b~0~1~~II~·4.~b~~~~~iJ~.b~0.'~1~"~I~I~I~6.rbo~I~I~IT'~'~11~7'.b~0~1~1~'i~'~'~'~8.~bo~'~1~1~i~I~'1~9~.6~0~'~II~I~'~I .'1~0~:5e5 Arttllusitell' 
2. MRM of 4 Channels ES+ 
397 TIC (Arteannu n B) 10~~~'~"~I~I~~i~.b·O~"MI~i~I~"M2~.6·0~'~"~I~"~3~.b·O~;~I~I~~li~·. ~0~1~1~1~I~iJ~.b~o~I~I~~16~.b~o~~·'~'7~I.bro~' ~lir'~'~'B~'.bro~'~~~9.b~OM'~'.' ~I'~I~'1~0::6e6 ArtulUl1Im B 
'\'0 1: MRM or 3 Channels ES+ 
Dibyclroout,misilue Add 3.67 TIC (DlhyIlroartemlslnlc ACid) 1°B~~~~~I~.6~0~~~1~2~.b·0~'~' ~i·'·"~3~.6·0~,,~A~; 4~.b~0"~~5~.b~0~"~i~~ rI 6~.b~0~~~7~.bro~~~B~I .bro~~~~9.b~O~· ~I.' ~1 ~'~1~0~;:7 
FIg. 1. Total ion current chromatography (TIC) with retention times and chemical structures for all metabolites of interest and the internal standard (f3-artemether). The 
chromatograms were acquired by multiple reaction monitoring (MRM) in positive electro-spray mode using analytical standards at a concentration of 5j.LgmL- I for all 
analytes and internal standard except for artemisinic acid and dihydroartem isinic acid which were determined at 60 j.LgmL- '. 
of run time. Fig. 1 shows the total ion current chromatogram (TIC) 
for all the analysed compounds. 
3.2. Recovery 
The recovery was assessed using ten equal samples of 1 g of 
dried A. annua (Madagascar variety). Six of these extracts were not 
spiked while four were spiked with a mixture of each analyte to 
giVe the final concentration in the prepared extract of 2.5 ~g mL-1 
for artemisinin, 5.0 ~g mL - 1 for 9-epi-artemisinin, artemisitene 
and arteannuin B, 30 ~g mL - 1 for dihydroartemisinic acid and 
artemisinic acid. Table 2 shows a recovery of between 103.59 and 
96.25% was obtained for the analytes investigated. 
'table 2 
Recovery of artemisinin and analogues from A annua. 
3.3. Specificity 
Fig. 2 shows the possible MRM transitions for artemisinin. Three 
or four transitions were monitored for the MS/MS experiment to 
identify and quantify each metabolite. The sum of combined tran-
sitions gave the total ion current (MRM) data while the signal 
with the highest m/z value was used for the quantification of each 
analyte. 
MS/MS based assay are inherently specific. However to investi-
gate the specificity of the method further, extracts of glandless A. 
annua and H. rhamnoides (Sea-buckthorn) were analysed. In these 
negative control extracts we found no components of interest in 
the chromatograms from the MS/MS experiments. The result for 
--~--------------------~--------~---------------------------------------~iked analyte quantities (J.LgmL - I) Artemisinin' (1 ) 9-Epi-artemisinin' (2) Artemisitene (3) Dihydroartemisinic acid' (4) Artemisinic acid (5) Arteannuin B (6) 
Mean quantity in un-spiked sample' 7.49 
Spiked quantityb 2.50 
'total quantity in spiked sample' 9.99 
Recovered quantities (J.LgmL- ') Artemisinin' 
0.13 0.05 
5.00 5.00 
5.13 5.05 
9-Epi-artemisin' Artemisitene 
15.15 0.00 0.39 
30.00 30.00 2.5 
45.15 30.00 2.89 
Dihydroartemisinic acid' Artemisinic acid Arteannuin B 
( ~) (3) (4) (5) (6) ____________________ ~(1~) ________ ~~ ________ ~~ ________ ~____________ ~~ ________ ~~ ________ _ 
SPiked sample l d 10.24 (101.56%) 5.08 (98.95%) 5.08 (98.94%) 52.14 (103.89%) 28.65 (92.78%) 3.06 (106.44%) 
SPikes sample 2d 10.60 (114.72%) 5.24 (102.14%) 4.97 (96.78%) 47.84 (90.74%) 30.62 (99.17%) 2.82 (96.93%) 
SPiked sample 3d 10.38 (106.53%) 4.92 (95.98%) 5.38 (104.72%) 51.87 (103.04%) 28.30 (91.65%) 3.09 (107.96%) 
SPiked sample 4d 9.97 (91.53%) 4.98 (97.08%) 5.46 (106.36%) 47.53 (89.80%) 31.31 (101.40%) 2.96 (102.71%) 
Mean spiked sample (J.LgmL - I) 10.30 (103.59%) 5.05 (98.53%) 5.22 (101 .70%) 49.85 (96.87%) 29.72 (96.25%) 3.05 (103.51 %) 
~dard deviation (J.LgmL - I) 0.26 (8.44%) 0.14 (2.70%) 0.23 (4.57%) 2.50 (7.64%) 1.47 (4.77%) 0.15 (4.74%) 
ren equal samples of 1 g dried Madag~scan A. an~ua leaves were extracted and prepared for analysi.s. ' Six of these extracts were u~-spiked while 4 were spiked at indicated 
eVels.b The total quantity' of analyte to samples IS calculated as the sum of the mean quantities to SIX un-spiked sample and the spiked quantity. Analyte levels in individual 
SPiked samples were determinedd and absolute and percentage (in bracket) recoveries presented. 
, Quantitative values corrected for percentage purity. 
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Fig. 2. Mult iple reaction monitoring (MRM) chromatogram of standard artemisinin 
(5Il-gmL- I ) showing the four transitions chosen for the experiment with their 
chemical formul as and signal intensit ies. 
the presence of trace level of artemisinin in the glandless biomass 
was not conclusive and this is being investigated further. 
3.4. Ion suppression (matrix effect) 
Quantitative analysis of plant and biological samples with posi-
tive electro-spray ionization coupled to tandem mass spectrometry 
is compounded by the presence of matrix components, which can 
interfere with the analysis hence resulting in ion suppression or 
enhancement effects. The common methods for the assessment of 
ion suppression are the post-column infusion method (38) and the 
post-extraction spike method (39). The spike method was used 
in our determination and this was assessed by comparing the 
response of the analyte in plant matrix to the response of the' 
Table 3 
Ion suppression due to A. annua plant matrix. 
Mean quanti ty spiked into plant matrix' 
Quantities in blank matrixb 
Sample 1 
Sample 2 
Sample 3 
Mean 
Standard error (SE) 
2.50 
2.49 (-0.22%) 
2.52 (0.85%) 
2.51 (0.28%) 
2.51 (0.30%) 
0.04 (0.24%) 
5.05 
4.92 ( -2.58%) 
5.58 (9.62%) 
5.54 (8.67%) 
5.35 (5.30%) 
0.21 (3.95%) 
analyte spiked into a blank matrix (mobile phase) sample that has 
gone through the sample preparation process (40 ). Signals from 
three samples for each analyte prepared in the mobile phase (25% 
formic (0.1%) acetonitrile in 0.1 % formic acid) were compared with 
the similar concentration in the plant matrix. Table 3 shows the 
values obtained for each of the analytes. 
There was a negligible (0.3%) suppression of artemisinin (1 ) 
signals resulting from the plant matrix compared with the blank 
(mobile phase). Other metabolites showed some evidence of ion 
suppression due to plant matrix. Less than 15% of suppression was 
observed in all analytes determined. The widest range was between 
about - 2.0 and 14.13% for artemisinic acid. The enhancement 
(- 2.0%) was within the margin of error (5.02%) for the determina-
tion. Similarly, a slight enhancement ( - 2.58%) was observed for one 
of the determinations of9-epi-artemisinin (2); this was also within 
the margin of error. An average suppression for all the determined 
compounds was between 0.3% for (1) to 8.06% for (5). 
3.5. Limit of detection (WD), lower limit of quantification (LWQ), 
and Precision 
The guideline by the international conference on harmonization 
(lCH) (41) for bio-analytical method validation was adopted fo r the 
definition and determination of precision, LOD and LLOQ. The limit 
of detection is defined as the lowest amount of analyte in a sample, 
which can be detected but not necessarily quantitated while lower 
quantification limit is the lowest amount of analyte in a sample, 
which can be quantitatively determined with suitable precision and 
accuracy. Both limits were calculated from the calibration curve 
following Miller and Miller (42 ). Injection precision (repeatability) 
was calculated with at least six determination of each analyte in a 
single day. The coefficient of variation (CV) fo r these determinations 
is below 10% for all metabolites investigated (Table 4). 
Within-day precision was determined for six concentration lev-
els covering the analyte calibration range and making a total of 
12- 17 analyses on a single day. Between-day precision was calcu-
lated fo r the same calibration range on three different days spread 
over a month, resulting in a total of 32-40 determinations. The 
range for the accuracy for both within and between day precision 
determinations was from 81.42 to 118.81 % while the coefficient of 
variance in both was less than 8.5% (Table 4 ). 
3.6. Regression indices and dynamic range 
Good linearity (r2 > 0.99) of the calibra tion curves for all the ana-
lytes of interest in both the mobile phase and the mobile phase 
spiked with the matrix is indicative of the robustness ofthe method. 
The regression and sensitivity indices in Table 4 are for the stan-
dards prepared in the mobile phase spiked with extracts of the 
glandless plant. The method is highly sensitivity for most of the 
analytes. LLOQ for arteannuin B is about 3.5 pg mL -1. However fo r 
(3)( ll-g mL- I) (4) ( ll-g mL - I) (5) (ll-gmL- I) (6) ( ll-gmL- I) 
5.08 32.72 30.88 2.49 
5.49 (7.95%) 32.86 (0.42%) 35.24 (14.13%) 2.61 (5.03%) 
5.70 (12.1 4%) 36.1 7 (9.54%) 34.57 (11.94%) 2.49 (0.0%) 
5.46 (7.37%) 34.20 (4.32%) 30.30 (-1.89%) 2.55 (2.48%) 
5.58 (6.83%) 34.41 (4.76%) 33.37 (8.06%) 2.55 (2.48%) 
0.08 (1.50%) 0.96 (2.64%) 1.54 (5.02%) 0.04 (1.47%) 
• Mean of three determinations of spiked standards at 2.5 ll-g mL - I for artemisinin (1) and arteannuin B (6), 51l-g mL - I for 9-epi-artemisinin (2) and artemisitene (3). 
Dihydroartemisinic acid (4) and artemisinic acid (5) were spiked at 30 Il-g mL- 1 each. 
b Three determination of blank matrix (mobile phase of 0.1% formic:O.l % formic in acetonitr ile, 75:25) spiked with standards at an equivalent level to spiked plant matrix. 
Pe rcentage suppression or enhancement is shown in brackets. 
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Flg.3. Top - MRM chromatogram for 9-epi-artemisinin (2) in A. annua extract also showing artemisinin (1) content Bottom - chromatogram of the same extract spiked at 
5 ~gmL- l of(2). 
dihydroartemisinic acid and artemisinic acid, the LLOQ is much 
higher at 0.6 and 1.0 j..Lg mL - 1 respectively. The dynamic ranges 
for these compounds reflect the same pattern with a lower range 
(0.15-10 j..Lg mL - 1) for all analytes except dihydroartemisinic acid 
and artemisinic acid with a range of 3.75-120 j..Lg mL -1. 
Table 4 
LOD. LLOQ, injection precision, within-day and between-day preciSions. 
3.7. Artemisinin, 9-epi-artemisinin and artemisitene 
Transitions used for the MS/MS analysis of artemisinin 
and 9-epi-artemisinin were 283 -+ 219 + 229 + 247 + 265 and 
283 -+ 209+219+247+265 respectively. The two analytes were 
--------------------------------------------------------------------------------------------------------------
---
(1) (2) (3) (4) (5) (6) 
LOD(~gmL- l l" 1.3 x 10- ' 1.0 x 10- 3 2.8 x 10- ' 2.0 x 10- 1 3.3 x 10- 1 1.2 x 10- 6 
LLOQ(~gmL- l l" 4.1 x 10- ' 3.0 x 10- 3 8.4 x 10- ' 6.0 x 10- 1 9.9 x 10- 1 3.5 x 10- 6 
Regression equation' y-857.32x+ 163.1 y - 344x - 35.84 y-388.54x - 21.01 Y - 13.98x + 54.16 y-21.64x+71.47 y - 96645x + 5947.7 
R2 value 0.99396 0.99623 0.99562 0.99408 0.99803 0.99547 
Injection precisionb 
Mean (~gmL-l) 5.67 (n - 10) 0.13 (n -8) 0.24(n-7) 19.54(n-6) nfa 0.32 (n - 6) 
ev (%) 4.48 4.54 6.24 6.20 nfa 9.89 
Within and between-day precision' 
Within day range (%) 93.22- 114.20 (n -12) 83.09-106.61 (n-16) 86.04- 11 6.35 (n -1 7) 87.26- 111 .75 (n - 14) 92.73- 118.81 (n-13) 82.32- 112.69 (n - 15) 
ev(%) 7.26 5.92 7.60 7.96 7.10 7.70 
Between day range (%) 82.78- 117.88 (n-36) 83.09- 109.07 (n - 37) 81.65-116.35 (n-40) 81.42- 114.33 (n - 38) 92.32-118.81 (n - 32) 82.32- 119.98 (n - 37) 
___ ev(%) 7.86 6.47 7.37 8.30 6.26 8.26 
nfa - undetermined values below method's LLOQ, 
• Calculation ba sed on 12 point calibration graph and the following formulas LOD - Yo + 350 and LLQD- 3LOD. where Yo is the signal equal to the blank signal (they intercept) 
and So is standard deviation of the blank (the random error in the y-direction) (41] . 
b Injection precision was assessed by n determination at 100% concentration. 
, Within and between-day precisions were determined over 6 concentration levels covering the calibration range for both precisions. 
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Fig. 4. (A) and (B) EIC for extracts and 9-epi-artemisinin standard respectively. 
Below are HRMS data for extract (C) and standard (D). " 
differentiated based on their retention times as shown in Fig. 3. We 
report here for the first time the detection of 9-epi-artemisinin in 
plant extract. The presence of 9-epi-artemisinin and artemisitene 
has been reported as impurities in artemisinin raw material 
[2,13,43). 
WHO has guidelines and recommendations for concentration 
limits for this isomer and other impurities in the raw material (2). 
However the source of the impurity has never been established. To 
verify the detection of the isomer in plant extract by our method 
3.67 
we employed a high-resolution mass accuracy approach using a 
Q-ToF instrument to examine the compound in the plant extract. 
Fig. 4 shows extracted chromatograms, EIC (A and B) and high res-
olution MS data (C and D) for the crude (untreated) extract and 
9-epi-artemisinin standard at m/z 283. 
A comparison of the EIC chromatograms and the HRMS sim-
ulated spectrum for both extract and standard show a peak in 
the extract with identical retention time as the 9-epi-artemisinin 
standard and an HRMS data difference between both peaks of less 
than 2 ppm. This confirms and validates the MRM results and estab-
lishes the presence of (2) in A. annua raw extracts. 
Acton and Klayman (44) first reported the isolation of (3) from 
plant extracts and its possible role in the biosynthetic pathway of 
artemisinin has been suggested [45,46). Acton and Klayman have 
also demonstrated the conversion of (1) into iso-artemisitene and 
(2) [44). Table 5 shows the levels of(1) and the related metabolites 
in four A. annua biomasses analysed by our method. The level of(2) 
in the analysed extracts was about tenfold lower than the detected 
levels of(3) in the extracts. 
3.B. Dihydroartemisinic and artemisinic acids 
In our method, the MRM for dihydroartemisinic acid (4) 
([M+Ht - 237) and artemisinic acid (5) ([M+Ht - 235) are similar 
(237/235 -7 190 + 200 + 218). Three main peaks were observed inA. 
annua plant extracts for these transitions (Fig. 5). The standard peak 
for (4) in Fig. 5, matched one of the main peaks while an impurity 
in the (4) standard matched the second peak. We were unable to 
confirm the composition of this impurity. Standard artemisinic acid 
peak at 5.93 min does not match any of the major peaks. A small 
peak in the plant extract with similar retention time to artemisinic 
acid standard was below the method's quantitation limit for the 
same (Table 4). This is consistent with work by Brown and Sy 
[45,47,48), who have shown that dihydroartemisinic acid rather 
than artemisinic acid is the true late-stage precursor to artemisinin 
in some A. annua chemotypes. 
A 
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Fig. S. (A) MRM TIC chromatogram for A. annua plant extract monitored for artemisinic acid (235 -+ 190 + 200 + 218). (B) MRM chromatogram for artemisinic acid standard 
at 40 I-l-gmL - 1. (Cl MRM of plant extract monitored for dihydroartemisinic acid (237 -+ 190+ 200 +218). (D) MRM of dihydroartemisinic acid standard at 10 I-l-gmL - '. 
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Table 5 
Levels of metabolites in four Artemisia biomasses. 
Source of biomass 
BIONEXX (Madagascar) 
Mediplant (Sw itzerland) 
REAP (Kenya) 
ANAMED (Germany) 
Itens. 
1t 
OS 
0.0 
Hens. 
x10S 
OS 
0.0 
(1 ) (mgg- ' ) 
10.00 ± 0.03 
10.63 ± 0.11 
10.66 ± 0.01 
6.45 ± 0.08 
"'" ~"'''l<1''''''.' 
.~ O1J04ll EK: 237.180010.05 +Al I! 
\ 
Hens. 
, eie(B5 O1Ja40 EK: 235.180010.05 +Al I! 
x10S 
~ 2 0 J 
Hens. ARTII ]I O1JOO9 EK: 237.1800t0.05 +AI M: x1 01 
0 rv 
Hens. ARTII elfe(Ba O1J OO9 EK: 235.180010.05 +AI to!: 
x10S 
4 j 2 1\ 0 Itens. IlHAA ~ O1Ja42 EK: 237.1800.+0.05 +AlI! x10S 
1 
'--
0 "--1---
(2) (lLg g- ') 
23.80 ± 0.12 
12.70 ± 0.07 
12.40 ± 0.06 
1.60 ± 0.0 
---:., c;s 
1 . • 
0." 
0 .0 
N1 0S 
" .0 
1 ." 
1 .0 
0 ." 
0 .0 
..... 
'"':.;-.;. 
2 3 7 .'0"0 
.. 
• 
0 
><1 04 
237" .1 8 4 8 
.. 
.. 
2 
0 
(3)( lLg 10' ) 
290.0 ± 1.0 
389.0 ± 4 .0 
110.0 ± 1.0 
64.0 ± 4.0 
235 .188 4 
23.', "1"2. 
235 . ., .,83 
23 • . ' '' :1. 
I 
:> .... :>"0 
239 .• 082 
23ft'18ft!!: 
(4) (mgg- ' ) 
58.15 ± 1.52 
6738 ± 1.22 
68.33 ± 2.64 
37.71 ± 1.01 
81.10 ± 1.05 
168.60 ± 2.11 
20.70 ± 0.07 
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FIg. 6. EIC at mlz 235 (M) and 237 (OHM) showing EIC of extracts and standards (left) and HRMS data (right). 
We also verified this result on the high resolution and mass 
accuracy Q-ToF instrument. The extracted ion chromatograms from 
the Q-ToF for A. annua extract, artemisinic acid standard and (4) 
standard at mlz 235 and 237 respectively are shown in Fig. 6 (left) 
With corresponding high resolution MS data (right). A small peak in 
both treated and untreated extract matched the retention time of 
the standard peak for (5) and a relatively larger peak in the extracts 
matched the standard peak for (4), confirming the results from the . 
MRM based assay. 
Figs. 5 and 6 shows peaks other than (4) and (5) in the extracts. 
The largest peak in Fig. 5C and D is likely a degradation product 
of DHM which we also observed in a stressed DHM reference 
standard. 
4. Conclusions 
In this study we report the development and validation of a fast, 
Simple, sensitive and selective analytical HPLC- MS/MS-ESI MRM 
method for the determination of artemisinin (1), 9-epi-artemisinin 
(2), artemisitene (3), dihydroartemisinic acid (4), artemisinic acid 
(5) and arteannuin B (6) in A. annua crude extracts. Using this 
method we report for the first time the presence of 9-epi-
artemisinin in A. annua extracts. Validation indices evaluated were 
satisfactory. Linearity in native matrix (r2) were >0.99 for all ana-
lytes while the LCD was at least 0.3 ILg mL - 1 for (5) and sensitivity 
as high as 1.2 pg mL -1 was obtained for (6). LLOQ was between 
11LgmL- 1 for (5) and 3.5pgmL- 1 for (6) and a dynamiC range 
of 0.15-10 ILg mL - 1 for all the analytes except (4) and (5) with a 
range of3.75-120 ILgmL - 1. The accuracy was between 82.32% and 
116.35% and the within day and between day variations for deter-
minations covering the calibration range for all metabolites was 
<19%. The method was shown to be robust, quick, sensitive and ade-
quate for a range of applications including high throughput (HTP) 
analysis. 
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Abstract 
Artemisia annua hot water infusion (tea) has been used in in vitro experiments against 
P. falciparum malaria parasites to test potency relative to equivalent pure artemisinin. 
High performance liquid chromatography (HPLC) and mass spectrometric analyses 
were employed to determine the metabolite profile of tea including the concentrations 
of artemisinin (47.S±0.8 mg. Lot), dihydroartemisinic acid (70.0±0.3 mg Lot), 
arteannuin B (1.3±0.0 mg LO\ isovitexin (lOS.0±7.2 mg Lot) and a range of 
polyphenolic acids. The tea extract, purified compounds from the extract, and the 
combination of artemisinin with the purified compounds were tested against 
chloroquine sensitive and chloroquine resistant strains of P. falciparum using the 
DNA-intercalative SYBR Green I assay. The results of these in vitro tests and of 
isobologram analyses of combination effects showed mild to strong antagonistic 
interactions between artemisinin and the compounds (9-epi-artemisinin and 
artemisitene) extracted from A. annua with significant (ICso <1 !J.M) anti-plasmodial 
activities for the combination range evaluated. Mono-caffeoylquinic acids, tri-
caffeoylquinic acid, artemisinic acid and arteannuin B showed additive interaction 
while rosmarinic acid showed synergistic interaction with artemisinin in the 
. Corresponding Author. Email: guy.barker@warwick.ac.uk: Fax: +44 (0)24 765 
23568. 
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chloroquine sensitive strain at a combination ratio of 1:3 (artemisinin to purified 
compound). In the chloroquine resistant parasite, using the same ratio, these 
compounds strongly antagonised artemisinin anti-plasmodial activity with the 
exception of arteannuin B, which was synergistic. This result would suggest a 
mechanism targeting parasite resistance defenses for arteannuin B's potentiation of 
artemisinin. 
Keywords: malaria, Artemisia annua, artemisinin, synergy, resistance, mechanism 
1. Introduction 
The use of Artemisia annua (Qing Hao) in traditional Chinese pharmacopeia includes 
the treatment of fevers and chills [1,2]. In the 1970s, the active principle in the 
extract was isolated and identified as artemisinin (1), a sesquiterpene lactone. The 
effectiveness of artemisinin is strueturally due to the trioxane pharmacophore and the 
activation of the compound occurs via the cleavage of the endoperoxide bridge [3]. 
The mechanism for the activation of artemisinins and their interaction with the 
parasite are not fully understood. Different but not mutually exclusive mechanistic 
models have been proposed with evidence for and against each model [4]. A number 
of studies [5,6] have suggested that artemisinins act by heme dependent activation of 
the trioxane bridge in the parasites' food vacuole to produce free radicals which then 
disrupt heme detoxification and therefore lead to parasite toxicity. This hypothesis 
and other alternative mechanisms for the mode of action of artemisinins have been 
studied and reviewed by several authors [3,4,7,8,9,10,11,12,13]. Artemisinin and its 
derivatives have now been established in various combination therapies (ACTs) as 
effective anti-plasmodial treatments against multidrug-resistant P. Jalciparum 
infection [14,15]. 
In some parts of Asia and Africa, a hot water infusion (tea) of the plant is used as a 
self-medication for malaria. The use of tea in this way has raised concern of the 
possible development of parasite resistance as a result of un-standardised use of 
artemisinin in these tea preparations [16]. Consequently, the World Heath 
Organisation (WHO) in a position statement has called for "extensive fundamental 
and clinical research" which demonstrates both efficacy and safety for the use of tea 
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and other non-phannaceutical fonus of A. annua extract before recommendation for 
treating malaria [1 7]. 
The recipes in ancient Chinese texts for preparing Qing Hao extracts for the treatment 
of fevers include soaking, followed by wringing or pounding, followed by squeezing 
the fresh herb [1,2,18]. In their study, Rath et al [19] found that adding boiling water 
to the leaves, stirring briefly and leaving covered for 10 minutes, then filtering and 
gently squeezing the leaves to release residual water gave the best extraction 
efficiency (86%) for artemisinin in the preparation, relative to the total amount of the 
compound in leaves. In the literature, a range of aqueous extraction efficiencies 
(25-90%) has been reported for artemisinin [19,20,21]. Due to the differences in 
the content of artemisinin in tea preparation, Van der Kooy and Verpoorte [21] 
quantified artemisinin in tea prepared by different methods. They observed that the 
extraction efficiency is temperatu1\:-sensitive and that efficiencies of above 90% are 
attainable. 
Figure 1. Structures of some artemisinin related compounds, flavonoids and 
acids identified in A. annua extract. 
In some studies evaluating the activity of A. annua extracts, the amount of artemisinin 
in these extracts cannot fully account for its effectiveness against Plasmodium 
parasites in vitro and in vivo [16,19]. Mouton et al however did not find any evidence 
of improved potency for their extracts relative to the artemisinin content [22]. Apart 
from artemisinin, there are around 30 other sesquiterpenes and over 36 flavonoids 
identified in the plant (Figure 1), some of which have shown limited anti-plasmodial 
properties [23]. Five flavonoids, including casticin (7), have been shown to potentiate 
the activity of artemisinin [24,25]. Interestingly, the potentiating effect of these 
flavonoids was not observed with chloroquine (CQ). Billia et al. [26] observed that 
although these flavonoids have no effect on hemin (chi oro ferriprotoporphyrin IX) 
themselves, they do catalyse a reaction between artemisinin and hemin. 
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Weathers and Towler [27] have shown that poly-methoxylated flavonoids like 
casticin are poorly extracted and unstable in the aqueous tea infusion. This suggests 
that compounds other than this class of flavonoids are likely to be responsible for the 
reported improvement in the potency of artemisinin in tea infusion. A recent analysis 
by Cabonara et al. [28] of tea prepared from A. annua leaves by infusion in hot water 
for 1, 24 and 48 hours, identified a series of caffeoyl and feruloyl-quinic acids as 
main components of the infusion, together with some flavonoids. Chlorogenic or 
caffeoylquinic acids (CQAs) are esters of caffeic and quinic acids (Figure 1). They 
possess a broad spectrum of phannacological properties, including antioxidant, 
hepato-protectant, antibacterial, anti-histaminic, chemo-preventive and other 
biological effects [29,30,31,32]. 
To our knowledge, only the interactions of artemisinin with the poorly extracted poly-
methoxylated flavonoids found .... m Artemisia tea have been studied. This study 
therefore aims at understanding other possible interactions and mechanisms involved 
in artemisinin activity in the plant extract, and the effects of these interactions on 
parasite resistance to artemisinin. 
2. Materials and Methods 
2.1 Chemicals 
Reference standards of artemisinin (98%), rosmarinic acid, caffeic acid and casticin 
were obtained from Sigma-Aldrich (Dorset, UK). Dihydroartemisinic acid (> 96%) 
was purchased from Apin Chemicals (Oxfordshire, UK). 9-Epi-artemisinin (98%) 
was sourced from Sensaphann Ltd (Sunderland, UK). Artemisitene, artemisinic acid 
and arteannuin B were kindly provided by Walter Reed Army Institute of Research 
(Washington, DC, USA). The chlorogenic acids (>99%) and isovitexin (>99%) were 
obtained from Biopurify (China). LC-MS grade formic acid in water, acetonitrile and 
HPLC grade acetonitrile were obtained from Fisher Scientific (UK). Purified water 
(-18 Mn cm- I ) was dispensed from a Milli-Q system (Millipore, UK). 
2.2 Plant materials 
High yielding, dried A. annua biomass was obtained from BIONEXX Madagascar 
and stored under dark, cool conditions until use. 
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2.3 Plant extracts 
A. annua tea was prepared according to published methods with slight modification 
[1,33]. Briefly, 1 L of boiling water was added to 5 g of dried plant material, stirred 
and stored in the dark for 1 hour. The extract was filtered in vacuo and lyophilised 
after freezing to obtain the dried tea extract which was used in the Plasmodium assays 
and in metabolite profiling. 
2.4 Sample preparation - solubility studies 
The solubility of artemisinin, artemisitene and 9-epi-artemisinin in aqueous solvent at 
room temperature (22°C) was determined by the method employed by Wang et al. 
[34], with modifications. A saturated solution was prepared by dissolving excess 
amount of the pure (> 99.0%) standard of each material in 1 mL de-ionised water (MS 
grade, Brucker, UK) and vortexed. This suspension was allowed to settle and the 
supernatant filtered through a "(l.1 J.lm syringe filter (Fisher Scientific, UK). 
Appropriate volume of the filtrate was diluted with the mobile phase for mass 
spectrometry (MSIMS) analysis. 
2.5 Mass spectrometry method/or artemisinins 
The method by Suberu et al. [35] was employed. Briefly, the MSIMS system was 
operated with an ESI interface in positive ionisation mode (ESI+). The cone and 
desolvation gas flow rates were set at 45 L h-1 and 800 L h-1, respectively. The MS 
parameters were automatically defmed using Waters IntelliStart® software for the 
tuning and calibration of the tandem quardrupole analyser (TQD) and subsequently 
manually optimized for all analytes. Capillary voltage was set at 2.8 Kilovolts, 
collision voltage at 7 volts, source temperature was 150°C and cone voltage was set 
at 24 volts. A multiple reaction-monitoring (MRM) transition of 
283-+219+229+247+265, 283-+209+219+247+265, 281-+217+227+245+263 for 
artemisinin, 9-epi-artemisinin and artemisitene was employed. Quantification was 
determined using MRM modes for the above transitions. The dwell time was 
automatically set at 0.161 seconds. Data were acquired by MassLynx v4.l software 
and processed for quantification with QuanLynx v4.l (Waters Corp., Milford, MA, 
USA). 
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The high performance liquid chromatography (HPLC) system coupled to the mass 
spectrometer consisted of a binary pump, a cooling auto-sampler with an injection 
loop of 10 ilL set at 10 °C. The column heater was set at 30°C and a Genesis® Lightn 
C18 column (100 x 2.1 mm; 4 ~m) (Grace, IL, USA) protected by an Acquity-LC 
column in-line filter unit (0.2 Ilm in-line tnt) was used for separation of metabolites. 
The mobile phase consisted of A: 0.1% formic acid in water and B: 0.1 % formic acid 
in acetonitrile used in the following gradient: 0-7.00 min, 25-98% B; 7-9.5 min, 98% 
B; 9.5-10 min, 98-25% B; 10-15 min, 25% B; at a flow rate of 0.4 mL min-I. Weak 
wash solvent was 10% acetonitrile, strong and needle wash solvent was a mixture of 
acetonitrile, propan-2-01, methanol and water (30:30:30: 1 0 v/v/v/v). 
2.6 HPLC methodfor acids andflavonoid 
Analysis of acids and flavonoid was performed on an Agilent 1100 series HPLC 
equipped with a quaternary puihp, auto-sampler, photodiode array (PDA) and a 
degasser. The chromatographic method by Carbonara et al. [28] was used in the 
analysis with slight modifications. Briefly, the solvent system consisted of A (0.1 % 
acetic acid, brought to pH 4 with NaOH) and B (0.1 % acetic acid in acetonitrile) 
using a gradient elusion of 0-60 min: 12-25% B, 60-80 min: 25-60% B, 80-85 min: 
60-100% B. The system was equilibrated back to 12% B for 5 minutes before the next 
run. Analytes were separated and resolved at a flow rate of 1 mL min-Ion a 
Phenomenex Luna C18 column (250 mm x 4.60 mm, 5}tm particle size) attached to a 
C18 guard column. Detection and quantification was at 310 nm for caffeic acid, 
chi orogenic acids and isovitexin. Rosmarinic acid was analysed at 330 nm 
wavelength. 
2.7 Plasmodium assay 
Determination of 50% growth inhibitory concentration (ICso) values of extracts, 
compounds and combinations against CQ-sensitive (CQS; HB3) and CQ-resistant 
(CQR; Dd2) strains of P. falciparum was performed at Georgetown University, 
Washington, DC, USA, using a previously reported protocol [36] with minor 
modifications. Typically, test samples were dissolved in DMSO to give a stock 
solution, followed by serial dilution using complete media (RPMI 1640 supplemented 
with 10% (v/v) type-O+ human serum, 25 mM HEPES (pH 7.4), 23 mM NaHC03, 11 
6 
mM glucose, 0.75 mM hypoxanthine and 20 I-lg/L gentamicin) to generate working 
stocks. 100 I-lL of these stock solutions were transferred into pre-warmed (37°C) 96-
well plates. 100 I-lL of asynchronous parasite culture at 2% parasitemia, 4% 
hematocrit was transferred into each drug (A. annua plant extract) pre-loaded well, for 
a final I % parasitemia, 2% hematocrit. The fmal concentration of DMSO was 2.5%. 
Plates were transferred to a gassed (90% N2, 5% O2, 5% CO2) airtight chamber and 
incubated at 37°C for 72 hours. Following this incubation, 50 I-lL of lOX SYBR 
Green I dye (diluted with complete media from a 10000X concentrate in DMSO) was 
added to each well and plates incubated for an additional I hour at 37°C to allow 
DNA intercalation. Fluorescence was measured at 530 nm (490 excitation) on a 
Spectra GeminiEM plate reader (Molecular Devices, USA). ICso values were obtained 
from sigmoidal curves fit of parasite growth vs. drug concentration using SigmaPlot 
10.0, and are the average of three replicates. CQ was included as a positive control in 
the assay. 
2.8 Combination analysis 
Interactions between compounds were evaluated by isobologram analysis [37,38]. 
Briefly, a master stock solution is prepared for each compound such that its 
concentration following four or five twofold dilutions approximates the ICso. These 
stock solutions were mixed at ratios of 0:4, 1:3, 1:1,3:1 and 4:0 (v/v) to give working 
combination stocks. Subsequently, the combination stocks were twofold serially 
diluted to generate a full dose concentration range for each v/v mixture, which were 
then analysed under standard growth inhibitory assay conditions (see above) to 
provide dose response curves and an ICso, for each component of each v/v mixture. 
2.9 Data analysis/or in vitro combination studies 
ICso values for each compound alone and in the combination were used to calculate 
FICs (fractional inhibition concentrations) as described elsewhere [39,40]. The FICs 
were summated to obtain the fractional inhibition concentration index (FICindex) for 
the combination as in the equation below: 
where: 
FICiDdex III FICA + FiCa 
FICA .. ICso of Drug A in Combination 
ICso of Drug A Alone 
7 
FIC
B 
.. ICso of Drug B in Combination 
ICso of Drug B Alone 
The following categorisation was used to detennine the type of interactions between 
compounds evaluated: synergy (FICindex <0.9), additivity (0.9<FICindex<I.5) and 
antagonism (FICndex > 1.5) [39,40]. 
3. Result and discussion 
3.1 Composition of A. annua tea 
Table 1 shows the metabolites in the aqueous extract analysed by both MSIMS and 
HPLC methods and their quantities in milligrams per litre of extract. The compounds 
analysed were based on the in extenso analysis by Carbonara et al. [28], who showed 
them to be among the major metabolites (quantitatively) in A. annua tea infusions. 
Some of these metabolites (like 3-caffeoylquinic acid) also have important dietary 
profiles [41,42]. In addition, artemisinin-related compounds, which we have 
previously detected in such extracts, were also analysed. The level of artemisinin 
reported [2,19,21,28,43] for tea extract is varied and the values obtained in this study 
(47.5 mg L-') are within the reported range. These could be due to variation in 
biomass and the tea preparation method that was employed, but might also be due to 
differences in the biomass-to-solvent ratio used. Carbonara et al. [28] used a solvent 
to biomass ratio of 26:1 (v/w), while this study, as well as others [19,21], employed 
the therapeutically recommended ratio (200:1, v/w or 5 g L-') [44]. 
Table 1. Metabolites in the aqueous A. annua extract analysed by both MSIMS 
and HPLC methods quantified as milligrams per litre of tea. 
Dihydroartemisinic acid (4) (70 mg L-') and arteannuin B (5) (1.3 mg L-') are the only 
biosynthetic precursors of artemisinin detected in the tea extract using our method 
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[3S]. Therefore artemisinin is the only compound among the metabolites we analysed 
in the tea with significant (ICso <1 I-tM) anti-plasmodial activity (Table 2). 
3-Caffeoylquinic acid (11) was found to be the most abundant (72 mg L-1) of the 
caffeic derivatives (11-17) in the analysed extract, followed by 3,S-di-caffeoylquinic 
acid (15) (S7 mg L-1). Caffeic acid (to) was the least abundant (0.8 mg L-1) of the 
evaluated acids. Isovitexin (8) was the only flavonoid analysed (lOS mg L- 1), being 
relatively abundant in the extract. Some classes of flavonoids have poor aqueous 
solubility and limited profiles of these compounds in aqueous extract have been 
reported [27,28]. Lower level ofrosmarinic acid (9) (1.1 mg L-1) was detected in our 
samples, compared to the levels found by De Magalbaes et al [43]. However, widely 
different concentrations of the acid were reported in the cultivars and samples they 
analysed. The acid was not detected in the analysis by Carbonara et al [28]. Van der 
Kooy and Verpoorte [21] have al~o shown that the method employed in preparing the 
hot water infusion does affect the amount of artemisinin and therefore other co-
metabolites extracted. These differences in profiles and concentration levels of 
metabolites seem to suggest that composition of prepared tea infusions differ and is 
significantly influenced by method of preparation and the Artemisia cultivar used. 
3.2 Anti-plasmodium extracts and bioactive compounds in A. annua 
Table 2 shows ICso anti-plasmodial values for pure compounds and extracts of A. 
annua plant. Between three- and seven-fold potentiation of artemisinin activity was 
observed for A .annua aqueous (tea) extract in CQ-sensitive (HB3) and CQ-resistant 
(Dd2) strains respectively. Only artemisitene (3) (ICso, 88.4±9.9174.1±7.8 nM, 
HB31Dd2) and 9-epi-artemisinin (2) (ICso, S9.2±1.7/62.2±1.0 nM, HB31Dd2) showed 
significant anti-plasmodial activities (ICso <1 fJM) among the artemisinin biosynthetic 
precursors evaluated. 9-Epi-artemisinin and artemisitene respectively showed about 
one third and one fourth of the activity of artemisinin. Acton et al. [4S] observed a 
similarly reduced activity for 9-epi-artemisinin and artemisitene, compared to 
artemisinin in D6 and W2 strains of P. falciparum. Artemisinin has a chiral molecular 
structure and the bioactivity of the molecule is influenced by its absolute 
configuration. 
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Table 2. ICso of extracts and components of A. annua in CQ-sensitive (HB3) and 
resistant (Dd2) strains. 
To investigate if solubility of these artemisinin analogues could be partially 
responsible for the reduced activity, we determined the aqueous solubilities of 
artemisinin, artemisitene and 9-epi-artemisnin. Table 3 shows the solubility of these 
compounds at experimental conditions. 
Table 3. Solubility of artemisinin, artemisitene and 9-epi-artemisinin in water at 
22°C and atmospheric pressure. 
~ 
Under these conditions, 9-epi-artemisinin has a higher solubility, about twice that of 
artemisinin or artemisitene. The lower bioactivity could not be explained based on the 
solubility data alone, although the experimental data was obtained at 22°C (Table 3). 
We do not expect the pattern observed to change significantly at physiological 
conditions. 
Woerdenbag et ai. [46] observed that the anti-cancer activity of II-hydroxy-II-epi-
artemisinin (Cll in older and C9 in newer references for the structure) was about 
threefold less than the conformer, which is the same threefold difference we observed 
in the anti-plasmodial activity for epimerisation at C9 (Table 2). If the threefold 
activity difference is consistent regardless of the differences in molecular targets and 
effect, this may suggest a common upstream differentiation point of molecule 
activation. The lower activity of 9-epi-artemisinin may therefore be due in part to a 
structural conformation that is relatively more difficult to activate compared to 
artemisinin. 
3.3 Antagonism of artemisinin with biosynthetic precursors 
Figure 2 shows the interaction of artemisitene and 9-epi-artemisinin with artemisinin 
and artesunate (6). These biosynthetic precursors of artemisinin have significant (lCso 
<1 JlM) anti-plasmodial activities (Table 2). The interaction of artemisinin with 9-epi-
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artemisinin and artemisitene was antagonistic, but the interaction of these compounds 
with artesunate was additive in both chloroquine sensitive (HB3) and resistant (Dd2) 
strains. 
Figure 2. Isobologram showing the plot of fractional inhibitory concentration 
(FIC) of 9-epi-artemisinin (EPI) and artemisitene (ATENE) against FIC of 
artemisinin (ART) and artesunate (ATSU). Panel A - interaction of EPI and 
ATENE with ART in chloroquine-sensitive (CQS) HB3 strain. Panel B - same as 
in A but in CQ-resistant (CQR) Dd2 strain. Panel C - interaction of EPI and 
A TENE with A TSU in HB3. Panel D - same as C but in Dd2 parasite. 
The reason for the observed antagonistic interaction with artemisinin at the 
combinations investigated is unclear. Structurally, artemisinin, 9-epi-artemisinin and 
'II 
artemisitene are differentiated at C9. The difference from artemisinin is epimerisation 
of the methyl group for 9-epi-artemisinin and a methylene group attached instead for 
artemisitene (Figure 1). Given the minor structural differences, it is likely that these 
compounds have identical molecular targets and therefore possibly compete for these 
when combined. Conversely, due to the relatively large difference in structure and 
mass of artesunate and 9-epi-artemisinin or artemisitene, these compounds, when 
combined, may act on the same targets as well as on different molecular targets with 
the possibility of positive polyvalent interaction. Similarly, Wagner [47,48,49] has 
reported an in vitro synergistic inhibitory effect upon combining ginkgolides A and B 
from Ginkgo bi/oba extract for PAF-induced thrombocyte-aggregation. The 
difference between ginkgolide A and B is an oxygen atom (16 Da). 
3.4 Analysis of other combinations 
Table 4 shows the interaction of co-metabolites in A. annua extracts with artemisinin. 
In the CQ-sensitive (HB3) strain, 3-caffeoylquinic acid (3CA) showed additive 
interaction at 1:3 (v/v), which became synergistic at higher ratio of the acid to 
artemisinin (1:10, 1:100 v/v). For casticin, the interaction at 1:3 (artemisinin to 
casticin, v/v) is antagonistic. Synergistic interaction is however reported [24,25] for 
combination ratios at the range of 1:10-1000 (artemisinin to casticin, v/v). 
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Therefore, using the FIC index of casticin (1.9) as a benchmark for potential positive 
interactions, compounds like isovitexin, caffeic acid and dihydroartemisinic acid that 
show antagonistic interactions at 1:3 may also, like casticin, interact synergistically at 
a higher ratio. Rosmarinic acid was synergistic at a 1:3 combination with artemisinin 
(v/v) and some chlorogenic acids were additive at this combination also. These 
compounds showing positive interactions with artemisinin may collectively be 
responsible for the potentiation of artemisinin in the tea extract. However, arteannuin 
B and artemisinic acid are poorly extracted in the aqueous extract. 
Table 4. Anti-plasmodial interactions of co-metabolites with artemisinin in CQ-
sensitive (HB3) and CQ-resistant (Dd2) strains. 
Casticin and 3-caffeoylquinic acid (3CA) are polyphenolic compounds that are 
natural anti-oxidants. Anti-oxidaJlts at cellular redox sites are considered a "double 
edged sword" able to act either as anti-oxidant or pro-oxidant depending on 
conditions, such as dosage levels and presence of metal ions [50,51]. This "double 
edged sword" characteristic of anti-oxidant polyphenols could help explain our 
observation. At a lower combination with artemisinin, casticin and 3CA were anti-
oxidative towards the ROS and carbon-centred radicals formed from artemisinin 
activation and, as a result, countered artemisinin activity in vitro. Conversely, at a 
higher concentration ratio to artemisinin, casticin and 3CA were pro-oxidative, 
enhancing the oxidative stress resulting from artemisinin's activation, leading to 
improvement in artemisinin's potency. A schematic isobologram to describe the 
interaction between an active pharmaceutical ingredient (API) like artemisinin (A) 
and synergists like casticin and 3CA (B, non-API) is shown in Figure 3. 
Figure 3. A schematic isobologram of the interaction of artemisinin (API) with 
anti-oxidant synergist (Non-API). 
3.5 Possible role of anti-oxidant defence network in resistance 
Rosmarinic acid at the combination ratio evaluated had a potentiating effect (FICindex 
0.89) on artemisinin in the CQ-sensitive (HB3) strain (Table 4) but this effect was not 
reproduced in the resistant (Dd2) strain; rather a strong antagonistic effect (FICndex 
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4.95) was observed. The effect of rosmarinic acid on artemisinin's ability to mitigate 
the resistance mechanism of the parasite could be partly explained by the fmding of 
CuI et al. [52] and others [53] who observed that in vitro resistance in P.falciparum is 
associated with increased pfmdr-l copy number and anti-oxidant activity. Some 
experiments with rosmarinic acid have reported strong anti-oxidant activity for the 
compound that is over three times that of trolox [54,55,56]. In the presence of 
rosmarinic acid, anti-oxidant activity may further be elevated thereby promoting 
increased resistance. A similar trend of activity in sensitive and resistant parasite 
strains in combination with artemisinin was observed for caffeic acid, 4-caffeoyl-
quinic acid (12) and isovitexin with reported anti-oxidant properties [57,58,59]. This 
supports the possible role of the anti-oxidant defence network in parasite resistance to 
artemisinin [60] 
3.6 Arteannuin B selectively potentiates the activity of artemisinin against parasite 
defence system 
Arteannuin B at 3:1 (v/v) combination with artemisinin showed additive or no 
interaction (FICindex 1.25) in the CQ-sensitive strain and a synergistic interaction 
(F1Cindex 0.34) in the resistant parasite strain (Table 4). This is about a three-fold 
improvement in artemisinin's potency against CQ-resistant P. falciparum. This is not 
reproduced in the CQ-sensitive strain. The potentiation of artemisinin by arteannuin 
B seems to be selectively directed at the parasites' chloroquine resistance mechanism. 
This combination could therefore help to better understand the mechanism(s) 
involved in parasite defence network. Reproducing this three-fold improvement in 
potency with other artemisinin analogues could also help in the development of 
therapeutics effective against emerging drug-resistant strains. 
Arteannuin B is an unusual a-methylene-y-Iactone, transfused via a tertiary hydroxyl 
group [61]. This structure could account for its easy fragmentation/ionisation 
observed in mass spectrometry and reported facile rearrangement in acidic conditions 
[35,62]. 
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4. Conclusions 
In this study we examine interactions between artemisinin and co-metabolites found 
in A. annua plant extracts for chloroquine sensitive (CQS; HB3) and resistant (CQR; 
Dd2) P. falciparum malarial parasites. The aqueous extract (tea) showed about three 
to seven-fold potentiation in the parasite strains. When pure compounds were 
combined, 9-epi-artemisinin and artemisitene interacted antagonistically with 
artemisinin at the combinations evaluated. 9-epi-artemisinin and artemisitene were the 
only artemisinin-related metabolites with significant anti-plasmodial activity (lC50 <1 
~M) among those evaluated. In CQS parasites, caffeic acids and their chI orogenic 
acid derivatives showed additive interactions with artemisinin at the combination ratio 
evaluated. 3-Caffeoylquinic acid's interaction with artemisinin turned synergistic with 
the increased ratio of the former in the combination. Rosmarinic acid showed 
synergistic interaction with artemisinin in the drug sensitive strain but the interaction 
with artemisinin in the drug resista!J.t strain was strongly antagonistic at the same level 
of combination. This antagonistic interaction in CQR parasites was also observed for 
caffeic acid and some of its derivatives known to have anti-oxidant properties. The 
observation supports literature evidence [52,53] for a potential role of anti-oxidants in 
parasite drug resistance. Therefore the effect of dietary anti-oxidants on artemisinin 
combination therapies used in the management of drug resistant P. falciparium 
malaria may need to be further investigated. 
Arteannuin B was found to selectively potentiate the activity of artemisinin in Dd2 
parasites, suggesting some interaction with the CQR mechanism, since the 
potentiation of artemisinin by arteannuin B was not reproduced in CQS parasites. As 
a result of this specificity, arteannuin B could potentially be used as a probe to better 
understand parasite drug resistance mechanisms and the combination might prove 
useful for treating CQR strains of malaria. 
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Tables: 
Table 1: Metabolites in the aqueous A. annua extract analysed by both MSIMS 
and HPLC methods quantified as milligrams per litre oftea. 
Compound 
Artemisinin 
Arteannuin B 
Dihydroartemisinic acid 
Caffeic acid 
3,S-Di-caffeoylquinic acid 
3-Caffeoylquinic acid 
4-Caffeoylquinic ac1d 
4,S-Di-caffeoylquinic acid 
S-Caffeoylquinic acid 
Isovitexin 
Rosmarinic acid 
Amount 
(mg L- t of tea)* 
47.S±O.8 
l.3±O.O 
70.O±0.3 
O.8±O.OO 
S7.0±1.7 
n.0±1.6 
20.4±1.6 
31.6±4.0 
9.0±O.7 
lOS.0±7.2 
l.l±O.O 
*Values are an average of triplicate determinations with ± S.E.M. 
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Table 2. ICso of extracts and components of A. annua in CQ-sensitive (HB3) and 
resistant (Dd2) strains. 
Compound/extracts 
Chloroquine (CQ) 
Artemisinin 
Artesunate 
Artemisitene 
9-epi-artemisinin 
Artemisia aqueous extract (Tea)b 
Artemisinic acid 
Arteannuin B 
Dihydroartemisinic acid 
Caffeic acid 
3-Caffeoylquinic acid 
4-Caffeoylquinic acid 
5-Caffeoylquinic acid 
3,4-Caffeoylquinic acid 
4,5-Caffeoylquinic acid 
3,4,5-Caffeoylquinic acid 
Rosmarinic acid 
Isovitexin 
Casticin 
HB3 strain 
21.8 ± 2.4 
22.6 ± 0.7 
8.8 ± 0.3 
88.4 ± 9.9 
59.2 ± 1.7 
7.6 ± 3.4 
77.8 ± 1.5 
3.2 ± 0.1 
21.1 ± 0.7 
60.4 ± 4.3 
69.4 ± 6.4 
61.4 ± 4.3 
84.8 ± 6.4 
36.2 ± 1.0 
29.3 ± 2.4 
181.4 ± 2.1 
65.1 ± 5.0 
72.5 ± 6.8 
17.9±4.7 
ICso (nM)R 
ICso (JlMt 
Dd2 strain 
202.9± 10.7 
21.2 ± 2.3 
5.6± 0.6 
74.1 ± 7.8 
62.2 ± 1.0 
2.9 ± 0.4 
61.6±7.5 
4.8 ± 0.4 
17.7±4.2 
47.5 ± 8.8 
61.4 ± 4.3 
53.6 ± 5.0 
85.3 ± 4.2 
49.0 ± 6.8 
43.2 ± 4.2 
88.2 ± 6.2 
65.0± 7.0 
48.1 ± 4.5 
12.2 ± 1.8 
RICso values are an average of at least three independent measurements each 
f,erformed in triplicate, and are shown ± S.E.M of the three independent experiments. 
ICso of extract determined based on the artemisinin content (i.e. ART ICso of extract) 
see Table 2. 
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Table 3: Solubility of artemisinin, artemisitene and 9-epi-artemisinin in water at 
22°C and atmospheric pressure. 
Compound Solubility [mg L-1]* at 22°C 
Artemisinin 74.27±2.10 
Artemisitene 74.21±2.99 
9-Epi-artemisinin 133.08±5.44 
*Values are an average of triplicate detenninations with ± S.E.M. 
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Table 4. Anti-plasmodial interactions of co-metabolites with artemisinin in CQ-
sensitive (HB3) and CQ-resistant (Dd2) strains. 
Art = artemisinin, CA = caffeic acid, 3CA = 3-caffeoylquinic acid, 4CA = 4-
caffeoylquinic acid, 5CA = 5-caffeoylquinic acid, 3,4 CA = 3,4-di-caffeoylquinic 
acid, 3,5CA = 3,5-di-caffeoylquinic acid, 4,5CA = 4,5-di-caffeoylquinic acid, TCA = 
3,4,5-tri-caffeoylquinic acid, ISO = siovitexin, CAS = casticin, A TCID = artemisinic 
acid, ARTB = arteannuin B, RA = rosmarinic acid, DHAA = dihydroartemisinic acid, 
A TENE = artemisitene. 
HB3 Dd2 
Combination FIe. d m ex Interaction FICindex Interaction 
1 :3 1.570 Antagonistic 4.046 Antagonistic ART:CA 
1 :3 1.172 Additive 2.088 Antagonistic ART:3CA 
1:10 " 
ART:3CA 0.685 Synergistic 1.087 Additive 
1 :100 0.781 Synergistic 1.177 Additive ART:3CA 
1:3 1.088 Additive 4.266 Antagonistic ART:4CA 
1:3 0.928 Additive 2.460 Antagonistic ART:5CA 
1:3 2.253 Antagonistic 4.862 Antagonistic ART:34CA 
1 :3 2.312 Antagonistic 4.749 Antagonistic ART:35CA 
1:3 2.315 Antagonistic 4.844 Antagonistic ART:45CA 
1:3 1.220 Additive 3.041 Antagonistic ART:TCA 
1 :3 1.534 Antagonistic 4.829 Antagonistic ART:ISO 
1:3 1.921 Antagonistic 3.034 Antagonistic ART:CAS 
1 :3 1.467 Additive 4.152 Antagonistic ART:ATCID 
1:3 1.250 Additive 0.342 Synergistic ART:ARTB 
1:3 0.890 Synergistic 4.952 Antagonistic ART:RA 
1:3 1.801 Antagonistic 2.861 Antagonistic ART:DHAA 
1 :3 3.480 Antagonistic 7.002 Antagonistic ART:ATENE 
ART 
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(4) dihydroartemisinic acid 
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OH 0 
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HO~CH.COOH 
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Caffeoyl group (CA) 
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I 
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H 
(8) isovitexin (9) rosmarinic acid 
RI R2 R3 
(11) 3-cafTeoylquinic acid CA H H 
(12) 4-cafTeoylquinic acid H CA H 
(13) 5-cafTeoylquinic acid H H CA 
(14) 3,4-di-cafTeoylquinic acid CA CA H 
(15) 3,5-di-cafTeoylquinic acid CA H CA 
(16) 4,5-di-cafTeoylquinic acid H CA CA 
(17) 3.4,5-tri-cafTeoylquinic acid CA CA CA 
Figure 1. Structures of some artemisinin related compounds, flavonoids and 
acids identified in A. annua extract. 
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Figure 2. Isobologram showing the plot of fractional inhibitory concentration 
(FIC) of9-epi-artemisinin (EPI) and artemisitene (ATENE) against FIC of 
artemisinin (ART) and artesunate (A TSU). Panel A - interaction of EPI and 
A TENE with ART in chloroquine-sensitive (CQS) HB3 strain. Panel B - same as 
in A but in CQ-resistant (CQR) Dd2 strain. Panel C - interaction of EPI and 
ATENE with A TSU in HB3. Panel D - same as C but in Dd2 parasite 
Substance A 
(API) 
Anatgonism at lower 
B concentration 
Synergy at higer 
B concentration 
Substance B 
(Non-API) 
Figure 3. A schematic isobologram of the interaction of artemisinin (API) with 
anti-oxidant synergist (Non-API 
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